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Abstract 
Pregnancy and acquisition of sexually transmitted infections: risk behaviors and incidence 
Chloe A. Teasdale 
 
This dissertation had three primary aims. The first aim was to systematically review evidence 
documenting incidence of sexually transmitted infections (STI) during pregnancy. Eighteen papers were 
included in the final review which reported incidence of five STIs: chlamydia, gonorrhea, human 
papillomavirus (HPV), herpes simplex virus type 2 (HSV-2) and human immunodeficiency virus (HIV).  
The review found that there are very limited data on incidence of STIs during pregnancy and even fewer 
data comparing risk between pregnant and non-pregnant women. Although data are limited, studies 
suggest that women continue to acquire STIs during pregnancy, with incidence varying by type of 
infection, population of interest and geographic setting. Highest incidence was found for HPV and 
chlamydia although some studies of chlamydia showed low proportions of pregnant women infected. 
Studies in which partners were known to be infected with HSV-2 and HIV showed higher rates of 
acquisition in pregnant women compared to studies where partner status was not known.  
The second aim of this dissertation was to describe the impact of pregnancy on behavioral risk 
factors and vaginal practices that are associated with increased risk of STI acquisition. Data for this and 
the following aim came from the Methods for Improving Reproductive Health in Africa (MIRA) study, a 
randomized clinical trial conducted in South Africa and Zimbabwe 2003-2006. The analysis for the 
second aim included women in the MIRA trial who had a pregnancy during follow-up. Pregnancy was 
found to decrease sexual activity, particularly in the third trimester, but women were more likely to 
report sex without condoms while pregnant. There were lower reports by women during pregnancy of 
other risk factors for STI acquisition, including anal sex, concurrent sexual relationships and new sex 
partners. Vaginal wiping and insertion of material into the vagina, potentially important mechanisms for 
 
STI acquisition, were also less common during pregnancy. The data from this aim present a complicated 
picture of risk for STIs during pregnancy as a result of increased unprotected sex but decreased 
frequency of other known behavioral risk factors. 
The third and final aim of the dissertation was to measure incidence of four STIs in pregnant and 
non-pregnant women and to evaluate whether women are at greater risk during pregnancy for 
acquiring four STIs: chlamydia, gonorrhea, trichomoniasis and HIV. This analysis included 4,549 women 
18-50 years of age, 17% (N=766) of whom had a pregnancy during follow-up. In general, women 
continued to be sexually active but reported less overall sex than non-pregnant women. Report of 
condom use was lower during pregnancy as were other types of high risk sexual behaviors, such as 
multiple sexual partners, sex in exchange for drugs or money and anal sex, as well vaginal practices.  STI 
incidence was measured during pregnancy and it was found that women continued to acquire STIs when 
pregnant. In addition, during periods when women became pregnant, they appeared to be a high risk 
for acquiring chlamydia, trichomoniasis and HIV. Finally, in examining the association between 
pregnancy status and STI risk, we found that in multivariable models adjusted for demographic and 
time-varying self-reported behavioral risk factors and vaginal practices, pregnancy was not associated 
with increased STI risk. However in visit intervals when women became pregnant, they appeared to be 
at higher risk for contracting chlamydia compared to non-pregnant periods.
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The World Health Organization (WHO) estimates that every year there are almost 500 million 
new cases globally of curable sexually transmitted infections (STI) including syphilis, gonorrhea, 
chlamydia and trichomoniasis.1 In addition, there are more than 536 million people living with herpes 
simplex virus type 2 (HSV-2) and an estimated 35 million people living with human immunodeficiency 
virus (HIV) worldwide.2,3 Women in sub-Saharan Africa (SSA) have particularly high rates of STIs, 60% of 
those living with HIV in SSA are female.3 Untreated STIs can lead to infertility and in pregnant women 
can cause stillbirth, neonatal death, and low birth weight.4 It is also possible for infected pregnant 
women to transmit STIs to their children. Transmitted in utero or during delivery, syphilis, chlamydia and 
gonorrhea can cause blindness and developmental disabilities.5-7 Mother-to-child transmission of HSV-2 
and HIV causes lifelong infection and can result in mortality in infected children.8-11   
STIs pose a risk to pregnant women in any setting, however in those with high STI prevalence 
these infections contribute to significant morbidity and mortality in women and children. Despite the 
evidence of continued high fertility rates in settings that also have high STI prevalence, there are few 
data on incidence of STIs during pregnancy. There is also little known about women’s sexual behavior 
and vaginal practices during pregnancy, both of which may impact STI acquisition. In light of the 
significant consequences of STIs for the health of women and children, it is critical to more fully 
characterize factors that influence risk for these infections during pregnancy, assess whether pregnancy 
is a time of increased vulnerability and understand the biological and behavioral pathways through 
which pregnancy may increase the risk of STI acquisition in women. This information could lead to more 
effective efforts to prevent STIs in women of reproductive age which would have a beneficial impact on 
women’s health and the health of their children.   
The overall goal of this dissertation is to evaluate whether pregnancy is a period of increased STI 
risk and to investigate the factors that may increase STI incidence during pregnancy. Chapter 2 presents 
results from a systematic literature review of the existing data on incidence of STIs among pregnant 
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women and the evidence for whether pregnancy is a time of increased risk of acquisition. This chapter 
provides and overview and assessment of the available data, synthesizing findings from all existing 
English-language studies published from 1980 to 2012 which measured incidence and/or compared 
incidence among pregnant and non-pregnant women.  
Chapter 3, the first of two analytic analyses, explores the impact of pregnancy on women’s 
sexual risk behaviors which are thought to contribute to STI acquisition. In addition to sexual risk 
behaviors, changes in vaginal practices, which are also thought to be important pathways of STI 
acquisition, are examined. Using data from a randomized clinical trial for HIV prevention, women’s 
behaviors were compared during pregnant and non-pregnant periods. For the analysis, only women 
with lab confirmed pregnancies were included, with follow-up time prior to and during pregnancies 
examined to describe the impact of pregnancy on women’s sexual risk behaviors and vaginal practices. 
Behavior change was measured using several different analytic approaches in order to fully characterize 
changes resulting from pregnancy. This analysis is unique in using prospective follow-up data to 
characterize sexual behavior change during pregnancy with data from the same women before and 
during pregnancies. In addition, the restriction of the analysis to only women who had a pregnancy 
helps to reduce unmeasured confounding between women who did and did not have pregnancies 
during the trial, adding strength to the findings on behavior change resulting from pregnancy.  
Chapter 4 uses data from the same randomized clinical trial to examine incidence of four STIs: 
chlamydia, gonorrhea, trichomoniasis and HIV and to compare incidence by pregnancy status. All 
women from the trial 18-50 years of age at with a follow-up visit within 6 months of enrollment were 
included in the analysis, including 766 (17%) women who had a pregnancy during follow-up. All follow-
up visits were classified according to whether women were pregnant or non-pregnant at the visit, as 
well as the type of hormonal contraception (HC) reported at non-pregnant visits. The analysis then 
examined differences in reported sexual risk behaviors and vaginal practices based on pregnancy status. 
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The analysis of differences in risk behaviors between pregnant and non-pregnant women took into 
account different numbers of visits attended by participants and adjusted for multiple observations per 
participant. Incidence of each of the four STIs was calculated for the pregnancy exposure groups using 
person time during follow-up. Cox proportional hazards models adjusted for time-varying exposure and 
time-varying and time-fixed covariates were used to compare STI incidence among pregnant and non-
pregnant women. In addition to these main analyses, several sensitivity analyses were also conducted to 
examine the potential impact of using different definitions of pregnancy (including women who were 
newly pregnant compared women in ongoing pregnancies), as well as to assess the impact of excluding 
a small number of participants who did not have adequate follow-up time for inclusion in the analysis.  
This dissertation represents one of the first thorough examinations of the question of sexual risk 
behavior change and incidence of four common STIs during pregnancy. The analyses utilize robust 
statistical methods with data from a randomized clinical trial with good follow-up, both of which are 
important strengths. In addition, the sensitivity analyses that were conducted help to address any 
questions regarding biases from exclusion of subjects or misclassification of pregnancy status. There are 
few previous analyses with which to compare the findings and this dissertation presents important new 
information about STI risk among pregnant women which may contribute to efforts to reduce risk and 









Incidence of sexually transmitted infections during pregnancy: systematic review of incidence and 





Background: Sexually transmitted infections (STIs) are common among pregnant women and pose 
significant threats to their health and the health of their children. Although high STI prevalence is 
reported among pregnant women in many parts of the world, STI incidence during pregnancy has not 
been well documented. 
Methods: A systematic literature search of English language peer review journal articles published from 
1980 to 2012 was conducted to describe STI incidence during pregnancy and to assess whether pregnant 
women are at greater risk for STI acquisition compared to non-pregnant women. Prospective follow-up 
studies with outcome data during pregnancy and studies with repeat screening in pregnant women from 
all geographic regions were included.   
Results: Eighteen papers were included in the final review with incidence of five STIs: chlamydia, 
gonorrhea, human papillomavirus (HPV), herpes simplex virus type 2 (HSV-2) and human 
immunodeficiency virus (HIV).  Four studies reporting new chlamydia infections found incidence of 4-9%. 
Recurrence of chlamydia during pregnancy (reinfection after treatment during the same pregnancy) 
reported in five studies was 9-32%. Only one study reported incidence of gonorrhea and found that 4% 
of women acquired infection during pregnancy. Two studies reported HPV incidence among pregnant 
women with 31% of pregnant women in Uganda and 12% in Holland acquiring a new high risk HPV type, 
respectively. In three studies of HSV-2, pregnant women with unknown partner status ranged from no 
new infections to incidence of 0.9 per 100 person years. In a study of women HSV-2-infected male 
partners, 14% of pregnant women acquired infection. Seven studies reported HIV incidence among 
pregnant women ranging from 1.64 (in Uganda and Zimbabwe) to 10.7 per 100 person years (in South 
Africa). Very few studies compared incidence among pregnant and non-pregnant women. Only one 
study of HPV compared incidence and did not find a higher incidence during pregnancy. In four studies 
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comparing HIV risk by pregnancy status, one study found that pregnant women had two-fold increased 
risk while three other studies did not show any difference. In nine studies that examined risk factors for 
STI acquisition during pregnancy younger age was found to be associated with increased incidence.  
Conclusions: There are very limited data on incidence of STIs during pregnancy but existing studies show 
that STI incidence does occur during pregnancy, possibly at high rates for some infections. Younger 
pregnant women and those with partners known to be infected with an STI appear to be at higher risk 






Sexually transmitted infections (STI) are highly prevalent around the globe and are very common 
among pregnant women. The World Health Organization (WHO) estimates that every year worldwide 
there are 448 million new cases of curable STIs including syphilis, gonorrhea, chlamydia and 
trichomoniasis.12 In addition, non-curable STIs, including HIV, herpes simplex virus type 2 (HSV-2) and 
human papillomavirus (HPV) are also highly prevalent. There are now over 34 million people living with 
HIV worldwide and the epidemic continues to disproportionately impact women, particularly in sub-
Saharan Africa (SSA) where 60% of those living with HIV are female.13 The majority of the 536 million 
people estimated to be infected with HSV-2 worldwide are women.2 HPV is the most prevalent STI 
globally and is found in 11.7% of women around the world.14 
STIs are responsible for significant morbidity in women particularly in relation to their 
reproductive health. Left untreated, chlamydia and gonorrhea can lead to infertility, while 
trichomoniasis and syphilis are associated with premature delivery.4,10,15  HPV causes cervical cancer 
which is the third most common cancer in women and the fourth most deadly cancer in women around 
the world.16 HIV is a leading cause of death for women of reproductive age17 and has been shown to 
increase maternal mortality by up to six fold.18 STIs also impact the health of children. Premature 
delivery resulting from infections can cause developmental delays19 and STIs that are transmitted from 
mother-to-child including chlamydia, gonorrhea and syphilis can cause blindness and other cognitive 
impairments,5-7 as well as, lifelong infection and death, in the case of HSV-2 and HIV.8,10,11,20,21 Mother-
to-child transmission (MTCT) of HIV is the most important driver of the HIV epidemic in children – over 
90% of infections in children result from MTCT.13  
Most previous studies examining STIs in pregnant women have described prevalence which has 
been shown to be high in many parts of the world, particularly among young women. Data from 
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Mozambique showed that 75% of pregnant women had at least one STI22 and a 2010 study of pregnant 
women from Zimbabwe found that half were infected with HSV-2, 25% with HIV and 12% with 
trichomoniasis.23 While pregnant women in high resource settings generally have lower STI prevalence 
than those in sub-Saharan Africa, up to 8% of pregnant women in the United States (US) have been 
found to have chlamydia.24,25 Among pregnant adolescents in the US, rates of STIs are much higher; one 
study found that 31% of pregnant 15-19 year olds were infected with either (or both) chlamydia and 
gonorrhea.26 
The question of whether pregnancy increases STI acquisition is important given the large 
numbers of pregnant women who are found to have these infections. STI prevalence data in pregnant 
women provides evidence of the significant health threat these infections pose and highlight the 
importance of routine screening during pregnancy to identify and treat infections in order to protect 
women’s health and to ensure optimal birth outcomes. Prevalence data however do not indicate when 
pregnant women are acquiring infections, whether they are infected prior to or during their pregnancy, 
so do not distinguish whether pregnancy is a time when women may be more likely to acquire STIs. 
Pregnancy has been hypothesized as a time of potentially increased vulnerability to STIs as a result of 
changes in behavioral and biological risk factors.   
STI acquisition may be higher during pregnancy as a result of changes in sexual risk behaviors, 
primarily lower rates of condom use which may result from the absence of contraceptive concerns. If 
pregnant women engage in more frequent unprotected sex, this could put them at higher risk for 
becoming infected with an STI. While existing studies on sexual behaviors of pregnant women have 
found that coital frequency tends to decline over the course of pregnancy,27-29 some data show that 
reported condom use is lower among pregnant women compared to non-pregnant women.30-33 
Pregnant adolescents have also been shown to be less likely to report use of condoms than non-
pregnant teens.34 Male partner sexual risk behavior may also explain high rates of STI incidence during 
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pregnancy. If some men are more likely to acquire new sexual partners during a woman’s pregnancy 
(higher rates of sexual partner concurrency) this could increase men’s risk of incident infection and 
make them more likely to transmit STIs to their pregnant partners. There are limited data on the sexual 
behaviors of male partners during pregnancy. A study in Malawi found that pregnant women reported 
fear of partner sexual concurrency during pregnancy30 however data from the Rakai community cohort 
did not find that men with pregnant partners were more likely to report concurrent sexual 
relationships.35   
STI acquisition during pregnancy could also be facilitated by biological changes that occur as a 
result of pregnancy, specifically cervical and immunologic changes. The lower female reproductive tract 
(FRT) and the mucosal tissue of the cervix are considered the main sites of STI acquisition in women.36-39 
The tissue of the cervix is a critical entryway for STIs, in particular HIV, because of the presence of 
receptor cells which promote infection.36,40 Changes to the cellular composition of the cervix during 
pregnancy, including cervical ectopy, could make women more vulnerable to infection. Cervical ectopy is 
a condition in which the more fragile epithelium cells of the endocervix extend to the outer areas of the 
ectocervix potentially increasing vulnerability to pathogens.36,41 Cervical ectopy is a common condition in 
the developing cervices of adolescents42 and the disproportionately high rates of HIV and other STIs 
among young women are thought to be associated with this condition.36,43,44 Cervical ectopy is also 
commonly found in pregnant women41,45,46 and women using oral contraceptives.43 In cross sectional 
data from a study in Kenya, cervical ectopy was present in half of the pregnant women studied.45 
Cervical ectopy has previously been shown to be associated with increased STI acquisition43 and with 
prevalent HIV infection in pregnant women.45  
In addition to cervical ectopy, there are other cervical changes that occur during pregnancy that 
may increase STI risk. Mouse models have shown that tissue “remodeling” of the cervix begins within 
days of pregnancy as part of the process of cervical ripening necessary for delivery of the fetus.47 In a 
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study of baboons, pregnancy was associated with a thinning of the squamous epithelial tissue and 
higher leukocyte counts in cervical tissues samples which could increase cervical tissue pathogen 
susceptibility.48 Although these studies were conducted in animals and did not specifically aim to 
examine cervical changes in relation to infection risk in humans, the data suggest that there may be 
significant changes occurring during pregnancy, possibly from the early stages of pregnancy, that alter 
the composition of the cervix making it more permeable and potentially more vulnerable to infectious 
agents.  
In addition to histological changes occurring in the cervix, hormonally-regulated immune 
function during pregnancy could also play a role in STI risk. Pregnancy is associated with up to 11-fold 
increases in progesterone concentrations and up to 4.8-fold increases in estrogen levels49 which are 
both known to alter innate and acquired immune function, including cell production, distribution of 
immune cells in the FRT and activation of specific immune cells.50-54 Hormonally-induced immune 
adaptation experienced during pregnancy has been observed in a number of ways including the 
alleviation of symptoms of autoimmune disorders,55 increased vulnerability to and severity of disease 
from pathogens such as influenza,54,56 and evidence of diminished immune response to vaccination in 
pregnant women.54 Pregnancy has thus been described as an immune-compromised state, an 
evolutionary adaptation thought to be necessary for sustaining a “semi-allogeneic” fetus.44,54,56   
Diminished immune capacity during pregnancy may put women at greater risk for STIs.  
However the precise mechanism for this has not been well characterized. Studies have linked hormonal 
fluctuations to alterations in antibody levels in vaginal secretions in women.52 Progesterone in particular 
has been a focus of attention with regard to HIV risk. Increased progesterone levels have been shown to 
increase acquisition of simian immunodeficiency virus (SIV) in primates (SIV is a virus related to HIV that 
is found in primates).57 In vitro and animal studies have also shown that increased progesterone levels 
during pregnancy can reduce the number of natural killer immune cells which are part of the body’s 
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defense against infection.58,59 Progesterone levels may also alter recruitment of immune cells causing 
inflammation of the genital tract which has been associated with risk of STI and HIV infection.60 Finally, 
data are mixed on the impact of progesterone levels on concentrations of CCR5 cells in the cervix.61,62 
CCR5 is considered the most important co-receptor (facilitator) of HIV infection in the FRT and in a small 
study, pregnant women in the second and third trimesters were found to have higher percentages of 
tissue cells in the FRT with CCR5 co-receptors compared to non-pregnant women.62 High progesterone 
levels in pregnant women may also cause the epithelium thinning described above that has been found 
in primates to increase vulnerability to pathogens.57 In addition to viral and bacterial infections, there 
may also be greater susceptibility to parasitic infections during pregnancy as a result of depressed 
immune function and/or increased inflammation.50 Studies in mice have shown greater susceptibility to 
certain parasites during pregnancy.63,64  
Studies showing direct evidence for an effect of immune depression or inflammation on 
infection risk during pregnancy are limited, particularly in humans. A study in mice found that pregnancy 
increased vulnerability to infection with several STIs including gonorrhea, chlamydia and HSV-2.52 
Anderson et al. investigated differences in the immunologic properties of the cervico-vaginal secretions 
of pregnant and non-pregnant women to estimate their anti-HIV capacity.39 Overall, they did not 
observe differences between samples from pregnant and non-pregnant women in terms of the cellular 
response to in vitro HIV challenge.  However significantly higher protein concentrations were found 
among pregnant women (it is not yet clear whether or how elevated protein concentrations might 
increase susceptibility to infection).39 Morrison et al. identified two markers of inflammation and 
immune activation (RANTES and SLPI) that were elevated prior to HIV sero-conversion among pregnant 
women but were not found to be associated with HIV infection in non-pregnant women.65 These data 
suggest that pregnancy may increase risk of HIV infection through inflammation, or that inflammation is 
a marker for risk of HIV acquisition among pregnant women.65  
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The evidence above suggests that there may be behavioral and/or biological changes that occur 
during pregnancy that could lead to increased STI acquisition among pregnant women compared to non-
pregnant women. Incidence data are therefore essential for understanding whether and how pregnancy 
may be a time of increased STI susceptibility in women. In addition to its etiologic importance, this 
information would have bearing on prevention and screening efforts for pregnant women. It is critical to 
understand whether screening offered only once during pregnancy is adequate to identify infections and 
to prevent negative health outcomes for women and children. There is evidence that when women 
acquire infections during pregnancy there is increased risk of MTCT for both HIV66 and HSV-267 
highlighting the importance of prevention of STIs during pregnancy. This paper will describe the findings 
from a systematic review of studies documenting incidence of STIs during pregnancy and comparisons of 
STI incidence among pregnant and non-pregnant women. All prospective studies examining incidence of 






This systematic review to examine incidence of STIs during pregnancy was conducted adhering 
to standard practices as outlined in the Preferred Reporting Items for Systematic reviews and Meta-
Analyses (PRISMA) guidelines.68 Existing peer-reviewed English language papers from any geographic 
region published between 1980 and 2012 were identified through electronic web-based searches of 
three online databases: Ovid/MEDLINE, PubMed and Embase (European database).  
The population of interest was pregnant women and therefore only studies that measured STI 
incidence during pregnancy were included. Incident infection during pregnancy was defined as a positive 
test following an initially negative test during the same pregnancy or incidence of infection after 
treatment for an STI found during the same pregnancy (i.e. reinfection or recurrence after treatment). 
Only studies measuring incidence were considered; this included prospective studies with active 
enrollment and follow-up (cohort studies and secondary analyses of randomized clinical trials (RCT)), as 
well as analyses of repeat STI screening in pregnant women collected through routine health care 
services or as part of a follow-up study. Only studies that measured incidence during pregnancy were 
included; studies were also included if they measured incidence in non-pregnant women as well as 
pregnant women, as were studies which reported incidence of multiple STIs. Studies were excluded if 
they did not include pregnant women, if they did not present data on repeat testing (incidence) during 
the same pregnancy (studies with testing in the postpartum period were excluded) and if they did not 
report findings for individual STIs by type.  Cross sectional studies, those otherwise limited to reporting 
prevalence of STIs among pregnant women, and papers that modeled incidence rather than directly 
observing incidence were excluded.  
Searches were conducted using both medical subject headings (MeSH) and keywords in the 
aforementioned online databases. The search strategy was based on identifying the population of 
15 
 
interest (pregnant women), the outcomes of interest (STIs) and the study designs (follow-up or 
prospective studies and those with repeat testing). Following this search strategy, the MeSH and 
keyword searches included the following terms: (1) population of interest: “pregnancy/pregnant”, 
“pregnancy complications”; (2) outcomes of interest: “chlamydia”, “chlamydia trachomatis”, 
“gonorrhea”, “gonorrhoe”, “trichomonas” “trichomonas”, “trichomonas vaginitis”, “trichomonas 
vaginalis”, “HIV”, “HIV seropositivity”, “HIV-1”, “syphilis”, “chancre”, “neurosyphilis”, “human 
papillomavirus”, “HPV”, “condylomata acuminate”, “genital warts”, “herpes simplex”, “herpesvirus 2”, 
“HSV 2”, “sexually transmitted diseases”, “sexually transmitted”, “STD”; (3) study design/measure of 
association: “incidence”, “acquisition”, “recurrence”, “reinfection”. The search results were further 
refined to exclude papers published prior to 1980 and after 2012, those that described results of studies 
not conducted in humans, those for which the full manuscript was not available in English and papers 
that were a format other than articles or reviews. 
A total of 3,036 unduplicated publications were identified through the search combining results 
from the online databases (Figure 2.1). Of the 3,036 titles found, 454 abstracts were reviewed for 
relevance; the remaining 2,582 titles were excluded based non-relevance, including studies of 
prevalence with no follow-up, studies of infections other than those of interest for this analysis, in vitro 
studies and non-human studies, modeling analyses, clinical guidelines and case series. Of the 454 
abstracts reviewed, 55 full manuscripts met the inclusion criteria and were selected for detailed review 
by the author and an independent additional reviewer.  Studies were divided into disease-specific 
groups and then categorized into tiers according to the study design and procedures for follow-up. Tier 1 
consists of RCTs and prospective studies with active and systematic follow-up. Tier 2 contains studies 
considered to have “passive” follow-up and/or studies with repeat testing during pregnancy that were 
not conducted with systematic follow-up (i.e. no fixed interval of time between testing) and those that 
relied on existing data, such as health facility data or patient held records for testing results. Tier 2 also 
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includes retrospective cohorts and cohorts for which recruitment procedures and exclusions of subjects 
were not fully reported as this may have introduced selection bias. Tier 3 consists of studies that only 
reported reinfection or recurrence among pregnant women who tested positive for curable STIs at 
enrollment and were followed after treatment to measure reinfection with the same STI.  
For the purposes of presenting results from the studies included in the review, a table was 
designed to present information on each study. Table 2.1 is organized by infection type (studies that 
included more than one STI are included in the sections for each individual STI) and by tier. Table 2.1 
includes information on the study location, population and incidence, risk factors for STI incidence and 
comparisons of incidence between pregnant and non-pregnant women for those studies that included 
non-pregnant women. Many of the studies included prevalence data at baseline for the full sample and 
follow-up incidence data from repeat testing on a smaller number of women included in the study; the 
total sample size reported in the study and sample size relevant to the findings on incidence are noted in 
Table 2.1. In studies using multivariable modeling, the factors that were adjusted for are also included.  
For all studies of curable STIs, results were examined to distinguish incidence among two groups of 
women: (1) those testing negative for STIs at the first test during pregnancy and (2) women who had a 
positive test for an STI at their first test during pregnancy, received treatment and were followed to 
measure repeat infection with the same STI (recurrence). It is important to differentiate incidence in 
these two groups as they represent different populations of pregnant women who may have very 
different risk factors and incidence of infection during pregnancy. Women who are positive at the first 
test during pregnancy may be at higher risk of acquiring the same infection during their pregnancy as a 
result of sexual risk behaviors, particularly if they have partners who are positive and do not receive 
treatment. For studies measuring recurrence, it is critical to understand whether the study included test 
of cure (TOC) after treatment for curable STIs – without TOC documentation, recurrence may be 
overestimated and reflect failure of treatment rather than acquisition of new infections. Table 2.1 
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included information on whether the studies reporting recurrence among women who were positive for 
an STI at the first test during pregnancy included TOC procedures.  
For the presentation of findings on incidence of STIs, separate estimates are shown in Table 2.1, 
where possible, for women who were negative at the first test and for recurrence in women who were 
positive at the first test. For some studies of curable STIs the estimated incidence proportions (including 
recurrence) reported by the authors were considered underestimates with regard to the two types of 
incidence of interest noted above (i.e. among women who tested negative at their first test during 
pregnancy and those who were positive at their first test). This occurred in studies in which the total 
number of women with repeat testing was used as the denominator for calculating incidence 
proportions rather than using the subsets of women with negative and positive first test results as 
separate denominators. For studies that calculated incidence proportions using women with repeat 
testing, results as reported by the authors are shown in Table 2.1. In addition, we re-calculated 
incidence proportions (where possible) using the available data in the paper using as the denominator 
women with negative first test results during pregnancy and those with positive first test results in order 
to distinguish new incident infections among women not infected at study enrollment from reinfection 






A total of 18 studies were included: five studies reporting incidence of chlamydia, one of which 
also included gonorrhea, two studies reporting HPV, four studies reporting HSV-2, and seven studies 
reporting HIV incidence among pregnant women. All of the studies reported incident infections (or 
reinfections) among women during the same pregnancy. Overall, eight studies were conducted in the 
US, two in Europe (one each in the Netherlands and Finland) and eight in sub-Saharan Africa (Botswana, 
Kenya, Malawi, Rwanda, South Africa, Tanzania, Zambia and Zimbabwe).  The ages of participants 
enrolled in the studies was not reported uniformly across all studies, two were exclusively in young 
adults (under 25 years) and adolescents (12-18 years of age), while the others included both young and 
adult women (up to age 45). The earliest study data came from 1978 and the most recent from 2009. 
Of the studies reporting chlamydia, four of five were considered tier 2 as a result of reliance on health 
facility records for some or all testing outcome data or because they did not define study selection 
exclusions and/or follow-up procedures.26,69-71 One additional study of chlamydia was considered tier 3 
because it only reported recurrence among women who were infected and then treated after the first 
test during pregnancy.72 Only one study was found reporting outcomes for gonorrhea26 (which also 
reported chlamydia) and was classified as tier 2 as the selection factors were not explained.  The two 
studies of HPV were considered tier 1 as both included active systematic follow-up and fully described 
participant exclusions.73,74 For the studies of HSV-2, one was considered tier 175 and three were 
considered tier 2 studies.76-78 Among the studies of HIV, four were tier 131,33,35,79 and three were tier 2 as 
a result of relying on routinely collected health data.30,32,80 One study of HIV did not report the individual 
figures for incidence (of HIV) among pregnant and non-pregnant women but only report the hazard ratio 
for the comparison of incidence among pregnant and non-pregnant women.32  
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Among the studies reporting outcomes for chlamydia, all five reported incident chlamydia 
infections as proportions. Four studies of chlamydia, all from the US, reported incidence of infection 
among women who were initially negative at the first test during pregnancy, these studies also reported 
recurrence in women who were positive at the first test during pregnancy and then tested subsequent 
to treatment.26,69-71 One additional study of chlamydia only included women who were infected with 
chlamydia at the first test during pregnancy.72 For the four studies reporting new infections among 
women who were negative at the first test during pregnancy, the reported incidence proportions ranged 
from 4% in women with unspecified ages to 9% in women 14-39 years of age.26,69-71 As noted, results 
from studies that used all women with repeat testing as the denominator for incidence proportions 
(women who tested negative and those positive for chlamydia at the first test) were recalculated to 
estimate separate incidence proportions for women with negative first tests and for women who had 
positive first tests. Incidence proportions were recalculated for two studies70,71 while results from one 
study could not be recalculated with the available data in the paper.26 Using the recalculated estimates, 
incidence of acquiring chlamydia among pregnant women who initially tested negative in pregnancy 
ranged from 4% to 11% (the original estimate of 9% for infections in this study was calculated using the 
number of new infections (numerator) divided by the total women at enrollment (including those who 
were positive for chlamydia); the recalculated figure for new infections is higher because the 
denominator is smaller (only women  initially negative) but the numerator remained unchanged).   
All five studies of chlamydia also reported incidence of recurrence or repeat infection. Only one 
of the studies72 had complete documentation of test of cure after the positive initial test while the 
remaining four either had no test of cure or incomplete data on test of cure. Reported incidence 
proportions for recurrence of chlamydia during pregnancy ranged from 9% in adolescents (12-18 years) 
to 32% in women of unspecified ages. Recurrence estimates were recalculated for one study,70 
increasing the upper range of estimates to 65% in women 14-39 years of age; estimates from a fourth 
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study could not be recalculated using the available data in the paper.26  Only one study of incident 
chlamydia during pregnancy reported risk factors and found that black race, age <25 years, being single 
and not completing high school were associated with acquiring chlamydia during pregnancy in the US .69 
No studies of chlamydia compared incidence among pregnant and non-pregnancy women.  
Only one study reported outcomes for incidence of gonorrhea during pregnancy which was 
conducted in US adolescents (12-18 years of age).26 This study reported incidence as a proportion. As 
noted in Table 2.1 and explained above for chlamydia outcomes, the incidence proportion of gonorrhea 
among pregnant women in this paper was calculated using all women with two tests during the same 
pregnancy as the denominator, rather than calculating separate incidence for women with initially 
negative tests and for those positive at the first test during pregnancy. The authors reported that out of 
all pregnant women with repeat testing, 4% had a negative test followed by a positive test result 
whereas 3% had two positive test results (there was no test of cure in this study).26 The authors did not 
present separate incidence proportions for women with negative and positive first tests and it was not 
possible to recalculate the incidence in this way using the data provided in the paper.   
Two studies reported HPV incidence among pregnant women, one in women under 25 years of 
age and the other in women 18-29 years of age. One study measured acquisition of both low and high 
risk HPV types73 while the other reported only high risk types74 (both studies defined high risk genotypes 
of HPV as 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68 and 73 as these types have been linked to 
cervical cancer). The two studies of HPV incidence included women with and without HPV at enrollment 
and measured acquisition of new HPV types during pregnancy (one study of HPV also included a 
comparison group of non-pregnant women74).  In the study from Uganda, 42.9% of pregnant women 
acquired a new HPV infection, 15.2% acquired new low risk HPV types and 30.5% acquired new high risk 
HPV types.73 This study also found that younger age was associated with acquiring new HPV infections 
during pregnancy. In the study from Holland, 11.8% of pregnant women acquired a new high risk HPV 
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infection.74 This study also examined HPV acquisition among non-pregnant women and found that 
15.7% acquired new high risk HPV infections during follow-up. The authors reported that there was no 
significant difference in the proportions of pregnant and non-pregnant women who acquired HPV  in 
nonlinear mixed modeling adjusted for age, education, smoking, history of STI and condom use 
(p=0.57).74  
There were four studies reporting HSV-2 incidence among pregnant women. One study 
conducted among women with known HSV-2-infected partners found that 14% of pregnant women 
acquired HSV-2. The authors reported that after adjusting incidence estimates for duration of pregnancy 
the HSV-2 incidence would have been 20%.75 This study did not include a comparison of non-pregnant 
women. Incidence of HSV-2 in three studies among pregnant women with unknown partner status was 
much lower – one study of 558 women in xxx found that no pregnant women acquired HSV-2.76 Boucher 
et al. reported that 0.25% of 1,580 women who were negative for HSV-2 at the first test during 
pregnancy became infected77 and Brown et al. found incidence of 0.9 per 100 person years in 7,046 
pregnant women in Seattle, Washington.78 No studies of HSV-2 incidence compared pregnant and non-
pregnant women.  Two studies examined risk factors for incidence of HSV-2 during pregnancy; one 
found that shorter duration of partnership was associated with higher HSV-2 risk 75 while the other 
found no significant predictors.78  
The largest number of studies reporting STI incidence among pregnant women were found for 
HIV. All seven studies were conducted in sub-Saharan Africa; incidence of HIV during pregnancy was 
reported in six of the seven studies and four studies compared HIV incidence among pregnant and non-
pregnant women. HIV incidence in pregnant women ranged from 1.64 (in Uganda and Zimbabwe) to 
10.7 per 100 person years (in South Africa).30,31,33,35,79,80 Among the three studies that reported HIV 
incidence among non-pregnant women, the range of estimates was 1.1 (Uganda) to 3.0 per 100 person 
years.31,33,35 Only one of the four studies comparing incidence among pregnant and non-pregnant 
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women found a higher risk among pregnant women; after adjusting for behavioral risk factors, including 
male partner risk behavior, pregnant women in Rakai, Uganda were found to have two fold increased 
risk of HIV infection compared to non-pregnant women (risk ratio: 2.0, 95%CI 1.3-3.1).35 Three other 
prospective cohort studies failed to find increased HIV risk that was statistically significant among 
pregnant women after adjusting for potential confounding.31-33 However, in the study of HIV sero-
discordant couples, pregnant women with HIV-infected male partners did appear to have higher risk 
(hazard ratio: 1.7) but the p-value was 0.08; it should be noted that the study only included 1,085 
couples with an HIV-uninfected woman.31 Risk factors for HIV infection were reported in five studies and 
included both demographic characteristics (younger age, never married and lower parity), behavioral 
risk factors (multiple, new and high sex partners, and alcohol use) and clinical characteristics (recent STI, 
bacterial vaginosis and other medical symptoms).30,32,33,35,79  One study reported no significant risk 






There are very limited data on incidence of STIs during pregnancy and even fewer data that 
compare risk between pregnant and non-pregnant women. Only 18 studies were found reporting new 
infections among pregnant women and five studies were identified that compared incidence of STIs in 
pregnant and non-pregnant women. The data included in this review were limited to only five types of 
infections; no studies were found on trichomoniasis and syphilis, STIs that can have significant impact on 
birth outcomes, was well as the health of women and children. The lack of data overall and on specific 
STIs highlights the need for more studies in order to describe STI incidence during pregnancy and to 
identify whether pregnancy increases the risk of STI acquisition. Although the data are limited, they 
suggest that women do acquire STIs during pregnancy although incidence varied within and across 
infection types, populations and geographic setting.  
The studies included in this review also varied in the types of incidence measures reported, from 
proportions to rates using person time, making comparisons somewhat challenging. Highest incidence 
was found for HPV73 and chlamydia70 although some studies of chlamydia showed low proportions of 
pregnant women infected.71 Studies in which partners were known to be infected with HSV-275 and HIV31 
showed higher rates of acquisition in pregnant women compared to studies where partner status was 
not known. Most of the studies measuring repeat infections of curable STIs (chlamydia and gonorrhea) 
had limited data on test of cure so while the findings are suggestive that women who have an STI at the 
first test during pregnancy may be at very high risk for a repeat infection during pregnancy, they may 
also indicate that pregnant women receive inadequate STI treatment. 
Overall the quality of evidence on incidence of bacterial STIs in particular is lacking. None of the 
studies of chlamydia or gonorrhea included full descriptions of follow-up and exclusion procedures and 
the studies tended to focus on reinfection (without test of cure in most cases) rather than newly 
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infected pregnant women. In addition, most studies only included characteristics of women who were 
included in the analyses (i.e. those with complete data at baseline and follow-up) and did not report 
characteristics of women who did not have repeat testing data and were excluded. The lack of 
information on women missing testing data is significant as selection bias may have been introduced 
and without further information on who was excluded, the potential bias is difficult to assess. It is 
possible that if women with more complete data (repeat testing) were less likely to have infections 
compared to those who only had one test or no testing data during pregnancy, the reported incidence 
proportions may have been underestimated and the STI incidence among pregnant women may in fact 
be higher. Conversely if women who were deemed to be at higher risk for STI acquisition were more 
likely to have repeat testing through targeted screening or study enrollment, the incidence reported 
may be an overestimate.  
There are also additional data quality concerns with regard to the evidence presented in this 
review. In relation to data on recurrence or repeat infections among pregnant women, only one of five 
studies of chlamydia and no studies of gonorrhea included test of cure to establish that women were 
free of infection before being retested. This may have led to overestimates of the incidence of 
recurrence of infections among pregnant women.  In addition, only two studies tested male partners for 
STIs, some others included information collected from women about their partners’ status and still 
others had no information on partner STI status or efforts to provide treatment for infected partners. 
Information on partner STI infections, while difficult to collect, is important for understanding the 
estimates of risk as women with infected partners are likely to have high rates of infection. Many of the 
studies that reported incidence as proportions had very small sample sizes, some with less than 100 
women. Given the small sample sizes, data quality issues, and geographic diversity of the studies, the 




Despite the limited evidence and limitations of many of the studies, there does appear to be 
continued incidence of STIs during pregnancy which suggests that repeat screening would benefit 
women, particularly those at highest risk for acquiring STIs during pregnancy. Unfortunately few studies 
examined risk factors for STIs during pregnancy so that it is difficult to know how repeat screening 
efforts could be targeted towards high risk women. Younger age (less than 25 years) does appear to 
increase STI risk among pregnant women30,32,33,35,69,71-73,79 and may result from biological factors, such as 
cervical ectopy,36,43,44 or from higher rates of behavioral risk factors, including lower reported rates of 
condom use.34 Further studies of pregnant adolescents could help to understand the potential 
interaction between pregnancy and younger age. The data also showed that women with infected 
partners may have higher risk of acquiring STIs.31,75 This finding underscores the need for expanded 
efforts to test partners and to provide treatment for curable STIs, as well as the need to enhance 
counseling for all pregnant women around safer sex practices. Although the number of studies was 
limited, it appeared that the risk of acquiring a new high risk HPV type was higher in sub-Saharan Africa 
compared to the Netherlands among young pregnant women.73,74 This finding is in keeping with data 
showing higher prevalence of STIs in sub-Saharan Africa and other low resource settings.1,14  
There is very little direct evidence addressing the question of whether pregnant women are at 
higher risk of acquiring STIs compared to non-pregnant women. Only five studies were found that 
directly compared incidence among pregnant and non-pregnant women, one on HPV and four on HIV 
(no studies were found reporting comparisons by pregnancy for bacterial or parasitic STIs). Among the 
studies comparing HIV incidence in pregnant and non-pregnant women, only one found that pregnant 
women were at increased risk.35 A closer reading of the studies on HIV highlights the complexity of 
evaluating whether and how pregnancy may increase HIV risk. In three of the studies of HIV, pregnancy 
was associated with decreases in many of the risk factors associated with HIV acquisition such as 
multiple sexual partners and high risk sex for drugs or money.32,33,35 Pregnant women did however 
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report more sex acts without the use of condoms which may have led to increased acquisition. More 
data are needed to evaluate the question of whether and how pregnancy may increase STI risk, not only 
for HIV but also for common curable STIs.  
Overall this review found that there are very limited data on incidence of STIs during pregnancy. 
The studies included in this review show that STI incidence does occur during pregnancy, possibly at high 
rates for some infections. Identifying pregnancy as a time of increased risk for STIs could lead to more 
effective interventions to reduce overall incidence of STIs among women. Reducing the number of 
maternal infections during pregnancy would not only decrease the impact of STIs on women’s health 
and improve birth outcomes, it would also decrease vertical transmission, particularly for HIV; incident 
HIV infections during pregnancy are accounting for a growing proportion of the new HIV infections 
among children around the world, including in the US.81-86 While there is no evidence regarding incident 
infection and MTCT in relation to other STIs, it is possible that, as with HIV, there may be higher risk of 
congenital infection with gonorrhea and chlamydia when women are infected during pregnancy. More 
research is needed to more fully describe STI incidence during pregnancy and to compare incidence 
during pregnancy to non-pregnant periods in order to establish whether and how pregnancy may make 






















*The only paper with data on gonorrhea also reported data on chlamydia  
 
Initial search of search of terms: 
MEDLINE/PubMed (N=3,581) 
Embase (N= 3,316) 
 After exclusions: 
MEDLINE/PubMed (N=2,829) 
Embase (N= 2,149) 
Exclusions: 
Non-English (N=942) 
Non-human study (N=371) 
Before 1980 or after 2012 (N=329) 







Final collection of papers for title 
review (N=3,036) 
Abstract review (N=454) 
Excluded (N=2,584) based on review of 
titles indicating inappropriate study design 
and/or study population  
Full paper review (N=55) 
Excluded (N=399)  
Included studies (N=18*) 
Excluded: 
Did not included pregnant women (N=4) 
Did not include incidence measures 
(prevalence, modeled incidence or not 
reported for individual STIs)(N=19) 
Incidence measured postpartum (N=12) 
Full text not available (N=2) 







Table 2.1 Studies with incidence of STIs during pregnancy  
Author Title Setting Years N 
Study 
population Incidence during pregnancy 
Comparison with 
non-pregnant  
























at <20wks (no 
age range 
specified) 
5.7% of pregnant women negative 
at first test during pregnancy 
acquired chlamydia (109 of 1929) 
Recurrence: 32% of pregnant 
women with positive first test had 
positive subsequent test (78 of 
244)  
No test of cure 





high school  
race, age (<25 or 
above), marital 
status, education 






























4%* of pregnant women negative 
at first test during pregnancy 
acquired chlamydia (4 of 95 
women)  
Recurrence: 9%* of pregnant 
women with positive first test had 
positive subsequent test (9 of 95)  
Incomplete test of cure data 
*Incidence proportion using all 
women rather than only those 
with negative/ positive  first test  
(see note below table), data in 
paper in sufficient to re-calculate 








Chlamydia continued  
Heggie
70














years of age 
attending 
prenatal care 
at one hospital 
in Cleveland, 
Ohio 
9%* of pregnant women negative 
at first test during pregnancy 
acquired chlamydia (12 of 131)  
Recurrence: 13%* of pregnant 
women with positive first test had 
positive subsequent test (17 of 
131)  
*Incidence proportion using all 
women rather than only those 
with negative/ positive first test; 
recalculated incidence using 
figures from paper:  
12 of 105 (11%) had negative first 
test and subsequent positive test 
Recurrence: 17 of 26 (65%) had 
positive first test and subsequent 
positive test  
No test of cure 
N/A Not reported Not reported 
Miller
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and under 19) 
3.9%* of pregnant women 
negative at first test during 
pregnancy acquired chlamydia (29  
of 752) 
Recurrence: 13.3% of pregnant 
women with positive first test had 
positive subsequent test (14 of 
105) 
*Incidence proportion using all 
women rather than only those 
with positive first test; 
recalculated incidence using 
figures from paper:  
29 of 647 (4.5%) had negative first 
test and subsequent positive test 
No test of cure   














Tier 3 (Repeat testing) 
Miller
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16.8% of pregnant with a positive 
first test and test of cure had 
second chlamydia infection during 
pregnancy (25 of 149) 
N/A younger age  Not reported 
 
Author Title Setting Years N 
Study 
population Incidence during pregnancy 
Comparison with 
non-pregnant  




























cohort at one 
Washington, 
DC hospital 
4%* of pregnant women negative 
at first test during pregnancy 
acquired gonorrhea (4 of 95)  
 
Recurrence: 3%* of pregnant 
women with positive first test had 
positive subsequent test (3 of 95)  
 
Incomplete test of cure data 
 
*Incidence proportion using all 
women rather than only those 
with negative/ positive  first test  
(see note below table), data in 
paper in sufficient to re-calculate 









Author Title Setting Years N 
Study 




Risk factors for 
incidence Adjustment 




























at one hospital 
in Kampala, 
Uganda 
42.9% (95%CI: 33.2-52.9) of 
pregnant women acquired new 
HPV type (45 of 105 women 
acquired new HPV type not found 
at first test); 15.2% (95%CI: 9.0-
23.6) acquired new low risk HPV 
type (16 of 105); 30.5% (95%CI: 
21.9-40.2) of pregnant women 
acquired new high risk HPV type 
(32 of 105 women) 









Holland 2007 102 Women 18-29 





community in 3 








11.8% of pregnant women 
acquired a new high risk type of 
HPV (6 of 51 women found to 
have a new high risk HPV type not 
found at first test); among non-
pregnant women 15.7% were 
found to have a new high risk HPV 
type not found at first test (8 of 
51) 
Incidence of 






ratio (aOR) 1.09 
(95%CI 0.20-
5.82)  








Author Title Setting Years N 
Study 




Risk factors for 
incidence Adjustment 





























14% of pregnant women acquired 
HSV2 (17 of 125 found to have 
HSV-2 antibodies at second test); 
estimate after adjustment for 










































during 3 month 
period at one 
hospital in 
Finland  
No women acquired HSV-2 during 
pregnancy 

































years of age 
attending one 
health facility in 
California 
0.25% of pregnant women 
acquired HSV-2 (4 of 1580 women 
found to have HSV-2 antibodies at 
second test) 



















prenatal care at 





HSV-2 incidence in pregnant 
women: 0.9 per 100 person years 
(19 of 2033 found to have HSV-2 
antibodies at second test); 
adjusted rate sero-conversion risk 
over all during pregnancy 1.4 +/- 
0.3 
N/A no significant 
predictors 









Author Title Setting Years N 
Study 




Risk factors for 
incidence Adjustment 
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2188 Women 15-49 





HIV incidence in pregnant women: 
2.3 per 100 person years (23 
pregnant women with 997 py of 
follow-up seroconverted during 
pregnancy); incidence in non-
pregnant (non-lactating women): 
1.1 p/py (275 women contributing 
24,161 py) 






















(reported by both 

























at four health 





under 17 and up 
to and over 40) 
HIV incidence in pregnant women: 
4.32 per 100 per person years (16 
of 372 women seroconverted 
during pregnancy) 





















































health or STI 
services at 
health facilities 
in Uganda and 
Zimbabwe  
HIV incidence in pregnant women: 
1.64 p/py (13 women contributing 
793 py seroconverted during 
pregnancy); incidence in non-
pregnant (HC use) women: 2.94 
p/py (126 women contributing 
4288 py); incidence in non-
pregnant (no HC use) women: 
2.70 p/py (39 women contributing 
1447 py) 


























































years of age) 
recruited from 
health centers in 
seven countries 
HIV incidence in pregnant women: 
7.35 p/py (12 women 
contributing347 py seroconverted 
while pregnant); incidence in non-
pregnant women 3.01 p/py (46 
women contributing 2905 py) 
HIV incidence in 
pregnant vs. 
non-pregnant 
women: HR 1.71 
(95%CI: 0.93-
3.12) 
not reported randomization 




































HIV incidence in pregnant women: 
4.0 per 100 person years (95%CI: 
2.2-7.2) (11 of 1087 





































(no age range 
specified, 
included women 
<20 and >40 
years) 
HIV incidence in pregnant women: 
10.7 per 100 person years (72 of 
2377 women seroconverted 
during pregnancy) 
N/A no significant 






















1358 Women 16 





testing clinics  
Not reported HIV incidence in 
pregnant vs. 
non-pregnant 


















*Studies where incidence proportion reported in paper was calculated using all women with repeat testing were recalculated to estimate proportions for women with 









Sexual behavior and vaginal practices during pregnancy: a comparison of pregnant and non-pregnant 






Background: Data suggest that pregnant women, particularly young pregnant women and those in 
resource limited settings have high prevalence of sexually transmitted infections (STI). We examined 
changes in sexual risk behaviors and vaginal practices during pregnancy. 
Methods: Data for the analysis came from the Methods for Improved Reproductive Health in Africa 
(MIRA) study which was conducted in South Africa and Zimbabwe 2003-2006. HIV-negative women aged 
18-45 years were included in this analysis. We used a cross-over design comparing behaviors during 
pregnant and non-pregnant periods in women with a lab confirmed pregnancy during follow-up. 
Modified Poisson regression models were fitted to estimate and compare sexual risk behaviors and 
vaginal practices during pregnant and non-pregnant periods.  
Results: Among the 4,948 women who were <45 at enrollment, 483 (10.1%) women who had a lab 
confirmed and known pregnancy and adequate follow-up time were included in the analysis. Compared 
to periods when women were not pregnant, pregnancy was associated with less frequent sex (adjusted 
risk ratio (ARR) 0.9;95%CI 0.8-1.0) but more unprotected sex acts (ARR 1.3;95%CI 1.2-1.5). Pregnancy 
was also associated with decreased reporting of other sexual risk behaviors including anal sex, multiple 
sexual partners and sex in exchange for drugs or money (ARR 0.7;95CI 0.6-0.9). Visits that occurred 
during pregnancy included lower reports of all types of vaginal practices including washing, wiping and 
insertion of cotton, cloth or paper for non-menstruation related reasons.  
Conclusion: We found that pregnancy decreased sexual activity but increased the risk of sex without a 
condom. The frequency of other high risk sexual behaviors known to be associated with STI acquisition 
was lower during pregnancy. Vaginal practices were also less common during pregnancy. These data 
present a complicated picture of risk for STIs during pregnancy as a result of increased unprotected sex 





Epidemiologic data suggest that pregnant women, particularly young pregnant women and 
those in resource limited settings, have high prevalence of sexually transmitted infections (STI).  Data 
from East and Southern Africa have shown that up to 7% of pregnant women are infected with 
chlamydia, 4% have gonorrhea88, up to 15% are infected with syphilis89 and more than a quarter of all 
pregnant women in East and Southern Africa have been shown to have trichomoniasis.88 Herpes simplex 
virus type-2 (HSV-2) and human immunodeficiency virus (HIV) have also been commonly found in many 
pregnant women in sub-Saharan Africa (SSA). A 2010 study from Zimbabwe found that half of pregnant 
women were infected with HSV-2 and 25% were HIV-infected.23 In South Africa, antenatal HIV 
prevalence in 2010 was over 30%. 90 Pregnant women in the United States (US) have also been found to 
have high STI prevalence; up to 8% of pregnant women may be infected with chlamydia 24,25 and 
pregnant adolescents have been shown to have combined prevalence of chlamydia and gonorrhea of up 
to 31%.26 These figures are higher than those in a nationally representative survey of youth 18-26 years 
of age in the US which found 4.7% of adolescent females to be infected with chlamydia and 0.4% to be 
infected with gonorrhea.91 
STIs cause considerable morbidity in women, with infections which can lead to infertility and 
other adverse health outcomes, including mortality in the case of HIV. 10,15 STIs are of particular concern 
during pregnancy as they cause birth complications including pre-term delivery and premature rupture 
of membranes which can be life threatening for both pregnant women and infants.10 In addition, some 
infections can be transmitted to infants through mother-to-child transmission (MTCT) causing congenital 
defects such as blindness and developmental disabilities, and in the case of HIV and HSV-2, lifelong 
infection and mortality for children perinatally infected.10,11 Evidence on HIV and HSV-2 suggests that 




Most studies of STIs in pregnant women have reported prevalent infections identified at routine 
screening during antenatal care. These data are important for assessing the magnitude of the STI 
epidemic among pregnant women however they do not provide information on etiology and timing of 
infection. There have been few studies examining when pregnant women acquire STIs – prior to, 
concurrent with or during their pregnancies. Evidence regarding whether and how pregnancy may be a 
time of increased risk for STI infection is very limited and questions remain regarding biological and 
behavioral mechanisms that may increase women’s STI susceptibility. In order to understand more 
about the risk of STI acquisition during pregnancy and the factors that may contribute to incidence 
during this period, more information is needed on sexual risk behaviors during pregnancy.  
Sexual risk behaviors and factors that have been previously associated with STI prevalence 
include sex without a condom (unprotected sex), frequency of sex, concurrent sexual partnerships, 
number of lifetime sex partners, transactional or “exchange” sex (for shelter, money or drugs) and 
engaging in anal sex without a condom have been associated with STI acquisition.93-97 There have been 
few examinations of whether these sexual risk behaviors change during pregnancy, particularly in low 
resource settings where STI prevalence is high. Existing studies on sexual behaviors of pregnant women 
have found that coital frequency tends to decline over the course of pregnancy with the least amount of 
intercourse in the third trimester.27-29 Data from a cross sectional survey of women in Malawi showed a 
decline in frequency of intercourse over the course of the pregnancy with pregnant women overall 
reporting fewer sex acts than non-pregnant women 30 whereas a study from South Africa showed 
relatively high rates of sexual activity in late pregnancy and less frequent sex in the post-partum period. 
In the South African study, 67% of women 24-30 weeks gestation reported sexual activity in the previous 
week whereas only 49% reported recent sexual activity at 3 months post-partum.98  
Sex without a condom has been more frequently reported by pregnant women compared to 




transmission appear to be less common among pregnant women including concurrent sexual 
partnerships and transactional sex. 32,33,35 There are few data on the sexual risk behaviors of male 
partners of pregnant women which is also a critical factor in women’s STI acquisition. Pregnant women 
in Malawi reported greater fear of male partner infidelity during pregnancy than non-pregnant women. 
30 However, in studies that have data from male partners, men in South Africa and Uganda were not 
more likely to report additional sex partners during pregnancy.35,98   
In addition to sexual risk behaviors, vaginal practices have been identified as a potentially 
important mechanism for STI acquisition. Vaginal practices include a broad array of behaviors such as 
douching or cleaning the vagina which may be done for hygienic reasons or for pregnancy prevention. 
Vaginal practices also include behaviors related to altering the vagina, such as inserting absorbent 
materials to tighten or dry the vagina which is considered sexually desirable in some settings.99,100 
Vaginal practices are commonly reported in studies conducted in sub-Saharan Africa and as a result have 
been studied as a potential causal factor in women’s STI risk 99-101, most notably in regard to HIV.  
However, limited data have also shown vaginal practices to be associated with increased risk for 
chlamydia 102 and other STIs.103 In a meta-analysis including over 20,000 women, use of cloth or paper, 
inserting materials to tighten or dry the vagina and cleaning with soap were associated with increased 
HIV infection.101 It is not fully understood how vaginal practices increase STI and HIV risk; it may be 
through abrasions to vaginal tissue or through alteration of the vaginal pH level which causes bacterial 
vaginosis (BV). BV has been estimated to increase women’s susceptibility to HIV by 40-70%.101,104 It has 
also been documented that some women engage in vaginal practices more often when they have 
transactional sex 100 which could increase risk if transactional sex partners are more likely to be infected 
with STIs or the sex involves more risky behaviors.  
There are few studies describing vaginal practices among pregnant women. In a cross sectional 




antenatal medical visits and 98% reported that it was a common practice.105 Data on other types of 
vaginal practices have not been widely reported among pregnant women. Given the limited data on 
vaginal practices during pregnancy and because they are considered an important modifiable behavioral 
risk factor for HIV infection, and potentially other STIs, it is critical to understand what role they may 
play in STI risk for pregnant women.  
In light of the high rates of STIs found among pregnant women, the risks associated with 
incident infections during pregnancy and the lack of data on whether pregnancy changes risk factors for 
acquiring STIs, more information describing the impact of pregnancy on behaviors associated with STI 
acquisition is needed. Using data from a randomized clinical trial (RCT) which assessed the diaphragm 
for HIV prevention in women, self-reported data on sexual and vaginal practices were examined to 
explore the impact of pregnancy on risk factors for STI acquisition. The analysis compares sexual risk 
behaviors and vaginal practices reported by the same group of women during pregnant and non-








The data for this analysis come from the Methods for Improved Reproductive Health in Africa 
(MIRA) study, an open-label RCT of the diaphragm and lubricant gel for prevention of HIV infection in 
women which has been previously described.106 Briefly, the trial enrolled HIV-negative women 18 years 
and older in Zimbabwe and South Africa from 2003 to 2006. The trial compared incident HIV infection in 
women who were randomized to one of two arms: the intervention arm received a clinician-fitted 
diaphragm, lubricant gel and condoms; the control arm received condoms only (both arms received 
counseling about behavioral risk reduction). As previously reported, the trial found low use of the 
diaphragm and did not find a benefit from the diaphragm for HIV prevention; the relative hazard in the 
intent to treat analysis between the diaphragm and condom vs. condom-only arm was 1.05 (95%CI 0.84-
1.32).106  
Study procedures 
During 12-24 months of follow-up (depending on when women were enrolled in the study), 
study participants attended quarterly visits with a clinician-administered interview on recent medical 
history, pregnancy and routine testing for chlamydia, gonorrhea, trichomoniasis and HIV at all visits and 
other STI testing based on symptoms (with treatment as needed). Study visits also included physical 
examinations when clinically indicated. Diagnosis of chlamydia, gonorrhea and trichomoniasis was 
assessed using urine samples and confirmed with DNA polymerase chain reaction (PCR) testing (Roche 
Pharmaceuticals, Branchburg, NJ, USA). HIV testing was conducted with two rapid tests on whole bloods 
samples from finger prick or venipuncture; Determine HIV-1/2 (Abbot Laboratories, Tokyo, Japan) and 
Oraquick (Orasure Technologies, Bethlehem, PA, USA) with discordant rapid tests confirmed with ELISA. 




during the study. All women testing positive for HIV were referred for care and treatment services and 
continued follow-up in the study. Women with positive tests for curable STIs were given treatment. 
At each visit, participants reported sexual activity, use of contraception and condoms, vaginal 
practices and diaphragm use (for those in the intervention arm) through clinician administered 
interviews and audio computer-assisted self-interviewing (ACASI). At all study visits, participants 
received risk reduction counseling and unlimited supplies of male condoms. Women who became 
pregnant during study follow-up continued in the study during and after pregnancy; those in the 
intervention arm were free to choose whether to discontinue use of diaphragm and gel during 
pregnancy. Participants who became HIV infected were referred to HIV care and treatment services. The 
MIRA trial was approved by institutional review boards (IRB) at the University of California at San 
Francisco, Research Council of Zimbabwe, the Medicines Control Authority of Zimbabwe, Biomedical 
Research Ethics Committee of the University of KwaZulu-Natal, Human Research Ethics Committee of 
the University of the Witwatersrand, and Western Institutional Review Board. The study was externally 
monitored and audited by Quintiles Corporation. The study is registered with ClinicalTrials.gov, number 
NCT00121459.   
We examined the association between pregnancy status and self-reported sexual behaviors for 
women in the MIRA trial with a documented pregnancy using a cross-over design restricting the analysis 
sample to only those women with a pregnancy during follow-up. The current secondary analysis of de-
identified data was deemed non-human subjects research by the Columbia University IRB. 
Participant inclusion criteria for analysis 
Only women in the MIRA trial who were HIV-negative and between the ages of 18 and 45 years 
of age at enrollment were included in this analysis of pregnancy (women older than 45 were excluded 




vaginal practices associated with pregnancy, follow-up visit data were examined only for women who 
had a lab confirmed and known pregnancy. Women who reported a pregnancy but did not have lab 
confirmation and those women who had a lab confirmed pregnancy but did not know about their 
pregnancies were excluded from further statistical analyses. In addition, women were only included in 
the analysis of follow-up data if they had at least one visit during a pregnancy and had a visit when they 
were not pregnant within 60 days prior to the pregnant visit. Women who only had non-pregnant visits 
after their pregnancy visit or who had had a non-pregnant visit greater than 60 days prior to the 
pregnancy visit were excluded.  
 
Follow-up visit inclusion criteria 
For the analyses of pregnant and non-pregnant visits, only scheduled quarterly follow-up visits 
with both laboratory and self-reported behavior data were examined; additional, off-schedule visits 
were excluded. Visits after HIV diagnosis for women who seroconverted were excluded as sexual and 
vaginal practices may have been influenced by the HIV diagnosis. In addition, visits that were more than 
6 months apart were excluded (women’s follow-up time was truncated at the last visit before a 6 month 
gap) in order to ensure that the comparison between pregnant and non-pregnant visits were in close 
proximity. For women with multiple pregnancies, only visits prior to and during the first pregnancy were 
included.  
Pregnancy status  
Pregnancy status was measured in two ways in the MIRA study: laboratory testing and self-
report. At all quarterly study visits a urine pregnancy test was administered  and women were asked 




as the date when they first knew they were pregnant. Women who became pregnant also reported 
resolution of pregnancies, including deliveries, miscarriages and terminations.  
For the analysis, data from pregnancy tests and self-report of pregnancies were used to classify 
pregnancy status for the interval preceding each visit (pregnancy status at the visit was assigned to the 
interval prior to the study visit). Because this analysis is interested in changes in behaviors resulting from 
pregnancy, determination of pregnancy status was contingent on women having knowledge of 
pregnancy prior to the study visit based on the assumption that in order for women to change behavior 
in response to pregnancy, they must be aware of the pregnancy. Specific information on how pregnancy 
exposure was assigned to visits/time intervals is below. 
 Visits classified as pregnant:  
o Visits with a positive lab pregnancy test and report of knowledge of pregnancy at least 
two weeks prior to visit  
o Visits occurring within first six weeks after a reported delivery date  
 Visits classified as non-pregnant:  
o Any visit with a negative lab pregnancy test, including visits where women were lab 
negative and did not report a pregnancy and also visits where women were lab negative 
but did report a pregnancy between visits (including reports of miscarriages and 
terminations in the period between the prior and current visit) 
o Visits with positive lab pregnancy tests but no report of knowledge of pregnancy before 
visit (including visits with report of knowing on same day as visit or less than two weeks 
prior to visit); the next scheduled visit after pregnancy was coded as a pregnant visit 
Visits that occurred between 6 weeks and 12 months after a reported delivery were considered 




the period after delivery and the focus of this analysis is on comparing non-pregnant periods prior to a 
pregnancy and the changes that occur during pregnancy.98,107 
Gestational age 
Visits that were identified as occurring during pregnancy were further classified according to the 
estimated gestational age at the visit. The date of last menstrual period was not collected for the study 
and therefore the first date women reported knowing of their pregnancy or the first positive pregnancy 
test were used to estimate gestational age. Delivery dates were also used to estimate gestational age 
(assuming a 40 week pregnancy) for women who reported the date of delivery. Gestational age was 
estimated in weeks and then visits grouped by trimester with visits in the first 28 weeks of pregnancy 
considered to be in the first/second trimester (“early pregnancy”) and visits after 28 weeks and up to 6 
weeks postpartum in the third trimester (“late pregnancy”) (behavior reported at visits in the first 6 
weeks postpartum were considered to have occurred mainly during pregnancy for the visit interval).  
Hormonal contraceptive use status 
Non-pregnant visits were classified according to hormonal contraceptive use as reported by 
women at all quarterly study visits. Hormonal contraceptive use was categorized into three groups: oral 
contraception (pills) (including combined and progesterone only pills), injectables (including Depo-
Provera and Net-N) and no hormonal contraceptive use which included visits where women only 
reported condom use, natural contraceptive methods or no contraceptive use.  
Sexual risk behaviors and intra-vaginal practices 
The aim of the analysis was to examine sexual risk behaviors and vaginal practices during 
pregnant and non-pregnant periods. Sexual behavior data was collected at enrollment and at each 
follow-up visit through ACASI. The information collected at each quarterly visits included the frequency 




or drugs, anal intercourse (with or without a condom), and new and multiple sexual partners. This 
information was reported by women for the interval between visits (3 months); most questions related 
to the entire visit interval, for instance how often they used condoms during the entire visit interval 
(every time, more than half the time, less than half the time, never), while some questions gave specific 
time frames such as condom use at their last sex act.  
Reported sexual risk behaviors were examined individually as dichotomous variables. In 
addition, a dichotomous variable was created to identify “high risk sex” indicated if women reported any 
of the following: vaginal sex without a condom, exchange sex, any anal intercourse, having two or more 
partners and having a new sex partner. Women also reported on male sexual partner behaviors at 
enrollment, including having a known HIV-positive partner, a partner who was away from home for >1 
month, suspecting or knowing that a partner had other sex partners, partners use of alcohol or drugs 
before sex and partners who forced sex. At follow-up visits, women only reported whether male 
partners were known or suspected to have other partners and abuse by partners. A indicator variable 
was created at enrollment to identify women with male partners who were “high risk”, those who were 
HIV+, away for more than 1 month, had known or suspected other partners and those who used drugs.  
Self-reported data on vaginal practices was also collected at all quarterly follow-up visits. 
Vaginal practices were classified into three categories: vaginal washing, wiping or insertion of products 
not related to menstruation. Frequency of the three types of vaginal practices as reported by women 
was assessed during categories for reported daily, weekly, monthly or none, and a summary variable 
indicating any (or no) engagement in each of the three vaginal practice behaviors.   
Statistical analysis 




Descriptive statistics were used to compare demographic characteristics and frequency of 
reported sexual behaviors and vaginal practices at enrollment for all women 18-45 years of age in the 
MIRA trial. Women with lab confirmed and known pregnancies were compared to women with no 
reported or lab confirmed pregnancies. Differences in characteristic and behaviors reported at 
enrollment were compared between women with and without pregnancies using chi-square tests for 
categorical variables and Wilcoxon tests for continuous variables.  
Association between pregnancy status and reported behaviors at follow-up visits 
Descriptive statistics were used to compare reported sexual behaviors and vaginal practices at 
all quarterly study follow-up visits prior to and during first pregnancies. Visits were classified as either 
pregnant or non-pregnant. To compare frequency of reported behaviors and in order to adjust for an 
unequal number of visits completed by individual study participants, logistic regression models fitted 
with general estimating equations (GEE) were used to measure the association between pregnancy 
status at a visit in order to estimate robust standard errors (for continuous variables linear regression 
with GEE was used). Unadjusted (univariable) logistic models were fitted with pregnancy status modeled 
as the independent variable and sexual risk behavior and vaginal practice as the dependent variables. 
Odds ratios with 95% confidence intervals are reported for the individual models run for each sexual risk 
behavior and vaginal practice. For modeling categorical dependent variables with more than two levels, 
individual logistic regression models was with GEE were fitted using a common referent group.   
Association between gestational age and HC use with reported behaviors at follow-up visits  
In addition to examining pregnant and non-pregnant visits, we also examined the association 
between sexual and vaginal practices with gestational age and HC use. For the gestational age 
comparison first/second trimester (early pregnancy) visits were compared to third trimester visits (late 




based on the type of HC reported: oral, injectable and no contraceptive use. These analyses were 
conducted using the same statistical approach described above.  
Pre/post pregnancy analysis 
A further analysis measured change across two visits for each woman, the visit just prior to her 
pregnancy and the first pregnant visit. For this analysis, McNemar’s test for paired binomial categorical 
data was used to compare reported behaviors at the two visits.  
Modeling risk of behaviors during pregnancy 
Finally, modified Poisson regression models were fitted to estimate risk ratio of sexual risk 
behaviors and vaginal practices in pregnant and non-pregnant periods (modified Poisson regression was 
used to estimate risk ratio using a dichotomous outcome variable and to correct variance estimates for 
repeated measures per participant).108 Pregnancy status was modeled as the dependent variable and 
sexual behaviors and vaginal practices were included as independent predictor variables in bivariate and 
multivariable models using an exchangeable correlation matrix. Multivariable models were adjusted for 
age, study randomization arm and study location (city).  All statistical procedures were conducted using 







Among the 4,948 women in the final analysis of the MIRA trial, 4,801 were 18-45 years of age at 
enrollment and had visit data eligible for this analysis (Figure 3.1). Among women 18-45 years, 3,830 
(79.8%) had no lab confirmed or reported pregnancies during follow-up, 26 (0.5%) women had only self-
reported pregnancies that were never lab confirmed and 283 (5.9%) women had a lab confirmed 
pregnancy but no visits where they had prior knowledge of the pregnancy. Among the 662 (13.8%) 
women who had lab confirmed and known pregnancies, there were a total of 676 pregnancies (14 
women had 2 pregnancies during follow-up) which resulted in 343 deliveries, 34 miscarriages, 5 
terminations, 38 pregnancies that ended with no information about the outcome, and 206 pregnancies 
that were ongoing at the woman’s last study visit. Among all women with lab confirmed and known 
pregnancies, 483 (73.0%) were included in the analysis. Of the 662, 179 (27.0%) women were excluded 
from the analysis for the following reasons: 56 women had no follow-up visits when they were not 
pregnant which was required for the crossover design; 121 women had a non-pregnant visits that were 
more than 6 months prior to their pregnant visit; and 2 women had a non-pregnant visits only after 
pregnancy (but no visits before).  
Enrollment: demographic characteristics, reported sexual risk behaviors and vaginal practices for women 
who never got pregnant compared to those included in the analysis  
Compared to the 3,829 (88.8%) of women with no pregnancies during follow-up, the 483 
(10.1%) women with lab confirmed/known pregnancies included in the analysis were more likely to 
come from the Harare, Zimbabwe sites and were more likely to be younger (Table 3.1). The median age 
of women with pregnancies included in the analysis was 24 years (range 18-44 years) compared to 27 
years (range 18-45) for women with no pregnancies (p<0.0001). Women with pregnancies were more 




Pregnant and non-pregnant women did not differ by marital status or cohabitation with male partners. 
(Table 3.1) 
At enrollment, more women who did not have pregnancies during follow-up reported using 
some form of contraception. Among women with no pregnancies, 27.9% reported current use of 
injectable hormonal contraceptives compare to only 13.3% of women no pregnancies. Women who 
went on to have pregnancies were more likely to report use of combined oral contraceptive pills at 
enrollment. (Table 3.1) More than 70% of women in both groups reported use of a condom at the last 
sex act but more than 70% of women in both groups also reported some sex in the last three months 
without a condom. (Table 3.1) Reported male partner characteristics did not differ by group; just over 
40% of women in both groups had a male partner who was at least five years older and roughly 30% of 
women in both groups reported knowing or suspecting male partners of having other sexual partners. 
Over 30% of women with and without pregnancies during follow-up reported verbal and/or physical 
abuse by male partners and over 36% in both groups reported sex when partners were under the 
influence of drugs or alcohol.  
At enrollment, similar proportions of women with and without pregnancies during follow-up 
reported all three types of vaginal practices (Table 3.1). Over 81% of women in both groups reported 
any vaginal washing, including 61% who reported daily washing. Just over half of women in both groups 
reported vaginal wiping, with roughly 40% reporting wiping as a daily activity. About half of women in 
both groups reported any vaginal insertion of cotton or other fabric and paper products not for 
menstruation but few reported daily insertion. 
At enrollment low prevalence of gonorrhea (<1% in both groups) was observed but almost 4% of 
women in both groups were infected with trichomoniasis at enrollment. Slightly more women who had 




with no pregnancies), however this did not reach the level of significance (p=0.09). Overall 57.7% of 
women had positive serological tests for HSV-2 at enrollment; significantly more women with no 
pregnancies during follow-up were HSV-2 positive at enrollment (59.0% vs.  48.7%; p<0.0001).  
In an additional analysis shown in Appendix 3.1, enrollment characteristics of women who were 
excluded from the analysis were compared to those who did not have pregnancies and those women 
who did have pregnancies during follow-up. The group of excluded women is a mixture of women who 
reported pregnancies and/or pregnancy outcomes between visits but never had a lab confirmed 
pregnancy, those with lab confirmed pregnancies who never had a visit with knowledge of the 
pregnancy and those who had large gaps between visits or no non-pregnant visits prior to a pregnancy. 
The excluded women were generally more similar to the women with pregnancies with regard to age 
and parity but were the least likely to be married of the three groups. (There were no differences in 
reported sexual behaviors or vaginal practices between those included and those excluded from the 
analysis (Appendix 3.1)).    
Association between pregnancy status and behaviors reported at follow-up visits 
The analysis comparing non-pregnant and pregnant visits attended by 483 women with lab 
confirmed/known pregnancies and at least one non-pregnant visit included 2,540 follow-up visits: 904 
(35.6%) during a pregnancy; 1.636 (64.4%) visits when the woman was not pregnant (Table 3.2). The 
median time between visits was 91 days [interquartile range (IQR): 90-95]; the median follow-up time 
for women (using visits included in the analysis) was 15 months [IQR: 12-21]. The median number of 
visits per woman (among visit included in the analysis) was 5 (range 2-8); and the median number of 
visits women had while pregnant was 2 (range 1-4) and while not pregnant was 3 (range 1-7).  
At almost all quarterly study visits, regardless of pregnancy-status, women reported some 




were pregnant (odds ratio (OR) 0.8; 95%CI 0.7-0.9). During pregnancy, women were more likely to 
report last sex without a condom (OR 0.8; 95%CI 0.7-0.9) and any unprotected sex (without a condom) 
in the past three months (OR 1.4, 95%CI 1.2-1.7). There were lower reports of other risk factors during 
pregnancy, including anal sex, having two or more sexual partners and having a new sexual partner in 
the past three months (Table 3.2). Overall, during pregnancy women were less likely to report high risk 
sex (indicated by any of the following: >2 sex partners, a sex partner, exchange sex or sex under the 
influence of drugs or alcohol) (OR 0.6, 95%CI 0.5-0.7) (Table 3.2). Differences in vaginal practices were 
observed during pregnant and non-pregnant periods; women were significantly less likely to report any 
vaginal washing, wiping and insertion of products during non-pregnant periods. In particular, vaginal 
wiping on a daily, weekly and monthly basis were lower during pregnancy; compared to non-pregnant 
periods, the odds of daily wiping during pregnancy was 30% lower (OR 0.7, 95%CI 0.6-0.8).   
Association between gestational age with behaviors reported at follow-up visits  
In an additional analysis, pregnant visits were categorized according to gestational age and 
differences in reported sexual behaviors and vaginal practices reported in the first and second trimester 
(early pregnancy) were compared to those reported in the third trimester (late pregnancy). Of the 904 
pregnant visits included in the analysis, 492 (54.4%) were estimated to have occurred during the 
first/second trimester and 412 (45.6%) occurred during the third trimester (Table 3.3). 228 (47.2%) 
women had both an early and late pregnancy visit, 174 (36.0%) had only a first/second trimester visits 
and 81 (46.8%) had only a third trimester visit. 
Compared to visits in early pregnancy, during the third trimester women reported less sex at 
visits, including report of any sex between visits (OR=0.39; 95%CI 0.22-0.72) and fewer reported >3 sex 
acts per week (OR=0.6; 95%CI 0.5-0.7). During the third trimester women were also more likely to report 




other differences in sexual risk behaviors between early and late pregnancy, nor were any differences 
observed in vaginal practices.  
Association between hormonal contraceptive use and behaviors reported at follow-up visits 
In another additional analysis, non-pregnant visits were categorized according to women’s 
reported hormonal contraceptive (HC) use and were compared to pregnant visits. Of the 2,540 visits 
included in the analysis, 1636 (64.4%) occurred when women were not pregnant; at 504 of the non-
pregnant visits (33.2%) women reported using oral contraceptives (including both combined and 
progesterone only pills), at 165 visits (10.1%) women reported that they were using injectable HC and at 
928 (56.7%) of visits women reported using no HC (these visits were compared to the 904 visits that 
occurred during a pregnancy).  
Compared to visits during pregnancy, women were more likely to report any sex and >3 sex acts 
per week at non-pregnant visits when they were using oral contraceptives (OR 2.1; 95%CI 1.3-3.4) (Table 
3.4). This differed from visits with report of injectable HC use where women were less likely to report 
any sex between visits compared to pregnant visits (OR=0.6; 95%CI 0.3-1.0). No difference was observed 
in any sex or sexual frequency between pregnant visits and non-pregnant visits where women were not 
using HC. Visits when women were using oral contraceptives and those where no HC was used included 
fewer reports of any sex without a condom in the previous three months compared to pregnant visits 
(OR for oral contraceptive visits=0.7; 95%CI 0.6-0.9). Visits with injectable HC use did not differ from 
pregnant visits with regard to report of unprotected sex. Compared to pregnant visits, reports of other 
sexual risk behaviors, including anal sex, having had more than one sex partner between visits and 
indication of any high risk sexual behaviors was significantly more common at all non-pregnant visits, 




Vaginal washing appeared to be more common at visits when women were using oral 
contraceptives compared to pregnant visits overall and on a daily and monthly basis, however, visits 
with injectable HC and no HC use did not differ from pregnant visits with regard to report of vaginal 
washing (Table 3.4). At visits when women were using oral or injectable HC, there were more reports of 
vaginal wiping (OR=1.8;95%CI 1.3-2.4) and they were much more likely to report insertion of materials 
(OR=1.7;95CI 1.0-2.7).  At visits with women were not using any HC, there were only differences 
observed in vaginal wiping compared with pregnant visits (Table 3.4).  
Pre/post pregnancy analysis  
As a further examination of the changes to sexual risk behaviors and vaginal practices during 
pregnancy, we conducted a matched analysis of paired data for each woman comparing the last non-
pregnant visit just prior to the first pregnant visit (Figure 3.2). There were significant changes observed 
in reporting of any sex without a condom; 15.7% of women who had not reported sex without a condom 
before pregnancy reported sex without a condom at the first visit during pregnancy (p<0.05). During 
pregnancy there appeared to be decreased anal sex and in having more than one sexual partner 
between visits, meaning that significantly more women changed from reporting these behaviors prior to 
pregnancy and not reporting them during pregnancy (compared to women who stayed the same in 
reporting or increased reporting of behaviors during pregnancy). More women also changed from 
reporting some type of high risk sex when not pregnant to reporting no high risk sex when pregnant 
(p<0.01). Pregnancy did not appear to change vaginal washing or insertion but did appear to decrease 
vaginal wiping (p=0.05).  
Modeling risk of behaviors during pregnancy  
In regression models adjusted for age, diaphragm randomization arm, city,  it appeared that 




frequent sex (adjusted risk ratio (ARR) sex >3 times per week 0.9;95%CI 0.8-0.9) (Table 3.5). Pregnancy 
was associated with less reported condom use at last sex (ARR=0.8, 95%CI 0.7-0.9) but more reports of 
any unprotected sex (ARR 1.3; 95%CI 1.2-1.5). Pregnancy was also associated with less reporting of anal 
sex (ARR 0.7, 95%CI 0.5-0.9) and lower risk of any indication of high risk sex (ARR 0.7;95%CI 0.6-0.9). 
Pregnancy was not associated with lower risk of vaginal washing or insertion of materials but was found 
to decrease the risk of vaginal wiping on a daily and weekly basis; pregnancy was associated with 26% 







This analysis examined changes in self-reported sexual behaviors and vaginal practices during 
pregnancy in order to understand pregnancy’s impact on potential risk factors for STI acquisition. We 
found that pregnancy tended to decrease sexual activity, particularly in the third trimester. We also 
observed that compared to non-pregnant periods, there was more vaginal sex without condoms 
reported during pregnancy but lower frequency of other risk factors for STI acquisition, including anal 
sex, concurrent sexual relationships and new sex partners. Vaginal wiping and insertion of material into 
the vagina, potentially important mechanisms for STI acquisition, were also less common during 
pregnancy. In a further examination of non-pregnant periods using pregnancy as a common reference 
group for comparisons, we found that, although the number of visits with injectable HC use was low, 
high risk sexual behaviors (anal sex, exchange sex, concurrency, new partners and drugs and alcohol use 
during sex) were reported most often when women were using injectable hormonal contraception, 
compared to oral contraceptives and no HC use. The association between vaginal practices differed 
depending on the type of HC use. At visits when women were using oral contraceptives, they were 
significantly more likely to report all types of vaginal practices compared to pregnant visits. For visits 
with injectable HC, vaginal wiping and insertion were more common than during pregnancy and only 
vaginal wiping was associated with non-pregnant visits where women were using no HC. There are few 
previous examinations of changes to sexual risk behaviors for STIs during pregnancy and no previous 
analyses of the impact of pregnancy on vaginal practices. These data are therefore an important 
contribution to developing better understanding of women’s risk for STIs during pregnancy. 
At enrollment in the randomized clinical trial from which woman in our analysis were selected, 
there were few demographic and behavioral differences distinguishing women who went on to have 
pregnancies from those who did not have pregnancies during study follow-up. Women who had a 




be married and to live with male partners. There were few differences in reported sexual behaviors and 
vaginal practices with similarly high proportions of women in both groups reporting unprotected sex, 
sex in exchange for drugs or money, having older partners and having high risk partners. While 70% of 
all women reported using a condom at last sex act, 70% of women also reported unprotected sex in the 
previous three months. Women who did not have a pregnancy during follow-up were significantly more 
likely to be infected with HSV-2 which was expected based on their older age which is associated with 
higher HSV-2 prevalence 2; there were no differences in other STIs at enrollment. A high proportion of all 
women (33%) reported physical or verbal abuse by male partners, including being threatened with a 
weapon. This finding is in keeping with previous reports of high levels of intimate partner violence from 
South Africa and Zimbabwe.109-112  
In the analysis of behavior change during pregnancy, our findings suggest that sexual activity 
decreases, particularly in the third trimester, and that sex not protected by a condom is more commonly 
reported during pregnancy. Both findings are consistent with previous studies from resource limited 
settings.30-33,35,98 We also found that while unprotected sex may be more common during pregnancy 
compared to non-pregnant periods, other risk behaviors, such as anal sex and having multiple 
concurrent sexual partners occur less during pregnancy. These findings are also in keeping with previous 
studies examining HIV risk during pregnancy 31-33,35 and highlight the complexities of estimating STI risk 
factors during pregnancy. Lower frequency of sexual activity and fewer additional sexual partners would 
suggest that women might have lower risk of acquiring STIs during pregnancy. In addition, women who 
become pregnant may be in more stable partnerships (we did not examine changes in relationship 
stability over time but this has been reported previously)113. The lower rates of condom use among 
pregnant women could however increase exposure to STIs, and risk could be further increased if male 




during pregnancy have only been measured in a small number of studies which have not shown an 
increase in partner concurrency during pregnancy.35,98  
Similar to other studies, at more than 60% of all follow-up visits women reported using a 
condom at the last sex act, including during pregnancy, however sex without a condom at any time 
between the visits was also reported frequently (over 68% of follow-up visits) regardless of pregnancy 
status. These findings indicate inconsistency in condom use which is one of the most important risk 
factors for STI acquisition. The women in this analysis were enrolled in an HIV prevention trial and were 
counseled at all study visits, including those during pregnancy, to use condoms for HIV and STI 
prevention. Despite counseling, most women reported some unprotected sex which increased 
significantly during pregnancy.  There has been little study of condom use during pregnancy, including 
qualitative studies on women’s understanding of continued risk for STIs in the absence of contraceptive 
concerns, and few evaluations of efforts to improve condom use during pregnancy. Greater efforts are 
needed to support women’s consistent condom use for those in relationships with positive men or men 
with unknown STI status and to ensure they understand the continued risk of STI acquisition during 
pregnancy.  
Potential bias in reporting of sexual behaviors is an important consideration when examining 
evidence from analyses such as this. Self-report of sexual behaviors, particularly with regard to use of 
condoms, has been shown to be an unreliable marker of risk.114,115 A study from Zimbabwe showed no 
association between reported condom use by women over two years of follow-up and HIV incidence.116 
In an analysis of 910 participants from MIRA trial sites in Zimbabwe, prostate specific antigen (PSA) in 
vaginal secretions was used as a biomarker of recent unprotected sex to validate self-reported condom 
use. The analysis found that almost half of the women with measureable PSA reported that they had not 
had any unprotected sex in the previous two days.117 A recent review of the studies using biological 




report condom use.118 Different reasons are put forward to explain the discrepancies found between 
self-report and biological markers of risk behaviors, including poor recall, misunderstanding of questions 
and deliberate misreport of behaviors as a result of social desirability bias.115 
The potential misclassification resulting from over reporting of condom use is concerning. This 
type of bias would generally be presumed to be non-differential, i.e. not systematically different based 
on pregnancy status, and would lead to an estimated effect that would be biased towards the null, in 
other words, the misclassification would mask any impact of pregnancy on risk behaviors. It is also 
possible that the misclassification could be differential based on pregnancy status, for instance if 
pregnant women were more accurate in reporting condom use while non-pregnant women over 
reported condom use, this would lead to a more concerning bias as it would suggest that pregnant 
women have more unprotected sex whereas they may in fact report accurately while non-pregnant 
women under report unprotected sex creating an effect of pregnancy where no, or potentially the 
opposite, effect exists. This potential bias could explain the effect of pregnancy that has been observed 
in several studies showing increased unprotected sex during pregnancy (including ours). Alternatively, 
pregnant women could be less accurate in reporting other risk behaviors, including anal sex, multiple 
partners and exchange sex which could be an explanation for the lower report of these behaviors during 
pregnancy. Unfortunately there are no existing studies that have tried to measure this type of potential 
bias by validating self-reported behaviors among pregnant women.  
Our analysis also found some differences in sexual behaviors based on the type of hormonal 
contraceptives that women were using. The comparison of reported behaviors across HC types to 
pregnancy status was conducted as a result of conflicting evidence regarding the impact of HC use on STI 
risk. Some studies have shown progesterone-only HCs to be associated with increased risk of infections 
including chlamydia 51, gonorrhea 119 and HIV 120 however evidence, specifically in regard to HIV, is 




high risk sex more frequently when they were using injectable HC compared to periods when they were 
pregnant or using oral contraceptives, however the number of visits when women were using injectable 
HC was low (in part because we excluded postpartum visits when women may have been more likely to 
be using this form of contraceptive)125. These results suggest that women’s behavior during non-
pregnant periods may vary depending on what type of HC type they are using. This has bearing for 
examinations of STI risk during pregnancy as comparisons to non-pregnant periods must take HC use 
into account in order to properly examine and adjust for risk behaviors.  
Vaginal practices were commonly reported by women in this analysis which is in keeping with 
other studies from sub-Saharan Africa. Vaginal washing was the most commonly reported practice with 
daily washing reported at over half of all visits, regardless of pregnancy status and any vaginal washing 
reported at over three quarters (77%)  of all follow-up visits. Vaginal wiping and insertion of cloth, 
cotton or paper for non-menstruation related reasons were less common but any engagement in these 
practices was reported at 42% and 12% of visits, respectively. A strong association was observed for 
decreased vaginal practices, all three types, during pregnancy. This is the first report comparing vaginal 
practices during pregnant and non-pregnant periods in the same women and as such there are no other 
data with which to compare it. The decrease in vaginal practices could be a result of less sexual activity 
during pregnancy or as a result of reduced frequency of exchange sex which has been found to be 
associated with intra-vaginal practices.100 It is also possible that the reduction in vaginal practices during 
pregnancy was in part caused by the general decline in these behaviors over study follow-up as reported 
by van der Straten et al.126 Pregnancies that occurred later in the study may have had lower report of 
vaginal practices not as a result of pregnancy but potentially as a result of this general trend. The 
reasons for changes in vaginal practices observed during pregnancy warrants further study as they are 
an important risk factor for STI acquisition and may also impact pregnancy outcomes. While douching 




reproductive health outcomes,127 the effect of other vaginal practices (wiping, insertion of other 
substances and materials) have not been studied.  
This analysis included more than 480 women with both pregnant and non-pregnant follow-up 
time. The data came from a randomized clinical trial with rigorous follow-up and data collection 
procedures. Data on sexual behaviors and vaginal practices were collected primarily through ACASI 
which may have contributed to more valid responses.117 This is one of the only studies to examine sexual 
behaviors during pregnancy and one of the few to compare data from pregnant and non-pregnant 
periods in the same women. The methods used were also a strength of the analysis, including a cross 
over design with women serving as their own controls which adjusted for factors and characteristics of 
women which may be associated with having a pregnancy and could not be easily adjusted for had we 
compared women with pregnancies to those without pregnancies. We examined changes in behavior 
using several different analytic approaches in order to accurately capture change at all visits and in 
specific time periods.  
There are several important limitations of the analysis. In addition to the issues discussed above 
relating to validity of self-report, there were also challenges with accurately classifying pregnancy 
exposure periods and gestational age. For the analysis we considered visits to be during a pregnancy 
only if the woman knew about the pregnancy prior to the visit in order to measure behavior change 
from pregnancy. It is possible that some women may not have accurately reported when they knew 
about their pregnancies which could have led to misclassification of visits. There were also challenges 
with regard to visits with reported miscarriages and terminations; visits where women were not 
pregnant according to lab testing but reported these events were considered non-pregnant as the date 
of the end of the pregnancy was not ascertained in the study. It is possible that women were pregnant 
during some part of these periods and their behavior may have been different as a result. In both 




attenuated the observed effect of pregnancy in changing sexual risk behaviors and vaginal practices. We 
also did not have data on last menstrual period and thus the estimates of gestation age are not based on 
when the woman became pregnant but rather when she knew or had a lab positive pregnancy test. This 
may have led to misclassification of gestational age and most likely results in women who were farther 
along in pregnancy being considered first or second trimester rather than third. Another limitation of 
the data was not having any information reported by male partners which is an important risk factor for 
women. Further study is needed of men’s behavior during pregnancy and whether they may engage in 
more concurrency which could increase women’s STI risk during this this period.  
These data provide important insights into the sexual risk behaviors and vaginal practices of 
pregnant women. The inconsistency of condom use found among women during non-pregnant periods 
and the high frequency of unprotected sex during pregnancy is evidence that greater efforts are needed 
to improve consistent condom use among women in high STI/HIV prevalence settings. Targeted efforts 
to increase condom use for STI prevention during pregnancy have not been studied but may be needed 
to prevent infections that pose threats to the health of pregnant women and their infants. Studies are 
also needed to understand the impact of vaginal practices that are common in sub-Saharan Africa on 
women’s health and pregnancy outcomes, as well as on STI risk. The analysis highlights some of the 






Figure 3.1 Patient flow diagram  
  
4,948 HIV-negative women analyzed in MIRA trial  
3830 women had no lab confirmed or 
reported pregnancies  
26 women had no lab confirmed 
pregnancies (only report) 
284 women had lab confirmed pregnancy but no visits 
when knew pregnant  
 23 deliveries 
 65 miscarriages 
 34 terminations 
 161 no outcome: 116 pregnant at last visit; 46 no 
recorded pregnancy outcome 
483 women included in analysis 
All with at least one non-pregnant prior to a 
pregnant visit during a first pregnancy (all visits 
within 6 months) 
179 women excluded due for follow-up time reasons  
 56 women had no visits during follow-up when not 
pregnant  
 121 women had pregnant and non-pregnant visits 
separated by more than 6 months 
 2 women had non-pregnant visits only after 
pregnancy   
146 women >45 years of age  4,802women <45 years of age  
5,045 women were randomized in the trial: 3 were excluded because they were underage, 3 women 
discontinued on date of randomization, 72 had no HIV results post-enrollment and 19 were found to 
have been infected with HIV at baseline (after testing positive during follow-up) 
946 women had a lab confirmed 
pregnancy or delivered  
662 women had a visit while pregnant (642) or 
within 6 weeks of delivery (20), total of 676 
pregnancies  
 393 deliveries 
 34 miscarriages 
 5 terminations 
 244 no outcomes: 206 pregnant at last visit; 38 
no recorded pregnancy outcome 
 
 
972 women had a lab confirmed and/or 




Table 3.1 Characteristics at enrollment by pregnancy status during follow-up, N=4,313 
Characteristics at enrollment Total  
Women with no 
pregnancies 




analysis p value 
 
N % N % N % 
 
 
4313 100.0% 3830 88.8% 483 11.2% 
 Study location       
    Harare 2155 50.0% 1881 49.1% 274 56.7% 0.01 
    Durban 1289 29.9% 1165 30.4% 124 25.7%  
    Johannesburg 869 20.2% 784 20.5% 85 17.6%  
Age        
     Median age (range) 27 (18-45) 27 (18-45) 24 (18-44) <0.0001 
     18-24 1635 37.9% 1388 36.3% 247 51.1% <0.0001 
     25-34 1751 40.6% 1552 40.5% 199 41.2%  
     >35 927 21.5% 890 23.2% 37 7.7%  
Completed high school (11 yrs school) 2263 51.5% 1987 51.9% 276 57.1% 0.03 
Paid employment 985 22.8% 888 23.2% 97 20.1% 0.13 
Married 2546 61.3% 2250 58.8% 296 61.3% 0.29 
Lives with male partner 2928 67.9% 2591 67.7% 337 69.8% 0.42 
Number of previous pregnancies        
     None 357 8.3% 294 7.7% 63 13.0% <0.0001 
     1 previous pregnancies 1373 31.8% 1178 30.8% 195 40.4%  
     2+ 2583 59.9% 2358 61.6% 225 46.6%  
Current birth control (not mutually exclusive)        
     Combined pills 940 21.8% 791 20.7% 149 30.9% <0.0001 
     Injectable hormones 1132 26.3% 1068 27.9% 64 13.3% <0.0001 
     Progesterone only pills 660 15.3% 600 15.7% 60 12.4% 0.06 
     Intrauterine device 16 0.4% 15 0.4% 1 0.2% 0.77 
     Condoms (male or female) (only) 1635 37.9% 1453 37.9% 182 37.7% 0.92 
     None (natural, withdrawal, tradition) 230 5.3% 192 5.0% 38 7.9% 0.01 
Regular sexual partner 1763 40.9% 1577 41.2% 186 38.5% 0.37 
Age at first sex (mean and range) 18 (10-31) 18 (10-31) 18 (11-26) 0.75 
Sex acts per week        
     None 1732 40.2% 1522 39.7% 210 43.5% 0.10 
     1-2 per week 264 6.1% 229 6.0% 35 7.3%  
     >3 per week 2317 53.7% 2079 54.3% 238 49.3%  
Number of sexual partners in past 3 months        
     None 250 5.8% 239 6.3% 11 2.3% 0.00 
     1 partner 3694 85.9% 3268 85.6% 427 88.4%  
     2+ 357 8.3% 312 8.2% 45 9.3%  
Condom use (male or female) at last sex 3040 70.5% 2701 70.5% 339 70.2% 0.88 
Condom use (vaginal sex) in last three months 
            Never 1259 29.3% 1123 29.4% 136 28.2% 0.69 
     Sometimes 1672 38.9% 1487 38.9% 185 38.3% 
      Every time 1371 31.9% 1209 31.7% 162 33.5% 






Table 3.1 continued  






pregnancies p value 
 
N % N % N % 
 Anal sex (ever) 629 14.6% 550 14.4% 79 16.4% 0.25 
Sex while intoxicated 156 26.9% 136 26.8% 20 27.8% 0.86 
High risk  1002 23.2% 879 23.0% 123 25.5% 0.22 
(>2 partners, exchange, anal, sex w/ drugs/alcohol)     
Partner age        
     Same age (+/-5 years) 2391 58.0% 2114 57.8% 277 58.9% 0.21 
     Younger (more than 5 years) 39 1.0% 38 1.0% 1 0.2%  
     Older (more than 5 years) 1694 41.1% 1502 41.1% 192 40.9%  
Partner tested HIV positive        
     Yes 150 3.5% 136 3.6% 14 2.9% 0.45 
     No/don't know 4149 96.5% 3680 96.4% 469 97.1%  
Partner away from home >2 months 472 10.9% 425 11.1% 47 9.7% 0.37 
Partner circumcised 927 21.6% 821 21.5% 106 22.0% 0.57 
Suspects/knows male partner concurrency 1302 30.3% 1164 30.5% 138 28.6% 0.39 
Physical or verbal abuse  789 33.3% 715 33.3% 74 33.0% 0.94 
Partner used force to get sex 234 9.9% 213 9.9% 21 9.4% 0.80 
Sex w/ partner w/ drugs or alcohol 1547 36.1% 1368 36.0% 179 37.1% 0.62 
Partner high risk  2685 62.2% 2386 62.3% 299 61.9% 0.87 
(HIV+, away >1 month, other partners, drugs)        
Vaginal washing        
     Daily 2632 61.2% 2331 61.1% 301 62.3% 0.54 
     Weekly 623 14.5% 562 14.7% 61 12.6%  
     Monthly or less 299 7.0% 268 7.0% 31 6.4%  
     None 747 17.4% 657 17.2% 90 18.6%  
     ANY 3566 82.7% 3173 82.9% 393 81.4% 0.41 
Vaginal wiping        
     Daily 1741 40.5% 1546 40.5% 195 40.4% 0.50 
     Weekly 418 9.7% 362 9.5% 56 11.6%  
     Monthly or less 267 6.2% 237 6.2% 30 6.2%  
     None 1875 43.6% 1673 43.8% 202 41.8%  
     ANY 2438 56.5% 2157 56.3% 281 58.8% 0.44 
Vaginal insertion (non-menstruation related)        
     Daily 560 13.0% 502 13.2% 58 12.0% 0.87 
     Weekly 144 3.4% 126 3.3% 18 373.0%  
     Monthly or less 178 4.1% 158 4.1% 20 4.1%  
     None 3415 79.5% 3028 79.4% 387 80.1%  
     ANY 898 20.8% 802 21.0% 96 19.9% 0.59 
Diaphragm arm 2132 49.4% 1901 49.6% 231 47.8% 0.45 
Positive for STI (enrollment)        
     Chlamydia 187 4.3% 159 4.2% 28 5.8% 0.09 
     Gonorrhea 33 0.8% 30 0.8% 3 0.6% 0.70 
     Trichomoniasis 157 3.6% 137 3.6% 20 4.1% 0.53 






Table 3.2 Risk behaviors reported at 2,540 follow-up visits (unadjusted frequencies) and association 
(odds ratio) with pregnancy status, N=483 women (odds ratios adjusted for clustering with GEE) 
 
Reported behaviors at follow-up 
Frequency of 








Odds ratio pregnant vs. 
non-pregnant periods 
 
N % N  % N % OR 95%CI p value 
 
2540 100.0% 1636 64.4% 904 35.6% 
   Any vaginal sex since last visit 2409 94.8% 1560 95.4% 849 93.9% 0.9 0.6-1.2 0.40 
Vaginal sex frequency per week       
     mean (range) 3.6 (0-10) 3.8 (0-10) 3.4 (0-10) 0.7 0.6-0.9 <0.0001 
     >3 times per week 1607 69.4% 1022 71.2% 585 66.5% 0.8 0.7-0.9 <0.01 
Condom use at last sex 1654 68.7% 1103 70.7% 551 64.9% 0.8 0.7-0.9 0.02 
Unprotected sex (any report)  1646 68.3% 1018 65.3% 628 74.0% 1.4 1.2-1.7 <0.01 
Anal sex since last visit 136 5.4% 104 6.4% 32 3.5% 0.5 0.4-0.8 <0.01 
Sex in exchange for money or drugs 79 3.3% 56 3.6% 23 2.7% 0.8 0.6-1.1 0.18 
>2 male sex partners since last visit 156 6.5% 130 8.3% 26 3.1% 0.3 0.2-0.5 <0.0001 
New sex partner  264 10.9% 188 12.0% 76 9.0% 0.7 0.5-0.9 <0.01 
Suspects/knows male partner 
concurrency 
573 23.7% 384 24.5% 189 22.3% 0.9 0.8-1.1 0.16 
High risk sex  431 17.0% 316 19.3% 115 12.7% 0.6 0.5-0.7 <0.0001 
(exchange, anal sex, >2 partners, sex with drugs/alcohol)      
Vaginal washing          
     Daily 1424 56.1% 914 55.9% 510 56.4% 0.8 0.7-0.9 0.01 
     Weekly 306 12.1% 200 12.2% 106 11.7% 0.9 0.7-1.1 0.17 
     Monthly or less 224 8.8% 162 9.9% 62 6.9% 0.7 0.6-0.9 <0.01 
     None (ref) 586 23.1% 360 22.0% 226 25.0% 1.0 - - 
     ANY 1954 76.9% 1276 78.0% 678 75.0% 0.8 0.7-0.9 <0.01 
Vaginal wiping          
     Daily 795 31.3% 543 33.2% 525 27.9% 0.7 0.6-0.8 <0.0001 
     Weekly 158 6.2% 113 6.9% 45 5.0% 0.6 0.5-0.8 <0.01 
     Monthly or less 117 4.6% 82 5.0% 35 3.9% 0.6 0.5-0.9 <0.01 
     None (ref) 1470 57.9% 898 54.9% 572 63.3% 1.0 - - 
     ANY 1070 42.1% 738 45.1% 332 36.7% 0.7 0.6-0.8 <0.0001 
Vaginal insertion (non-menstruation related)         
     Daily 173 6.8% 118 7.2% 55 6.1% 0.8 0.6-1.0 0.06 
     Weekly 50 2.0% 35 2.1% 15 1.7% 0.7 0.4-1.2 0.22 
     Monthly or less 75 3.0% 54 3.3% 21 2.3% 0.7 0.5-1.1 0.09 
     None (ref) 2242 88.3% 1429 87.4% 813 89.9% 1.0 - - 








Table 3.3 Risk behaviors reported at 904 pregnant visits (unadjusted frequencies) and association 
(odds ratio) with gestational age at pregnant visit, N=483 women (odds ratios adjusted for clustering 
with GEE) 
 









report at 3rd 
trimester visits 
Odds ratio 1st/2nd vs. 3rd 
trimester periods 
 
N  % N % N % OR 95%CI p value 
 
904 100.0% 492 54.4% 412 45.6% 
   Any vaginal sex since last visit 849 93.9% 473 96.1% 376 91.3% 0.4 0.2-0.7 0.0024 
Vaginal sex frequency per week 
              mean (range) 3.4 (0-10) 3.6 (0-10) 3.2 (0-10) 0.6 0.5-0.8 <0.0001 
     >3 times per week 585 66.6% 341 71.6% 244 60.6% 0.6 0.5-0.7 <0.0001 
Condom use at last sex 551 64.9% 298 63.0% 253 67.3% 1.2 1.0-1.6 0.09 
Unprotected sex (any report)  628 74.0% 364 77.0% 264 70.2% 0.7 0.5-0.9 0.02 
Anal sex since last visit 872 96.5% 476 96.8% 396 96.1% 1.2 0.6-2.3 0.58 
Sex in exchange for money or drugs 23 2.7% 9 1.9% 14 3.7% 1.7 0.9-3.4 0.11 
>2 male sex partners since last visit 26 3.1% 15 3.2% 11 2.9% 0.8 0.5-1.2 0.23 
New sex partner  76 9.0% 42 8.8% 34 9.0% 0.9 0.6-1.4 0.63 
Suspects/knows male concurrency 189 22.3% 113 23.9% 76 20.2% 0.8 0.6-1.0 0.06 
High risk sex  115 12.7% 59 12.0% 56 13.6% 1.1 0.8-1.6 0.64 
(exchange, anal sex, >2 partners, sex with drugs/alcohol)       
Vaginal washing          
     Daily 510 56.4% 275 55.9% 235 57.0% 1.0 0.8-1.2 0.90 
     Weekly 106 11.7% 61 12.4% 45 10.9% 0.9 0.7-1.2 0.56 
     Monthly or less 62 6.9% 38 7.7% 24 5.8% 0.8 0.5-1.2 0.29 
     None (ref) 226 25.0% 118 24.0% 108 26.2% 1.0 - - 
     ANY 678 73.8% 374 76.0% 304 73.8% 1.0 0.8-1.2 0.65 
Vaginal wiping          
     Daily 252 27.9% 135 27.4% 117 28.4% 0.9 0.7-1.2 0.54 
     Weekly 45 5.0% 24 4.9% 21 5.1% 1.2 0.7-1.8 0.51 
     Monthly or less 35 3.9% 19 3.9% 16 3.9% 1.0 0.6-1.9 0.92 
     None (ref) 572 63.3% 314 63.8% 258 63.3% 1.0 - - 
     ANY 332 36.7% 178 36.2% 154 37.4% 1.0 0.8-1.2 0.82 
Vaginal insertion (non-menstruation related)         
     Daily 55 6.1% 27 5.5% 28 6.8% 1.2 0.8-1.8 0.50 
     Weekly 15 1.7% 7 1.4% 8 1.9% 1.4 0.6-3.8 0.45 
     Monthly or less 21 2.3% 13 2.6% 8 1.9% 0.7 0.3-1.8 0.51 
     None (ref) 813 89.9% 445 90.5% 368 89.3% 1.0 - - 




Table 3.4 Risk behaviors reported at 2,540 follow-up visits (unadjusted frequencies) and association 
(odds ratio) between hormonal contraceptive type and pregnant status, N=483 women (odds ratios 
adjusted for clustering with GEE) 
 
Reported behaviors at follow-up Total 
Frequency of 
report at 







report at no 










% 543 21.4% 165 6.5% 928 36.5% 904 35.6% 
Any vaginal sex since last visit 2409 94.8% 534 98.3% 148 89.7% 878 94.6% 849 93.9% 









     mean (range)* (not or) 3.6 (0-10) 4.2 (0-10) 3.3 (0-10) 3.6 (0-10) 3.4 (0-10) 
     >3 times per week 1607 69.4% 1357 79.0% 102 68.5% 563 67.4% 585 66.6% 
Condom use (male or female) at last sex 1654 68.7% 374 70.0% 97 65.5% 632 72.0% 551 64.9% 
Unprotected sex (any report)  1646 68.3% 361 67.6% 105 71.0% 552 68.0% 74 74.0% 
Anal sex since last visit 136 5.4% 34 6.3% 18 10.9% 52 5.6% 32 3.5% 
Sex in exchange for money or drugs 79 3.3% 11 2.1% 5 3.3% 40 4.5% 23 2.7% 
>2 male sex partners since last visit 156 6.5% 18 3.4% 25 16.7% 87 9.8% 26 3.1% 
New sex partner  264 10.9% 40 7.5% 23 15.4% 125 14.1% 76 9.0% 
Suspects/knows male partner 
concurrency 
573 23.7% 87 16.3% 46 30.9% 251 28.4% 189 22.3% 
High risk sex  431 17.0% 81 14.9% 46 27.9% 189 20.4% 115 12.7% 
(exchange, anal sex, >2 partners, sex with drugs/alcohol)             
Vaginal washing               
     Daily 1424 56.1% 333 61.3% 90 54.6% 491 52.9% 510 56.4% 
     Weekly 306 12.1% 51 9.4% 22 13.3% 127 13.7% 106 11.7% 
     Monthly or less 224 8.8% 59 10.9% 14 8.5% 89 9.6% 62 6.9% 
     None (ref) 586 23.1% 100 18.4% 39 23.6% 221 23.8% 226 25.0% 
     ANY 1954 76.9% 443 81.6% 126 76.4% 707 76.2% 678 75.0% 
Vaginal wiping               
     Daily 795 31.3% 202 37.2% 54 32.7% 287 30.9% 525 27.9% 
     Weekly 158 6.2% 34 6.3% 10 6.1% 69 7.4% 45 5.0% 
     Monthly or less 117 4.6% 27 5.0% 13 7.9% 42 4.5% 35 3.9% 
     None (ref) 1470 57.9% 280 51.6% 88 53.3% 530 57.1% 572 63.3% 
     ANY 1070 42.1% 263 48.4% 77 46.7% 398 42.9% 332 36.7% 
Vaginal insertion (non-menstruation related)              
     Daily 173 6.8% 46 8.5% 13 7.9% 59 6.4% 55 6.1% 
     Weekly 50 2.0% 6 1.1% 3 1.8% 26 2.8% 15 1.7% 
     Monthly or less 75 3.0% 17 3.1% 6 3.6% 31 3.3% 21 2.3% 
     None (ref) 813 89.9% 474 87.3% 143 86.7% 812 87.5% 813 89.9% 






Table 3.4 (continued)  
Reported behaviors at follow-up OR pregnant vs. OC 
OR pregnant vs. 
injectable 
OR pregnant vs. no HC 
use 
 







  Any vaginal sex since last visit 2.1 1.3-3.4 <0.01 0.6 0.3-1.0 0.05 1.1 0.8-1.7 0.53 





       mean (range)* (not or) 1.7 1.3-2.0 <0.0001 1.1 0.8-1.5 0.73 1.3 1.1-1.5 <0.01 
     >3 times per week 1.5 1.2-1.9 <0.01 1.0 0.7-1.5 0.83 1.2 1.0-1.4 0.05 
Condom use (male or female) at last sex 1.3 1.0-1.6 0.05 1.0 0.7-1.5 0.95 1.3 1.0-1.5 0.02 
Unprotected sex (any report)  0.7 0.6-0.9 <0.01 0.7 0.5-1.1 0.17 0.7 0.6-0.9 <0.01 
Anal sex since last visit 1.9 1.2-3.1 0.01 2.5 1.2-5.3 0.01 1.7 1.1-2.5 0.01 
Sex in exchange for money or drugs 1.1 0.7-1.8 0.74 1.0 0.3-3.1 0.97 1.4 1.0-1.9 0.07 
>2 male sex partners since last visit 2.0 1.3-3.0 <0.01 3.5 1.5-8.3 <0.01 3.6 2.3-5.7 <0.0001 
New sex partner  1.0 0.7-1.5 0.88 1.6 0.9-2.7 0.11 1.7 1.3-2.1 <0.01 
Suspects/knows male partner 
concurrency 
1.0 0.8-1.2 0.73 1.1 0.7-1.7 0.57 1.2 1.0-1.5 0.06 
High risk sex  1.4 1.0-2.0 0.03 2.2 1.4-3.4 <0.01 1.8 1.4-2.2 <0.0001 
(exchange, anal sex, >2 partners, sex with drugs/alcohol) 
 
   
 
   
 Vaginal washing    
 
   
 
   
      Daily 1.3 1.1-1.6 <0.01 1.3 1.0-1.7 0.08 1.12 1.0-1.3 0.15 
     Weekly 1.1 0.8-1.5 0.51 1.2 0.8-1.8 0.27 1.14 0.9-1.4 0.22 
     Monthly or less 1.6 1.1-2.4 0.01 1.3 0.9-1.9 0.16 1.30 1.0-1.7 0.06 
     None (ref) 1.0 - - 1.0 - - 1.00 - - 
     ANY 1.3 1.1-1.6 0.01 1.3 1.0-1.8 0.07 1.16 1.0-1.4 0.08 
Vaginal wiping    
 
   
 
   
      Daily 1.6 1.3-2.0 <0.0001 1.5 1.1-2.1 <0.01 1.31 1.1-1.5 <0.01 
     Weekly 1.7 1.2-2.4 <0.01 2.0 1.2-3.3 <0.01 1.41 1.1-1.9 0.02 
     Monthly or less 1.8 1.1-2.8 0.01 2.2 1.1-4.3 0.02 1.38 1.0-1.9 0.06 
     None (ref) 1.0 - - 1.0 - - 1.00 - - 
     ANY 1.7 1.5-2.1 <0.0001 1.8 1.3-2.4 <0.01 1.35 1.2-1.6 <0.0001 
Vaginal insertion (non-menstruation related)   
 
   
 
   
      Daily 1.5 1.0-2.1 0.04 1.6 0.9-3.0 0.12 1.17 0.8-1.6 0.36 
     Weekly 1.1 0.5-2.1 0.87 1.1 0.3-3.6 0.87 1.63 0.9-3.0 0.10 
     Monthly or less 1.5 0.9-2.4 0.15 1.8 0.8-4.2 0.19 1.31 0.8-2.1 0.27 
     None (ref) 1.0 - - 1.0 - - 1.00 - - 














Proportion women changed from not reporting before pregnancy to report during pregnancy
Proportion of women changed from reporting before pregnancy to NOT reporting during pregnancy
*p<0.05; **p<0.01; ***p<0.001 
(behavior increased when pregnant)        












Table 3.5 Association between pregnancy status and reported risk behaviors and vaginal practices at 
follow-up visits, N=483 women, 2,540 visits (modified Poisson risk regression) 
 
Risk behavior Univariable   Adjusted 
 
RR 95%CI p-value  RR 95%CI p-value 
    
   
  Any vaginal sex since last visit 0.8 0.6-1.0 0.05  0.84 0.7-1.1 0.12 
    
   
  Vaginal sex >3 times per week 0.9 0.8-1.0 0.03  0.9 0.8-1.0 0.04 
    
   
  Condom use (male or female) at last sex 0.9 0.8-1.0 0.01  0.8 0.7-0.9 <0.01 
    
   
  Unprotected sex (any report) 1.3 1.1-1.5 <0.01  1.3 1.2-1.5 <0.0001 
    
   
  Anal sex since last visit 0.7 0.5-1.0 0.01  0.7 0.5-0.9 0.01 
    
   
  Sex in exchange for money or drugs 0.8 0.6-1.2 0.30  0.8 0.6-1.2 0.27 
    
   
  >2 male sex partners since last visit 0.6 0.4-0.8 <0.01  0.5 0.3-0.7 <0.01 
    
   
  New sex partner 0.8 0.7-1.0 0.07  0.8 0.7-1.0 0.03 
    
   
  Suspects/knows male partner concurrency 0.9 0.8-1.1 0.21  0.9 0.8-1.0 0.10 
    
   
  High risk sex 0.8 0.6-0.9 <0.01  0.7 0.6-0.9 <0.01 
(exchange, anal sex, >2 partners, new partner, new regular partner)    
  
    
   
  Vaginal washing 
   
   
       Daily 0.9 0.8-1.1 0.29  0.9 0.8-1.1 0.32 
     Weekly 0.9 0.8-1.1 0.36  0.9 0.8-1.1 0.33 
     Monthly or less 0.7 0.6-0.9 0.01  0.7 0.6-0.9 <0.01 
     None (ref) 1.0 - -  1.0 - - 
     ANY 0.9 0.8-1.0 0.14  0.9 0.8-1.0 0.15 
Vaginal wiping 
   
   
       Daily 0.9 0.8-0.9 <0.01  0.9 0.8-1.0 0.01 
     Weekly 0.8 0.6-1.0 0.04  0.8 0.6-1.0 0.04 
     Monthly or less 0.8 0.6-1.1 0.13  0.8 0.6-1.1 0.14 
     None (ref) 1.0 - -  1.0 - - 
     ANY 0.8 0.8-0.9 <0.01  0.8 0.8-0.9 <0.01 
Vaginal insertion (non-menstruation related) 
   
   
       Daily 0.9 0.8-1.2 0.52  0.9 0.8-1.2 0.49 
     Weekly 0.9 0.5-1.4 0.57  0.9 0.5-1.4 0.57 
     Monthly or less 0.8 0.6-1.1 0.12  0.8 0.6-1.1 0.12 
     None (ref) 1.0 - -  1.0 - - 
     ANY 0.9 0.7-1.0 0.12  0.9 0.7-1.0 0.11 
  
*Compares pregnant visits (reference) to non-pregnant/non-postpartum visits; adjusted models include age, 














Background: Prevalence of sexually transmitted infections (STI) is high among pregnant women in 
certain settings. Few studies have documented STI incidence among pregnant women and whether 
pregnancy increases STI acquisition. We compared STI incidence among pregnant and non-pregnant 
person time among women in a randomized clinical trial.  
Methods: Data came from the Methods for Improving Reproductive Health in Africa (MIRA) study, a 
randomized clinical trial conducted in South Africa and Zimbabwe from 2003-2006. Women 18-50 years 
of age were included in the analysis if they had at least one follow-up visit within 6 months of the date 
of enrollment that included pregnancy and STI testing. All visits included laboratory testing for four STI 
(chlamydia, gonorrhea, trichomoniasis, and HIV) and self-reporting of sexual behaviors and vaginal 
practices. Logistic models were used to examine differences in reported behaviors at follow-up visits by 
pregnancy status. Cox proportional hazards models for individual STI were fitted using pregnancy status 
as a time-varying exposure and reported sexual behaviors and vaginal practices as time-varying 
covariates in adjusted models. Non-pregnant months were further divided by use of hormonal 
contraceptive methods, with months not using hormonal contraception used as the reference group. 
Results: 4,549 women from the MIRA study were included in this analysis (91.9% of all enrolled), 766 
(16.8%) of whom had a lab confirmed pregnancy during follow-up. Median follow-up time was 18 
months [interquartile range (IQR): 12-24]. During pregnancy, most women continued to be sexually 
active but reported less sex. Compared to women who were pregnant, women who were not pregnant 
reported more condom use at last sex (odds ratio(OR) 1.5;95%CI 1.3-1.7) and also more high risk sexual 
behaviors (OR 1.5;95%CI 1.3-1.8). Vaginal practices also appeared to decrease in frequency during 
pregnancy. In multivariable models comparing pregnant periods to non-pregnant periods when women 




However, in analysis of risk in the periods when women became pregnant, they were also at increased 
risk of chlamydia (adjusted hazards ratio (aHR)1.9;95%CI 1.3-2.8).  
Conclusions: In this analysis, we found differences in sexual risk behaviors and vaginal practices 
depending on a woman’s pregnancy status among women enrolled in an RCT in southern Africa. 
Pregnancy did not increase risk of STI acquisition.  However, during the time periods when women 
became pregnant they were also at higher risk for chlamydia infection. Greater efforts are needed to 







High prevalence of sexually transmitted infections (STI) has been observed in some populations 
of pregnant women. Data from routine screening in antenatal care settings in sub-Saharan Africa have 
shown prevalence of bacterial STIs, including chlamydia, gonorrhea and syphilis, to be as high as 
15%.10,22,23,88 Viral STIs (HIV, HSV-2 and HPV) are also very common with up to 30% of pregnant women 
infected with HIV in southern Africa and almost half of all women under 30 years of age infected with 
Herpes Simplex Virus type 2 (HSV-2) across sub-Saharan Africa.2,90  Pregnant adolescents have been 
found to have very high STI prevalence; a study from Portugal found more than 11% of pregnant 
teenagers to have trichomonasis and almost 5% to be infected with gonorrhea.128 Among incarcerated 
pregnant women in the Los Angeles, 11% were infected with chlamydia and gonorrhea prevalence was 
3%.129  
STIs can cause chronic pain as well as permanent infertility in women who do not receive 
treatment. STIs are of particular concern during pregnancy as they can lead to adverse pregnancy 
outcomes including stillbirth and low birth weight which jeopardize the health of women and their 
infants.4,10,17 STIs, primarily HIV, also contribute significantly to maternal mortality;130 HIV is the leading 
cause of maternal mortality in high prevalence settings with infection increasing risk of death for 
pregnant women and mothers up to six-fold.18 An additional concern for pregnant women infected with 
STIs is mother-to-child transmission (MTCT), which can cause serious impairment in children, including 
blindness and developmental delays.7 MTCT of HIV and HSV-2 causes lifelong infection and mortality in 
infected children.8,9,11,21 Data have also shown that incident infection with HIV and HSV-2 during 
pregnancy may confer higher risk of MTCT; however the extent to which MTCT is increased for incident 




Despite evidence of high STI prevalence among some groups of pregnant women, there have 
been few examinations of the timing of STI acquisition in relation to pregnancy. Timing of infection is 
critical for understanding the etiology of STIs in pregnant women for establishing whether women may 
be at greater risk of acquiring STIs while they are pregnant. Studies examining STI incidence during 
pregnancy are few but have shown that acquisition of common infections continues during 
pregnancy.26,69-71,73-75,77,78 A small number of studies have also shown that in settings with high HIV 
burden, women have high risk of infection during pregnancy.80 Further, modeling studies have 
suggested high rates of new HIV infections early in pregnancy (or concurrent with conception).132,133 
Studies comparing incidence of STIs in pregnant and non-pregnant women are very limited and the 
question of whether pregnancy increases STI acquisition risk has only been examined in relation to HPV 
and HIV.31,33,35,74 No increased risk for high risk HPV types was found in pregnant women in Holland,74 
however several studies have shown greater risk of HIV acquisition during pregnancy.31,33,35  
More data are needed to understand whether pregnancy is a time of increased risk for STI 
acquisition, and if so, which STIs pregnant women are most likely to contract and what behavioral and 
biological factors may contribute to this increased risk. Pregnant women may have higher risk of 
acquiring STIs as a result of changes in sexual risk behaviors, particularly sex without a condom.93,94 
There have been few studies examining sexual behaviors of pregnant women or of behavioral changes 
that occur during pregnancy. Available data show that women continue to be sexually active during 
pregnancy, with diminishing frequency as pregnancy progresses.27,29,30 Several studies have shown that 
pregnant women report lower use of condoms compared to women who are not pregnant.30-33 Other 
behavioral risk factors, such as transactional sex in exchange for drugs or money and other types of high 
risk sex, including multiple concurrency of sexual partners and anal sex, are less commonly reported 




women reporting more unprotected sex during pregnancy compared to non-pregnant periods, but less 
frequency of these other high risk behaviors.  
In addition to sexual risk behaviors, vaginal practices, including douching, cleaning, wiping and 
insertion of materials and substances into the vagina, have also been studied as potential behavioral risk 
factors for STI acquisition, particularly HIV.99,101 Women may engage in vaginal practices for hygienec 
purposes, pregnancy prevention, and with the goal of drying and/or tightening the vagina for sex.100 
Women in sub-Saharan Africa have reported particularly high rates of vaginal practices.99 A recent large 
pooled analysis of data found that insertion of cloth or paper into the vagina and cleaning with soap 
were associated with increased HIV risk.101 Limited data have also shown vaginal practices to be 
associated with incidence of chlamydia102 and other STIs.103 The mechanism through which vaginal 
practices increase STI and HIV risk has not been determined; it  may be through abrasions to vaginal 
tissue or alteration of vaginal pH levels leading to bacterial vaginosis (BV) which has been estimated to 
increase women’s susceptibility to HIV by up to 70%.101,104 No studies (aside from this dissertation) have 
examined changes to vaginal practices during pregnancy, making it difficult to understand the potential 
impact of vaginal practices on STI risk specifically among pregnant women. Data from the previous 
chapter of this dissertation suggest that among women in South Africa and Zimbabwe, frequency of 
vaginal practices decreased somewhat during pregnancy.  
Biological changes that occur during pregnancy could also impact women’s STI risk including 
alternations in immune function and physiological changes to the cervix. Significant increases in 
concentrations of progesterone and estrogen during pregnancy may alter innate and acquired immune 
function in a number of ways 49-54 including by reducing the number of natural killer immune cells which 
protect against pathogens,58,59 by contributing to inflammation of the genital tract,60 and/or by 
increasing concentrations of chemokine receptor-5 cells in the cervix which are important co-receptors 




during pregnancy. Cervical ripening that occurs in preparation for delivery may contribute to risk by 
increasing exposure of more vulnerable endocervical cells to pathogens entering the lower female 
genital tract; cervical ectopy, a condition in which columnar epithelial tissue of the inner cervix 
protrudes to the outer cervix, may also occur more frequently during pregnancy and increase risk in the 
same way.36-39,41,45,46 While data suggest biologically plausible ways through which pregnancy could 
increase STI risk, further studies are needed to explore and measure the impact of these potential 
pathways of risk.   
In light of the significant consequences of STIs for women and children and the lack of data on 
whether and how pregnant women may be at greater risk for acquiring infections, it is critical to 
document whether pregnancy is a time of increased vulnerability and to understand the biological and 
behavioral risk factors for STI acquisition among pregnant women. This information could lead to more 
effective efforts to prevent STIs in women of reproductive age which would have a beneficial impact on 
women’s health and the health of their children. In this analysis, we examined differences in sexual risk 
behaviors and vaginal practices according to pregnancy status, measured incidence of four common STIs 
among pregnant and non-pregnant women and compared STI acquisition based on pregnancy status. 








The data for this analysis came from the Methods for Improving Reproductive Health in Africa 
(MIRA) study (see chapter 2 for more information).  
Study procedures 
Detailed study procedures are described in chapter 2 including ethical approvals. For this 
analysis, we examined the association between pregnancy status and risk of acquiring one of four STIs: 
chlamydia, gonorrhea, trichomoniasis and HIV. Women enrolled in the MIRA trial 18-50 years of age 
were included in the analysis if they had at least one follow-up visit that occurred within 6 months of the 
date of enrollment that included both pregnancy and STI testing. For the statistical analysis, pregnancy 
status was treated as a time-varying exposure and selected sexual risk behaviors and vaginal practices 
were treated as time-varying covariates. 
Participant inclusion criteria for analysis 
Only women included in the final analysis of the MIRA trial who were between the ages of 18 
and 50 years of age at enrollment were included in this analysis. All women were HIV-negative at 
enrollment. Women who tested positive for treatable STIs at enrollment, including chlamydia, 
gonorrhea, trichomonasis and syphilis, were not excluded from the analysis, however women who were 
negative at enrollment but tested positive for these infections at the 2 week study visit after enrollment 
were excluded. Women were also excluded from the analysis if they did not have a first study visit 
within 6 months of the date of their enrollment in order to avoid missing information during gaps in 





Follow-up visit inclusion criteria 
For the analyses, only scheduled quarterly follow-up visits were examined (off-schedule, 
additional study visits were excluded). Visits that occurred more than 6 weeks after a woman gave birth 
were also excluded as incidence of STIs during the post-partum period may differ from other non-
pregnant periods.107 In addition, visits that took place more than 6 months from the prior visit were 
excluded in order to ensure that visit schedules were relatively standardized and to improve the ability 
to attribute pregnancy and STIs to a given time period. Finally, visits that occurred after an HIV diagnosis 
for women who seroconverted were excluded as behaviors may have changed as a result of the HIV 
diagnosis.  
Exposure measurement: pregnancy and hormonal contraceptive use status 
As in the previous analysis, pregnancy status was ascertained through laboratory testing and as 
reported by women at scheduled follow-up visits. Women were considered pregnant at a quarterly 
study visit if they had a lab positive human chorionic gonadotropin (HCG) urine pregnancy test 
(laboratory results determined pregnant status regardless of the woman’s knowledge of the pregnancy 
prior to the visit). For the main analysis women were considered non-pregnant at visits with a negative 
pregnancy test even at visits when they reported pregnancies during the interval between the current 
and previous visits (visits with a negative pregnancy test but report of miscarriages or terminations 
between visits were also classified as non-pregnant). Pregnancy status at a given visit was applied to 
determine exposure status during the interval of time prior to that visit; i.e. if a woman was pregnant at 
her third quarterly visit, she was considered to have been pregnant for the full period of time between 
the second and third quarterly visit. For all analyses, women who attended a visit within 6 weeks of 
giving birth were considered pregnant at the study visit because they would have been pregnant for 




For a planned additional analysis, we distinguished time between visits based on whether 
women were pregnant for the full amount of time from those when women became pregnant.  Visits 
when a woman had a lab confirmed pregnancy test and had been pregnant (lab confirmed) at the 
previous visit were considered “established” pregnancies (the woman was pregnant for the full period of 
time between visits). Visits when women had lab confirmed pregnancy tests but at the previous visits 
had not been pregnancy were classified as “newly” pregnant indicating that the pregnancy occurred at 
some point between the previous and current visit. The purpose of this analysis was to distinguish 
between behavior change and incident infections that may have occurred at or near the time of 
conception from those that occurred during established, ongoing pregnancies. (For a sensitivity analysis, 
we also examined a broader definition of pregnancy status which included all lab confirmed and self-
reported pregnancies in order to examine whether inclusion of miscarriages, terminations and other 
self-reported pregnancies would alter results.) 
In addition to classifying women by pregnancy status at study visits, visits that were categorized 
as non-pregnant were further classified according to the type of hormonal contraceptive used which 
was self-reported by women at all visits. Hormonal contraceptive use at visits was categorized into three 
groups: oral contraceptives (including combined estrogen and progesterone and progesterone-only 
pills), injectable hormonal contraceptives (Net-En and Depo Provera), and no use of hormonal 
contraceptives which included women who reported only use of condoms, diaphragm and natural 
methods or no method.  
Outcome: STI incidence 
There were four STI outcomes examined in this analysis: chlamydia, gonorrhea, trichomoniasis 
and HIV. At all quarterly study visits participants were tested for all four STIs. Diagnosis of chlamydia, 




Pharmaceuticals, Branchburg, NJ, USA). HIV testing was conducted with two rapid tests on whole blood 
samples from finger prick or venipuncture; Determine HIV-1/2 (Abbot Laboratories, Tokyo, Japan) and 
Oraquick (Orasure Technologies, Bethlehem, PA, USA). Discordant rapid tests were confirmed with 
ELISA. PCR testing of stored blood samples taken at enrollment were tested at the time of a positive HIV 
test during follow-up to ensure HIV-negative status at enrollment (women found to be HIV-infected at 
enrollment were excluded). Assays were performed at laboratories in Zimbabwe and South Africa which 
were monitored for quality control during the study. All women testing positive for HIV were referred 
for care and treatment services and continued follow-up in the study. Women with positive tests for 
curable STIs were given treatment at the study site.  
For the analysis, the time to first incident infection of each of the four STIs was examined 
(incident infection was defined as the first positive test after a previous negative test) using a Cox 
proportional hazards model. STI infection outcomes were assigned to the quarterly study visit with 
positive test results and matched with the behavioral data that was self-reported at the same visit 
corresponding to their report on the period prior to the visit. Positive STI test results from non-quarterly 
visits (when women sought additional services generally due to symptoms) were carried forward to the 
subsequent quarterly study visit in order to be matched with the corresponding reported behavioral 
data from the same visit interval.   
Covariates  
We examined both time-fixed and time-varying hypothesized confounders in the analysis. The 
time-fixed covariates were age at enrollment, education (completion of high school), intervention arm 
(diaphragm or control), contraceptive use at enrollment, binary variables indicating any high risk sexual 
behaviors and high partner risk at enrollment. High risk sex at enrollment and during follow-up was 




two or more sexual partners, a new sexual partner or sex under the influence of drugs or alcohol. Male 
partner high risk sexual behavior (only measured at enrollment) which was reported by women, was 
indicated by known HIV-infected status, being away from home for more than one month in past year, 
use of drugs during sex and if the woman knew or suspected her male partner of having other sex 
partners. Time-varying covariates (measured at all quarterly study visits) included any reported vaginal 
sex and frequency of sexual activity between study visits, use of condom at last sex act, any unprotected 
sex (without a condom) between visits, sex in exchange for money or drugs, two or more sex partners, 
having a new sex partner, suspecting or knowing that a male partner had other partners and a binary 
indicator variable indicating any high risk sexual risk behaviors (exchange sex, anal sex, 2 or more 
partners, new sex partner, sex under the influence of drugs or alcohol). Vaginal practices, categorized as 
any report of washing, wiping or inserting paper products into the vagina (not for menstruation), were 
also treated as time-varying covariates and examined by frequency (daily, weekly, monthly or no report) 
and as a binary variable indicating any report.  
Statistical analysis 
Enrollment characteristics  
Descriptive statistics were used to compare demographic characteristics and frequency of 
reported sexual behaviors and vaginal practices at enrollment for women 18-50 years of age included in 
the analysis according to whether they had at least one pregnancy during follow-up. Women with lab 
positive pregnancies were compared to women with no reported or lab-confirmed pregnancies for 
characteristics and behaviors reported at enrollment using chi-squared tests for categorical variables 
and Wilcoxon tests for continuous variables. We also examined differences between women included in 




month time lag between enrollment and their first quarterly visit in order to determine any potential 
bias in the exclusion of participants.  
Association between pregnancy status and reported behaviors at follow-up visits  
Descriptive statistics were used to compare reported sexual behaviors and vaginal practices at 
quarterly follow-up visits according to pregnancy status and non-pregnant visits with or without HC-use. 
To compare frequency of reported behaviors and measure associations between pregnancy (and HC-
use) status at visits, general estimating equations (GEE) models with robust standard errors were used 
to account for multiple observations per participants. Unadjusted (univariable) logistic regression GEE 
models were fitted with pregnancy status modeled as the independent variable (pregnant visits were 
the referent group) and sexual risk behavior and vaginal practice were treated as dependent variables. 
Crude odds ratios with 95% confidence intervals are reported for each sexual risk behavior and vaginal 
practice. For modeling dependent variables with more than two categories (such as vaginal practice 
frequency), individual logistic GEE models were run comparing each categorical level of the variable to a 
common reference level for the variable (for example three individual models were run comparing daily, 
weekly and monthly vaginal washing to the reference category of “no vaginal washing”).  
We also conducted the same analyses distinguishing between established and new pregnancies 
to examine differences in behaviors based on known pregnancy. For the analysis of behaviors reported 
at visits during established pregnancies vs newly pregnancy visits, the referent group for was established 
pregnancy visits. We further conducted sensitivity analysis repeating these models using the broader 
definition of pregnancy that included self-reported pregnancies.  
STI incidence rate calculations 
To estimate incidence of STIs during pregnant and non-pregnant periods, each of the four STIs 




the study to the first diagnosis of each STI or the end of study follow-up (in this analysis). In order to 
calculate incidence rates, follow-up time at risk was estimated by summing the intervals of time 
between visits for each participant. For intervals between visits that culminated in a positive test 
(incident STI infection), the midpoint between the last visit when the participant was negative and the 
visit with the positive test was used to estimate follow-up time at risk for that visit interval. Incidence 
rates were calculated for each of the exposure groups: pregnant, non-pregnant/oral HC, non-
pregnant/injectable HC and non-pregnant/no HC use. Incidence rates (in person years) for each 
exposure group were calculated by dividing the corresponding follow-up time at risk for each exposure 
into the number of cases that occurred when women were in the corresponding exposure groups. In 
addition, overall incidence of each STI using all incident infections and all follow-up time, regardless of 
exposure group, was also calculated. 
Modeling of incidence of STIs and comparison between pregnant and non-pregnant periods 
Cox proportional hazards models were fitted to examine the relationship between pregnancy 
status and incidence of each of the four STIs separately and a composite measure of first incidence 
infection with any of the four STIs. Pregnancy was treated as a time-varying exposure and sexual risk 
behaviors and vaginal practices were treated as time-varying covariates; demographic and enrollment 
characteristics were modeled as time-fixed covariates. Univariable and multivariable Cox proportional 
hazards models were fitted using time-fixed and time-varying covariates accounting for different follow-
up time per participant. Adjusted models included the following a priori hypothesized confounders: 
time-fixed demographic variables (age, study location, education and randomization arm), as well as 
enrollment characteristics (contraceptive use, report of high risk sex, having a high risk partner and 
having an STI including chlamydia, gonorrhea, trichomonasis or HSV-2) as well time-varying sexual risk 
behaviors and vaginal practices (see above). In a separate analysis, multivariable models were adjusted 




status on the outcomes; no differences were found between those models, thus the models using a 
priori covariates are reported. Study location was also tested for potential effect measure modification 
on the multiplicative scale using a cross-product term to examine whether the relationship between 
pregnancy and STI incidence differed by study location.   
We further implemented these models comparing established and newly pregnant status.  
Finally, we conducted two additional sensitivity analyses of these models using the broader definition of 
pregnancy as well as a complete case analysis including only those women who attended all scheduled 
follow-up visits in order to examine potential biases associated with follow-up time that was not 
accounted for (gaps as a result of missed follow-up visits). 
 
Impact of location on enrollment characteristics, reported behaviors at follow-up and differences in 
incidence  
In addition to examining whether location was an effect modifier in the relationship between pregnancy 
status and STI outcomes as described above, location was also examined to determine differences in 
demographic characteristics and reported sexual risk behaviors at the time of enrollment and at study 
follow-up visits. Unadjusted logistic regression models were used to examine differences at enrollment 
among individual women, and at all follow-up visits models used GEE to account for unequal numbers of 
visits attended by participants. Incidence rates of each of the four STIs by pregnancy status was 





Of the 4,948 women analyzed in the MIRA trial, 4,935 were 18-50 years of age at enrollment 
and 4,552 had at least one follow-up visit with STI and pregnancy testing that was within six months of 
the date of enrollment and prior to HIV infections (Figure 4.1). 382 women did not have a follow-up visit 
within six months of enrollment and were excluded; four additional women were excluded because they 
tested positive for chlamydia or trichomoniasis at the two week study visit. Among the 4,549 women 
included in the analysis (91.9% of all enrolled), 766 (16.8%) women had a lab confirmed pregnancy and 
of the 24,337 visits included in the analysis, 1,609 (6.6%) were during a pregnancy. Median follow-up 
time among women included in the analysis was 18 months [interquartile range (IQR): 12-24]; among 
women with pregnancies, median follow-up was 15 months [IQR: 12-21] and among those with no 
pregnancies, it was 18 months [IQR: 12-24] (p=0.47).  
Enrollment: demographic characteristics, reported sexual risk behaviors and vaginal practices  
At enrollment, women who went on to have pregnancies during follow-up were more likely to 
be from Zimbabwe (compared to South Africa) and were younger; the median age for women who had a 
pregnancy was 25 years (range: 18-47) whereas the median age of women who did not have a 
pregnancy was 28 years (range: 18-50) (p<0.0001) (Table 4.1). Women with pregnancies during follow-
up were more likely to have completed high school and were less like to have children at enrollment. 
There were no differences between women with and without pregnancies in other demographic 
characteristics, including employment and marital status or cohabitation with male partners at 
enrollment. Women who had pregnancies during follow-up were more like to report use of oral 
contraception and to have had 2 or more sexual partners at enrollment compared to women who did 
not have pregnancies (Table 4.1). Women without pregnancies were more likely to report injectable 




enrollment compared to those who had pregnancies during follow-up. There were no other differences 
in reported sexual behaviors, male partner characteristics or STI status at enrollment.  
In a separate analysis shown in Appendix 4.1, enrollment characteristics were examined to 
identify differences between women with pregnancies during follow-up, those without, as and the 386 
women aged 18-50 years who were excluded from the analysis. Among the excluded women, 62 (16.1%) 
had a lab confirmed pregnancy during follow-up. Excluded women were younger than women who did 
not have pregnancies but somewhat older than women with pregnancies (Appendix 4.1). Excluded 
women as a group were also more likely than women without pregnancies and less likely than women 
with pregnancies to have completed high school; they were also more likely than women with 
pregnancies to have had a previous pregnancy. Women who were excluded reported significantly more 
sex per week than either group of women included in the analysis and were more likely to have a male 
partner of the same age (Appendix 4.1). 
Association between pregnancy status and behaviors reported at follow-up visits 
Women were pregnant at 1,609 (6.6%) of follow-up visits included in the analysis. At the 
remaining non-pregnant visits: 8,375 (34.4%) included report of oral contraceptives, at 6,028 (24.8%) 
women reported injectable HC use and at 8,325 (34.2%) women reported no HC use (including 
condoms, natural or no methods). Compared to visits during pregnancy, women were more likely to 
report any vaginal sex and >3 sex acts per week at non-pregnant visits when they were using oral HC 
(any sex: OR 1.7; 95%CI 1.3-2.3) and less likely when using no HC (any sex: OR 0.6; 95%CI 0.5-0.8) (Table 
4.2). At all non-pregnant visits, regardless of HC type, women were significantly more likely to report last 
sex with a condom and less likely to report any unprotected sex (without a condom) compared to visits 
when women were pregnant; the odds of reporting sex without a condom between visits were 30% 




0.6-0.8). Women using injectables and those not using HC were almost twice as likely to report two or 
more sex partners and more frequently reported new sex partners between visits (Table 4.2). High risk 
sex (anal sex, sex in exchange for drugs or money, two or more sexual partners or a new sexual partner) 
was more commonly reported during periods when women were using injectables or no contraception 
compared to when women were pregnant (Table 4.2).  
Vaginal washing appeared to be more common at visits when women were using oral HC 
compared to pregnant visits overall and on a daily and monthly basis. However, the odds of vaginal 
washing did not differ between visits during pregnancy and when women were using injectables or 
reported no HC use (Table 4.2). Vaginal wiping was significantly more common at visits women were not 
pregnant, regardless of the type of HC use or when they were not using any HC; at visits with no HC use, 
the odds of vaginal wiping were 30% higher than at pregnant visits (OR 1.3;95%CI 1.1-1.4) and were 40% 
higher at visits with reported oral HC use (OR 1.4;95%CI 1.2-1.5). Non-pregnant status was also 
associated with increased frequency and overall reporting of vaginal insertion of paper products 
compared to visits when women were pregnant (Table 4.2).   
In the analysis distinguishing between established and new pregnancies, 800 (3.3%) of all visits 
occurred were newly pregnant visits and 809 (3.3%) were during established pregnancies (Table 4.4). At 
newly pregnant visits, only 24.3% of women knew about their pregnancies before the visit while most 
(75.6%) learned of their pregnancy at the visit. Newly pregnant women were more than twice as likely 
to report any vaginal sex compared to women with established pregnancies (OR 2.3;95%CI 1.6-3.1) but 
were significantly less likely to report unprotected sex during the visit interval when they became 
pregnant (OR 0.7;95%CI 0.6-0.9). During newly pregnant visits, women were more likely to report two or 
more sexual partners and were more likely to report high risk sex compared to established pregnancy 
visits (OR 1.3;95%CI 1.1.-1.7). These findings were similar to the main analysis which showed that non-




wiping and insertion, were also more commonly reported by women when they were newly pregnant 
compared to during established pregnancy visits (Table 4.4).  
Results from the sensitivity analysis using the broader definition of pregnancy led to 1,744 
(7.2%) visits being classified as occurring during pregnancy (Table 4.3) and did not differ from the main 
analysis.   
STI Incidence rate  
The overall incidence rate of chlamydia in the 4,949 women included in the analysis was 6.7 per 
100 person years (py) (Table 4.5). Chlamydia incidence was 9.9/100py during pregnancy, 10.1/100py 
during injectable HC use and 4.1/100py during oral HC use. Gonorrhea incidence across all follow-up 
time was lower overall (2.7/100py) but was highest during periods when women were pregnant at 
4.9/100py and lowest when women reported oral HC (1.6/100py). Trichomoniasis incidence was the 
most common of all the STI measured; the incidence was 7.1/100py overall, and was highest during 
pregnancy 9.2/100py. HIV incidence among the women included in this analysis was 3.9/100py across all 
follow-up periods with the highest incidence occurring when women reported using injectable HC 
(4.8/100py) and when they were not using any HC (4.4/100py). The HIV incidence rate during pregnancy 
was 3.8/100py and 2.6/100py when women were using oral HC (Table 4.5).  
In the analysis which separated visits during established pregnancies from first pregnancy visits, 
incidence of chlamydia was lower during established pregnancies, 3.8/100py, compared to first 
pregnant visits when it was very high, 15.4/100py (Table 4.5). For gonorrhea however, the opposite was 
true, most infections occurred during established pregnancies (6.2/100py) whereas the incidence rate at 
newly pregnant visits was 3.8/100py. Trichomoniasis incidence was similar among women with 
established pregnancies and for those who were newly pregnant with both periods somewhat higher 




3.0/100py, compared to those with new pregnancies who had the highest HIV incidence among all 
exposure groups, 4.6/100py (Table 4.5).  
Sensitivity analysis using the broader definition of pregnancy did not change these results 
substantially (Table 4.5). Trichomoniasis and HIV incidence rates were slightly higher in these models, 
increasing to 9.6/100py and 4.4/100py, respectively.   
Modeling of incidence of STIs and comparison between pregnant and non-pregnant periods  
In unadjusted models, pregnancy was associated with an increased risk of chlamydia compared 
to periods when women were not pregnant and reported no HC use (hazard ratio (HR) 1.5;95%CI 1.1-
2.2). In multivariable adjusted models however, the effect of pregnancy on chlamydia incidence was 
attenuated and the effect was no longer significant (Table 4.5a). Pregnancy did not appear to increase 
the hazards of gonorrhea, trichomoniasis or HIV infection (Tables 4.5b-d). Neither oral nor injectable HC 
use was associated with increased hazards of any of the four STIs (Tables 4.5a-d). There also was no 
association found between pregnancy status and the combined STI composite of incidence of any of the 
four STIs (Table 4.5e). Location was not found to be an effect modifier of the relationship between 
pregnancy and STI risk in adjusted models.   
Other factors that appeared to be associated with increased hazard of chlamydia infection in 
adjusted models included being from South Africa (compare to women in Zimbabwe), younger age (aHR 
18-25 vs. >35 5.6;95%CI 3.8-8.2), having an STI at enrollment (aHR 1.5;95%CI 1.2-1.9), reporting 
unprotected sex since last visit (aHR 1.3;95%CI 1.0-1.7) and suspecting or knowing a male partner to 
have other sexual partners (aHR 1.3;95%CI 1.0-1.6) (Table 4.5a). The same factors were associated with 
gonorrhea incidence in adjusted models. For trichomonasis, only women in Johannesburg, South Africa 
appeared at higher risk compared to women in Zimbabwe (aHR 1.2;95%CI 1.2-2.0) but age was not 




from Johannesburg (aHR 2.0;95%CI 1.4-2.9), younger age (aHR 18-24 vs >35 2.6;95%CI 1.7-3.9), use of 
injectable contraceptives at enrollment (aHR 1.8;95%CI 1.0-3.1), STI at enrollment (aHR 2.1;95%CI 1.5-
2.8) and suspecting or knowing of partner concurrency (aHR 1.5;95%CI 1.1-2.0) (Table 4.5d).  
Vaginal practices did not appear to be associated with risk of chlamydia, gonorrhea or 
trichomoniasis in unadjusted or adjusted models (Table 4.5a-c). Vaginal wiping was associated with 
increased hazard of HIV (aHR 1.5;95%CI 1.1-2.0)(Table4.5d). 
In the analysis distinguishing between established and new pregnancies, women who were 
newly pregnant had almost twice the hazard of incident chlamydia infection compared to non-pregnant 
women who were not using HC (aHR 1.9;95%CI 1.3-2.8) (Table 4.6a). Established pregnancy status did 
not increase chlamydia risk compared to non-pregnant time. Hazard of incident gonorrhea, 
trichomoniasis and HIV incidence did not appear to be higher during either established or new 
pregnancies compared to when women were not pregnant women and not using HC (Table 4.6b-d). 
There also was no association found between new or established pregnancy status and the combined 
STI composite of incidence of any of the four STIs (Table 4.6e) 
The two sensitivity analyses, using the broader definition of pregnancy status (Appendix 4.4a-d) 
and the complete case analysis (Appendix 4.54a-d), to examine any biases introduced by visit gaps, did 
not show any differences from the main analysis. 
Impact of location on enrollment characteristics, reported behaviors at follow-up and differences in 
incidence  
The analysis of differences in characteristics at the time of enrollment is show in Appendix 4.6 
and found that women from Zimbabwe were more likely to be younger than 24 years of age (OR 0.6; 
95%CI 0.5-0.7)  and to use oral contraceptive compared to women in either Durban or Johannesburg. At 




0.9), while women in Zimbabwe were least likely to report that their male partners as high risk 
(Appendix 4.6). At follow-up visits, Zimbabwean women were most likely to be pregnant and to report 
use of oral contraceptives at visits when they were not pregnant. Women in Durban and Johannesburg 
reported less sex between visits compared to women in Zimbabwe, as well as more condom use but also 
more high risk behaviors such as sex with multiple partners and new sexual partners (high risk sex 
reported by women in Johannesburg compared to women in Zimbabwe OR 1.9; 95%CI 1.7-2.1) 
(Appendix 4.6). All three types of vaginal practices were more commonly reported by women from 
Zimbabwe compared to women in Durban.  
Incidence of the four STIs measured in the study also varied by location with Zimbabwe showing 
the lowest incidence for all (Appendix 4.7). Chlamydia incidence was 3.6 /100py in Zimbabwe compared 
to 10.3/100py in Durban and 10.8/100py in Johannesburg. Women in Durban and Johannesburg had 
higher incidence of gonorrhea at 4.3/100py and 3.8/100py, respectively, whereas incidence in 
Zimbabwe was 1.5/100py. The rate of trichomoniasis incidence was also lower in Zimbabwe compared 
to Durban and Johannesburg. Finally, HIV incidence was highest in Durban at 6.8/100py compared to 






In this secondary analysis of data from an RCT conducted in South Africa and Zimbabwe, we 
examined the association between pregnancy status and incidence of four common STIs: chlamydia, 
gonorrhea, trichomoniasis and HIV. The analysis included 4,549 women 18-50 years of age who 
attended over 24,300 study visits. Roughly 17% (N=766) of women had a pregnancy during follow-up 
and attended 1,609 visits (7% of all study visits) while pregnant. We found that during pregnancy, most 
women continued to be sexually active but reported less overall sex than non-pregnant women. We also 
found that reporting of condom use was lower during pregnancy but other types of high risk sexual 
behaviors, such as multiple sexual partners, sex in exchange for drugs or money and anal sex, were less 
commonly reported during pregnancy. Vaginal practices also appeared to decrease in frequency during 
pregnancy. We also found that incidence of all four measured STIs continued during pregnancy and that 
in periods when women became pregnant they appeared to be a high risk for acquiring chlamydia, 
trichomoniasis and HIV. Finally, in examining the association between pregnancy status and STI risk, we 
found that in multivariable models adjusted for demographic and time-varying self-reported behavioral 
risk factors and vaginal practices, pregnancy was not associated with STI risk. However in visit intervals 
when women became pregnant, they appeared to be at higher risk for contracting chlamydia compared 
to non-pregnant periods.  
At enrollment, the women who went on to have pregnancies during follow-up were younger, 
somewhat more educated, had lower parity and were more likely to be using oral contraceptives 
compared to injectable contraception. These findings are in keeping with other previous reports from 
HIV prevention trials,134-136 including a review of data from ten vaginal microbicide trials.137 In addition, 
women with pregnancies during follow-up were more likely to be infected with HSV-2 at enrollment 




(SSA), increases with age.2 We did not find other significant differences at enrollment between women 
who went on to have pregnancies during follow-up compared to those who did not.   
In the examination of sexual risk behaviors and vaginal practices, pregnant women reported 
somewhat less sex but were more likely to report sex without a condom and  less likely to report high 
risk sexual behaviors that are associated with STI acquisition. These findings are in keeping with previous 
studies29-33 and are evidence of the complicated picture of pregnant women’s STI risk. In the analysis 
distinguishing between established and new pregnancies, newly pregnant women were much more 
likely to report sexual activity compared to during established pregnancies but were significantly less 
likely to report unprotected sex. This finding is interesting given that newly pregnant women must have 
had some vaginal sex without a condom in order to become pregnant and it may suggest biases in 
reporting of condom use by women based on pregnancy status. Over reporting of condom use is known 
to be common in studies,114,115,117,118 however factors associated with differential reporting of sexual risk 
behaviors, including pregnancy status, have not been established. If women who are not pregnant or do 
not know they are pregnant are more likely to report condom use compared to pregnant women, which 
our data suggest, this could lead to differential misclassification of this important predictor of STI 
acquisition. Further studies are needed to understand and measure the potential biases associated with 
differential misreporting of condom use by pregnancy status.   
We found higher incidence of chlamydia, gonorrhea and trichomoniasis when women were 
pregnant compared to the overall incidence rate for all follow-up visits. There are few data with which 
to compare our findings on chlamydia, gonorrhea and trichomoniasis as there have not been many 
previous analyses examining incidence of STIs during follow-up studies of pregnant women. The HIV 
incidence we report during pregnancy, 3.8 per 100 person years, is similar to three previous reports 
from cohorts in sub-Saharan Africa; pregnant women in our study had higher incidence than that 




per 100 person years)33 but very similar to infection rates in a multi-country study (conduct in seven SSA 
countries) which found incidence during pregnancy to be 3.6 per 100 person year.31 These incidence 
rates are in keeping with previous studies of HIV infection in non-pregnant women in Southern African 
women which have found incidence ranging from 3.0 to 6.5 per 100 person years.138-140 Our data are 
further confirmation that women in Southern Africa face high HIV infection risk and that they continue 
to be at risk during pregnancy.  
Our analysis did not find that pregnancy increased the risk for acquiring chlamydia, gonorrhea, 
trichomoniasis or HIV in adjusted models. There are few data with which to compare these findings as 
there have been no previous studies measuring increased risk of chlamydia, gonorrhea and 
trichomoniasis during pregnancy. Our findings showing no increased risk of HIV is in keeping with three 
previous analyses which used follow-up data from prospective cohorts and RCTs to examine increased 
risk during pregnancy and also found no effect of pregnancy in adjusted models.31-33 One further study, 
conducted in Rakia, Uganda in over 2,100 women did find increased risk35 however this finding has not 
been replicated.  
While the focus of this analysis was on evaluating whether pregnancy increased STI risk, we also 
examined other factors that were associated with acquisition of infections. Women from South Africa 
appeared to have significantly higher STI incidence of all four infections which has previously been 
reported from this study.141 Younger age (18-25 compared to women 35 and older) was also strongly 
associated with incidence of chlamydia, gonorrhea and HIV which is in keeping with previous 
analyses.138,142 Other demographic and enrollment factors, including education, contraceptive use (at 
enrollment), and having a high risk partner were not significant predictors of risk. Having an STI at 
enrollment was a strong and significant predictor of risk for all STI outcomes in this analysis which may 
suggest, in part, that women’s male partners were infected and may have re-infected them over the 




reported by women over the course of follow-up in general did not appear to be good predictors of risk. 
In particular reporting of unprotected sex and condom use at last sex were inconsistent in predicting risk 
– while associated with increased risk of chlamydia and gonorrhea, they were not associated with 
trichomoniasis or HIV incidence. This inconsistency is in keeping with previous findings from other 
studies117 and as noted above, reporting of these factors appeared to be systematically different among 
pregnant and non-pregnant women which may contribute to the conflicting findings for the four STIs.  
One risk factor that was independently associated with increased risk for all STI outcomes was 
women suspecting or knowing that male partners had other sexual partners. In our study, women 
reported that male partners were more likely to have other sexual partners (known or suspected) during 
non-pregnant periods compared to pregnancy periods. This finding is not consistent with a previous 
analysis from Malawi in which women reported more suspected male partner concurrency during 
pregnancy.30 While sexual concurrency is thought to be one of the most important risk factors for STI 
acquisition,143,144 reported knowledge of a partner’s concurrency has not been widely reported as a 
predictor of STI incidence. In a small study in Jamaica, women’s report of male partner concurrency was 
found to be associated with women’s STI prevalence.145 These data suggest that women may have some 
information about their own STI risk and that despite this, may be unwilling or unable to protect 
themselves from infection. This finding warrants further examination in order to understand the reasons 
that women continue to have unprotected sex with male partners who are having concurrent 
partnerships.  
Vaginal practices were also examined as risk factors for STI infection and were not found to 
consistently increase risk, although vaginal wiping was associated with HIV incidence in our study. At 
enrollment and during follow-up a high proportion of women reported vaginal practices: at enrollment, 
more than 80% of women reported some vaginal washing with more than 60% reported daily washing. 




women, respectively, at enrollment. These findings confirm previous reports of high rates of vaginal 
practices among women of reproductive age in sub-Saharan Africa.99 This analysis (along with the 
previous chapter of this dissertation) provides some of the first data on changes in vaginal practices 
during pregnancy, which appear to decrease. The finding that vaginal wiping was associated with HIV 
risk is consistent with a recent large pooled analysis101 but differ from two previous studies which found 
douching to be associated with higher incidence of chlamydia, gonorrhea and trichomoniasis.102,103 One 
reason that vaginal practices may not have been associated with increased acquisition of other STIs 
could in part be a result of the observed decrease in vaginal practices over the course of the trial which 
was reported in a previous analysis.126  
Our analysis is unique in distinguishing STIs acquired during established pregnancies from those 
contracted during the visit intervals in which women became pregnant. We found that chlamydia risk 
was much higher in visit intervals when women became pregnant – 15.4/100py compared to 3.8/100py 
during established pregnancy visits, with newly pregnant status conferring almost twice the hazards 
when compared to non-pregnant women (aHR 1.9;95%CI 1.3-2.8). We also found that women had 
significantly higher risk of chlamydia infection during periods when they become pregnant compared to 
non-pregnant periods. These finding are novel but not necessarily surprising – in periods when women 
became pregnant they were, by definition, having at least some sex not protected by condoms thus 
exposing them to STIs from infected partners. There are few previous studies that have examined 
concurrency of incident pregnancy and STI acquisition. These findings suggest that some women may be 
taking risks with regard to STIs in order to become pregnant and that partners of younger women, who 
were more likely to become pregnant, are more likely to be infected with STIs, specifically chlamydia. 
Further studies are needed to explore the reasons women are engaging in unprotected sex and what 




This study has a number of strengths. This analysis is one of only a few longitudinal studies to 
examine whether women are at greater risk of acquiring STIs during pregnancy. While several previous 
studies have looked at pregnancy as a risk factor for HIV, there are no previous examinations of 
increased risk of chlamydia, gonorrhea and trichomoniasis with prospective follow-up including periods 
when women were not pregnant. Previous studies have also not included data on vaginal practices 
which are considered important risk factors for HIV and other STI infections. The analysis is further 
strengthened by using data from a rigorously conducted RCT with high rates of follow-up and study 
completion. Our statistical analysis also allowed for changes in behaviors by including time-varying 
covariates.  
The analysis also has some important limitations. One of the main limitations is that women 
self-reported sexual risk behaviors and vaginal practices and we did not have the means through which 
to validate any information. As noted above, we observed differential reporting of unprotected sex by 
women when they were newly pregnant suggesting that there may be systematic biases in this 
important risk. The impact of this potential bias most likely would bias our results towards the null by 
making pregnant women appear to have more unprotected sex and thus reducing any real effect of 
pregnancy on STI outcomes after adjustment for this misclassified condom use variables. Unfortunately 
we cannot know the extent of the bias or the impact on our results. Women also self-reported 
contraceptive use and may also be misclassified according to what type of hormonal contraceptives they 
were using. This misclassification could have had an impact on our results as conflicting data have 
shown that women using injectable progesterone-only hormonal contraceptives are at increased risk for 
STIs, including chlamydia, gonorrhea and HIV.51,119,120 If women who were using injectable HC were 
classified as not using any HC and injectable HC use increase STI risk, this could have biased our results 
towards the null masking any increased risk from pregnancy. Another limitation is that we did not have 




women’s knowledge of male partner behaviors which may have been inaccurate or incomplete. Finally, 
our statistical analysis included a multilevel exposure variable (pregnancy and HC use status) which led 
to multiple comparisons which could have increased the likelihood of a type error in finding statistical 
significance.  
This analysis provides important information about women’s risk of acquiring sexually 
transmitted infections, including HIV. Overall we did not find that pregnancy increased the risk for 
acquiring chlamydia, gonorrhea, trichomoniasis or HIV. Women were more likely to acquire chlamydia in 
periods when they become pregnant. Younger age, having had an STI previously and knowledge of a 
partner’s concurrency were important risk factors for STI incidence. We also presented novel 
information about changes in sexual risk behaviors and vaginal practices during pregnancy. These data 
are important for understanding STI risk among women of reproductive age and may contribute to 





Figure 4.1 Patient flow diagram  
4,948 HIV-negative women analyzed in MIRA trial* 
4,553 women had at least one visit after enrollment that 
was within 6 months of enrollment 
382 women had only one visit during follow-up or 
had a first visit that was >6 months after 
enrollment 
4,549 women were included in the analysis  4 women tested positive for chlamydia 
or trichomoniasis at the 2 week visit 
13 women >50 years of age  4,935 women <50 years of age  
5,045 women were randomized in the trial: 3 were excluded because they were underage, 3 women discontinued 
on date of randomization, 72 had no HIV results post-enrollment and 19 were found to have been infected with 




Table 4.1 Characteristics at enrollment of 4,549 MIRA participants with and without pregnancies 
during follow-up 
Characteristics at enrollment Total  
Women with no 
pregnancies  
Women with lab 
confirmed 
pregnancies p value 
 
N % N % N % 
 4549 100.0% 3783 83.2% 766 16.8% 
Study location        
    Harare 2255 49.6% 1847 48.9% 408 53.3% 0.02 
    Durban 1372 30.2% 1173 30.9% 199 26.0%  
    Johannesburg 922 20.3% 763 20.2% 159 20.8%  
Age        
     Median age (range) 27 (18-50) 28 (18-50) 25 (18-47) <0.0001 
     18-24 1725 37.9% 1342 35.5% 383 50.0% <0.0001 
     25-34 1782 39.2% 1472 38.9% 310 40.5%  
     >35 1042 22.9% 969 25.6% 73 9.5%  
Completed high school (11 yrs school) 2347 51.6% 1904 50.3% 443 57.8% <0.01 
Paid employment 1039 22.4% 883 23.4% 156 20.4% 0.07 
Married 2695 59.3% 2245 59.4% 450 58.8% 0.75 
Lives with male partner 3081 67.7% 2572 68.0% 509 66.5% 0.33 
Number or previous pregnancies        
     None 387 8.5% 280 7.4% 107 14.0% <0.0001 
     1 previous pregnancy 1446 31.8% 1151 30.4% 295 38.5%  
     2+ previous pregnancies 2716 59.7% 2352 62.2% 364 47.5%  
Current birth control (not mutually exclusive)       
     Combined pills 991 21.8% 770 20.4% 221 28.9% <0.0001 
     Injectable hormones 1129 24.8% 1029 27.2% 100 13.1% <0.0001 
     Progesterone only pills 663 14.6% 566 15.0% 97 12.7% 0.10 
     Intrauterine device 16 0.4% 15 0.4% 1 0.1% 0.47 
     Condoms (male or female) (only) 1723 37.9% 1419 37.5% 304 39.7% 0.25 
     None (natural, withdrawal, tradition) 247 5.4% 194 5.1% 53 6.9% 0.05 
Regular sexual partner 1852 40.7% 1537 40.6% 315 41.1% 0.44 
Age at first sex (mean and range) 18 (10-31 18 (10-31) 18 (11-27) 0.36 
Sex acts per week        
     None 1877 41.3% 1551 41.0% 326 42.6% 0.65 
     1-2 per week 275 6.1% 227 6.0% 48 6.3%  
     >3 per week 2397 52.7% 2005 53.0% 392 51.2%  
Number of sexual partners in past 3 months       
     None 273 6.0% 249 6.6% 24 3.1% <0.0001 
     1 partner 3877 85.5% 3222 85.4% 655 85.5%  
     2+ 387 8.5% 300 8.0% 87.0 11.4%  
Condom use (male or female) at last sex 3200 70.4% 2653 70.1% 547 71.4% 0.48 
Condom use (vaginal sex) in last three months       
     Never 1338 29.5% 1132 30.0% 206 26.9% 0.16 
     Sometimes 1767 38.9% 1449 38.4% 318 41.5%  
     Every time 1433 31.6% 1191 31.6% 242 31.6%  
Exchange for money or drugs past 3 months 360 7.9% 303 8.0% 57 7.4% 0.59 
Anal sex (ever) 669 14.8% 53 14.7% 116 15.1% 0.74 





Table 4.1 continued 
Characteristics at enrollment Total  
Women with no 
pregnancies  
Women with lab 
confirmed 
pregnancies p value 
 
N % N % N % 
 High risk  1059 23.3% 874 23.1% 185 24.2% 0.53 
(>2 partners, exchange, anal, sex w/ drugs/alcohol) 
     Partner age 
            Same age (+/-5 years) 2510 57.8% 2077 57.7% 433 58.2% 0.11 
     Younger (more than 5 years) 50 1.2% 47 1.3% 3 0.4% 
      Older (more than 5 years) 1785 41.1% 1477 41.0% 308 41.4% 
 Partner tested HIV positive 
            Yes 156 3.4% 135 3.6% 21 2.7% 0.24 
     No/don't know 4380 96.6% 3635 96.4% 745 97.3% 
 Partner away from home >2 months 490 10.9% 413 10.9% 77 10.1% 0.49 
Partner circumcised 976 21.5% 805 21.4% 171 22.3% 0.70 
Suspects/knows partner concurrency 1392 30.7% 1159 30.7% 233 30.4% 0.86 
Physical or verbal abuse  821 33.0% 693 33.0% 128 33.4% 0.86 
Partner used force to get sex 244 9.8% 208 9.9% 36 9.4% 0.76 
Sex w/ partner with drugs or alcohol 1622 35.9% 1351 36.0% 271 35.5% 0.80 
Partner high risk  2836 62.3% 2363 62.5% 473 61.8% 0.71 
(HIV+, away >1 month, other partners, drugs) 
      Vaginal washing 
            Daily 2778 61.2% 2289 61.0% 480 62.7% 0.59 
     Weekly 658 14.5% 558 14.8% 100 13.1% 
      Monthly or less 320 7.1% 263 7.0% 57 7.4% 
      None 781 17.2% 652 17.3% 129 16.8% 
      ANY 3756 82.6% 3119 82.5% 637 83.2% 0.80 
Vaginal wiping 
            Daily 1832 40.4% 1525 40.5% 307 40.1% 0.55 
     Weekly 435 9.6% 353 9.4% 82 10.7% 
      Monthly or less 293 6.5% 239 6.3% 54 7.1% 
      None 1977 43.6% 1654 43.9% 323 42.2% 
      ANY 2560 56.3% 2117 56.0% 443 57.8% 0.43 
Vaginal insertion (non-menstruation related) 
           Daily 598 13.2% 504 13.4% 94 12.3% 0.83 
     Weekly 159 3.5% 130 3.5% 29 3.8% 
      Monthly or less 189 4.2% 156 4.1% 33 4.3% 
      None 3589 79.1% 2979 79.0% 610 79.6% 
      ANY 946 20.8% 790 20.9% 156 20.4% 0.58 
Diaphragm arm 2273 50.0% 1890 50.0% 383 50.0% 0.99 
Positive for STI (enrollment) 
            Chlamydia 195 4.3% 155 4.1% 40 5.2% 0.16 
     Gonorrhea 34 0.8% 29 0.8% 5 0.7% 0.74 
     Trichomoniasis 166 3.7% 133 3.5% 33 4.3% 0.29 




Table 4.2 Risk behaviors reported at follow-up visits by 4,549 women and the association with 
pregnancy status (unadjusted odds ratios) (N=24,337 visits) 
 




Oral HC use 
visits 
Injectable HC 
use visits No HC use visits 
 
N % N % N % N % N % 
 
24337 100.0% 1609 6.6% 8375 34.4% 6028 24.8% 8325 34.2% 
Any vaginal sex since last visit 22933 94.2% 1520 94.5% 8172 97.6% 5637 93.5% 7604 91.3% 
Sex >3 times per week 15948 65.5% 1045 65.0% 6049 72.2% 3908 64.8% 4946 59.4% 
Condom use (male or female) 
at last sex 
16856 69.3% 993 61.7% 5812 69.4% 4122 68.4% 5929 71.2% 
Unprotected sex (any report)  14334 58.9% 1172 72.8% 4991 59.6% 3663 60.8% 4508 54.1% 
Sex in exchange for money or 
drugs 
728 3.0% 39 2.4% 259 3.1% 195 3.2% 235 2.8% 
2 or more male sex partners 
since last visit 
1584 6.5% 72 4.5% 254 3.0% 452 7.5% 806 9.7% 
New sex partner  2831 11.6% 159 9.9% 720 8.6% 846 14.0% 1106 13.3% 
Suspects/knows partner 
concurrency 
6064 24.9% 365 22.7% 1647 19.7% 1684 27.9% 2368 28.5% 











     Daily 13312 54.7% 893 55.5% 4938 59.0% 3150 52.3% 4331 52.0% 
     Weekly 2819 11.6% 198 12.3% 742 8.9% 756 12.5% 1123 13.5% 
     Monthly or less 2197 9.0% 130 8.1% 837 10.0% 549 9.1% 681 8.2% 
     None (ref) 5901 24.3% 380 23.6% 1839 22.0% 1547 25.7% 2135 25.7% 











     Daily 7096 29.2% 460 28.6% 2759 32.9% 1579 26.2% 2298 27.6% 
     Weekly 1581 6.5% 90 5.6% 456 5.4% 413 6.9% 622 7.5% 
     Monthly or less 1223 5.0% 72 4.5% 448 5.4% 317 5.3% 386 4.6% 
     None (ref) 14329 58.9% 979 60.9% 4693 56.0% 3693 61.3% 4964 59.6% 
     ANY 9900 40.7% 622 38.7% 3663 43.7% 2309 38.3% 3306 39.7% 
Vaginal insertion (non-









     Daily 1823 7.5% 92 5.7% 696 8.3% 414 6.9% 621 7.5% 
     Weekly 530 2.2% 30 1.9% 173 2.1% 119 2.0% 208 2.5% 
     Monthly or less 798 3.3% 37 2.3% 293 3.5% 182 3.0% 286 3.4% 
     None (ref) 21076 86.6% 1442 89.6% 7194 85.9% 5285 87.7% 7155 85.9% 





Table 4.2 continued 
Reported behaviors at follow-up OR pregnant vs. OC 
OR pregnant vs. 
injectable 
OR pregnant vs. no HC 
use 
 







  Any vaginal sex since last visit 1.7 1.3-2.3 <0.0001 0.8 0.6-1.1 0.12 0.6 0.5-0.8 <0.01 
Sex >3 times per week 1.5 1.3-1.7 <0.0001 0.9 0.8-1.1 0.42 0.8 0.8-0.9 0.01 
Condom use (male or female) at 
last sex 
1.3 1.1-1.5 <0.01 1.3 1.2-1.5 <0.0001 1.5 1.3-1.7 <0.0001 
Unprotected sex (any report)  0.7 0.6-0.8 <0.0001 0.7 0.6-0.8 <0.0001 0.6 0.5-0.7 <0.0001 
Sex in exchange for money or 
drugs 
1.5 1.0-2.1 0.04 1.5 1.0-2.2 0.05 1.4 1.0-2.0 0.07 
2 or more male sex partners 
since last visit 
1.1 0.8-1.5 0.65 2.0 1.4-2.7 <0.0001 2.5 1.9-3.4 <0.0001 
New sex partner  1.0 0.8-1.2 0.92 1.4 1.2-1.7 <0.01 1.5 1.2-1.8 <0.0001 
Suspects/knows male partner 
concurrency 
1.0 0.9-1.3 0.80 1.3 1.2-1.6 <0.0001 1.3 1.1-1.4 <0.01 
High risk sex*  1.1 1.0-1.3 0.10 1.5 1.2-1.8 <0.0001 1.5 1.3-1.8 <0.0001 






     Daily 1.2 1.0-1.3 0.01 1.1 1.0-1.2 0.16 1.1 0.9-1.2 0.36 
     Weekly 1.0 0.8-1.2 0.97 1.1 0.9-1.3 0.32 1.1 1.0-1.3 0.15 
     Monthly or less 1.5 1.2-1.8 <0.01 1.2 1.0-1.5 0.08 1.1 0.9-1.4 0.37 
     None (ref) 1.0 - - 1.0 - - 1.0 - - 
     ANY 1.2 1.1-1.3 <0.01 1.1 1.0-1.3 0.10 1.1 1.0-1.2 0.09 






     Daily 1.3 1.2-1.5 <0.0001 1.1 1.0-1.3 0.11 1.2 1.1-1.4 <0.01 
     Weekly 1.2 1.0-1.5 0.13 1.3 1.0-1.6 0.03 1.4 1.1-1.7 <0.01 
     Monthly or less 1.4 1.1-1.7 0.02 1.2 0.9-1.6 0.18 1.1 0.9-1.5 0.30 
     None (ref) 1.0 - - 1.0 - - 1.0 - - 









     Daily 1.5 1.2-1.9 <0.0001 1.3 1.0-1.6 0.05 1.4 1.1-1.8 <0.01 
     Weekly 1.4 1.0-2.1 0.08 1.2 0.8-1.8 0.47 1.5 1.0-2.2 0.04 
     Monthly or less 1.6 1.2-2.7 <0.01 1.3 0.9-1.9 0.11 1.6 1.2-2.8 <0.01 
     None (ref) 1.0 - - 1.0 - - 1.0 - - 
     ANY 1.5 1.3-1.8 <0.0001 1.3 1.0-1.5 0.02 1.5 1.2-1.8 <0.0001 




Table 4.3. Risk behaviors reported at follow-up visits by 4,549 women and the association with 
pregnancy status distinguishing established and new pregnancies* (unadjusted odds ratios) (N=24,337 
visits) 
*Established pregnancies defined as those identified at previous visit while newly pregnant is first visit of 
pregnancy 












No HC use 
visits 
 
N % N % N % N % N % N % 
 
24337 100.0% 809 3.3% 800 3.3% 8376 34.4% 6028 24.8% 8325 34.2% 
Any vaginal sex since 
last visit 
22933 94.2% 754 93.2% 766 95.8% 8173 97.6% 5636 93.5% 7604 91.3% 
Sex >3 times per week 15948 65.5% 500 61.8% 545 68.1% 6050 72.2% 3907 59.4% 4946 59.4% 
Condom use (male or 
female) at last sex 
16856 69.3% 507 62.7% 486 60.8% 5812 69.4% 4122 68.4% 5929 71.2% 
Unprotected sex (any 
report)  
14334 58.9% 582 71.9% 590 73.8% 4992 59.6% 3662 60.8% 4508 54.1% 
Sex in exchange for 
money or drugs 
728 3.0% 22 2.7% 17 3.0% 259 3.1% 195 3.2% 235 2.8% 
2 or more male sex 
partners since last visit 
1584 6.5% 20 2.5% 52 6.5% 254 3.0% 452 7.5% 806 9.7% 
New sex partner  2831 11.6% 68 8.4% 91 11.4% 720 8.6% 846 14.0% 1106 13.3% 
Suspects/knows partner 
concurrency 
6064 24.9% 169 20.9% 196 24.5% 1648 19.7% 1638 27.9% 2368 28.5% 













     Daily 13312 54.7% 461 57.0% 432 54.0% 4938 59.0% 3150 52.3% 4331 52.0% 
     Weekly 2819 11.6% 92 11.4% 106 13.3% 742 8.9% 756 12.5% 1123 13.5% 
     Monthly or less 2197 9.0% 57 7.1% 73 9.1% 837 10.0% 549 9.1% 681 8.2% 
     None (ref) 5901 24.3% 198 24.5% 182 22.8% 1839 22.0% 1547 25.7% 2135 25.7% 













     Daily 7096 29.2% 237 29.3% 223 27.9% 2759 32.9% 1579 26.2% 2298 27.6% 
     Weekly 1581 6.5% 44 5.4% 46 5.8% 456 5.4% 413 6.9% 622 7.5% 
     Monthly or less 1223 5.0% 30 3.7% 42 5.3% 448 5.4% 317 5.3% 386 4.6% 
     None (ref) 14329 58.9% 497 61.4% 482 60.3% 4693 56.0% 3693 61.3% 4964 59.6% 
     ANY 9900 40.7% 311 38.4% 311 38.9% 3663 43.7% 2309 38.3% 3306 39.7% 








     Daily 1823 7.5% 48 5.9% 44 5.5% 696 8.3% 414 6.9% 621 7.5% 
     Weekly 530 2.2% 15 1.9% 15 1.9% 173 2.1% 119 2.0% 208 2.5% 
     Monthly or less 798 3.3% 17 2.1% 20 2.5% 293 3.5% 182 3.0% 286 3.4% 
     None (ref) 21076 86.6% 728 90.0% 714 89.3% 7194 85.9% 5285 87.7% 7155 85.9% 





Table 4.3 continued 
Reported behaviors at 
follow-up 
OR established 
pregnant vs. newly 
pregnant 
OR established 
pregnant vs. OC use 
OR established 
pregnant vs. injectable 
OR established 
pregnant vs. no HC use 
 









  Any vaginal sex since 
last visit 
2.3 1.6-3.1 <0.0001 1.8 1.6-2.7 0.01 1.1 0.8-1.4 0.76 0.2 0.6-1.1 0.13 
Sex >3 times per week 1.8 1.6-2.1 <0.0001 1.5 1.3-1.8 <0.0001 1.2 1.0-1.4 0.05 1.1 0.9-1.2 0.51 
Condom use (male or 
female) at last sex 
1.2 0.9-1.4 0.11 0.8 0.7-1.0 0.09 1.2 1.0-1.5 0.05 1.4 1.1-1.6 <0.01 
Unprotected sex (any 
report)  
0.7 0.6-0.9 <0.01 1.1 0.9-1.4 0.16 0.7 0.6-0.9 <0.01 0.6 0.5-0.8 <0.0001 
Sex in exchange for 
money or drugs 
1.3 0.9-2.0 0.22 0.8 0.5-1.3 0.38 1.3 0.8-2.1 0.22 1.3 0.8-1.9 0.29 
2 or more male sex 
partners since last visit 
2.0 1.1-3.5 0.02 2.5 1.4-4.5 <0.01 3.6 2.0-6.5 <0.0001 4.7 2.6-8.3 <0.0001 
New sex partner  1.2 0.9-1.5 0.19 1.4 1.1-1.8 0.03 1.7 1.3-2.2 <0.0001 1.8 1.4-2.9 <0.0001 
Suspects/knows male 
partner concurrency 
1.0 0.9-1.2 0.69 1.1 0.9-1.3 0.32 1.4 1.2-1.7 <0.01 1.3 1.1-1.6 <0.01 
High risk sex* 1.3 1.1-1.7 0.01 1.3 1.1-1.7 0.03 1.7 1.4-2.2 <0.0001 1.8 1.4-2.2 <0.0001 








     Daily 1.2 1.1-1.4 0.02 1.0 0.9-1.2 0.63 1.1 0.9-1.3 0.16 1.1 0.9-1.2 0.32 
     Weekly 1.1 0.9-1.3 0.61 1.1 0.9-1.4 0.36 1.2 0.9-1.4 0.19 1.2 0.9-1.5 0.10 
     Monthly or less 1.7 1.3-2.2 <0.0001 1.3 1.0-1.8 0.04 1.4 1.1-1.8 0.01 1.3 1.0-1.7 0.06 








     ANY 1.3 1.1-1.5 <0.01 1.1 0.9-1.3 0.24 1.2 1.0-1.4 0.05 1.2 1.0-1.3 0.05 








     Daily 1.4 1.2-1.7 <0.0001 1.1 0.9-1.3 0.15 1.2 1.0-1.4 0.36 1.3 1.1-1.5 <0.01 
     Weekly 1.2 0.9-1.7 0.12 1.1 0.8-1.5 0.54 1.4 1.0-1.8 0.04 1.4 1.1-1.9 0.01 
     Monthly or less 1.7 1.2-2.4 <0.01 1.5 1.1-2.2 0.04 1.5 1.1-2.2 0.03 1.4 1.0-2.0 0.05 








     ANY 1.5 1.3-1.7 <0.0001 1.2 1.0-1.4 .03 1.3 1.1-1.5 <0.01 1.4 1.2-1.6 <0.0001 






     Daily 1.6 1.2-2.2 <0.01 1.1 0.7-1.6 0.73 1.3 0.9-1.8 0.11 1.5 1.1-2.0 0.02 
     Weekly 1.4 0.8-2.4 0.18 1.0 0.5-1.9 0.95 1.2 0.7-2.0 0.56 1.5 0.9-2.6 0.12 
     Monthly or less 1.8 1.2-2.7 0.01 1.2 0.7-2.1 0.56 1.5 0.9-2.3 0.10 1.8 1.8-2.8 0.01 








     ANY 1.6 1.3-2.1 <0.01 1.1 0.8-1.4 0.61 1.3 1.0-1.7 0.04 1.6 1.2-2.0 <0.01 









Table 4.4 Incidence rates of four STIs by pregnancy and hormonal contraceptive exposure group 
 
  Overall Pregnant visits 
Non-pregnant & oral 
HC use visits 
Non-pregnant & 
injectable HC use 
visits 
























Chlamydia 400 5935 6.7 38 383 9.9 84 2066 4.1 146 1440 10.1 132 2045 6.5 
Gonorrhea 165 6130 2.7 20 406 4.9 34 2114 1.6 49 1508 3.2 62 2103 2.9 
Trichomoniasis 420 5935 7.1 36 390 9.2 115 2040 5.6 109 1469 7.4 160 2036 7.9 




Additional analysis distinguishing between established pregnancies (pregnant for full visit interval) vs newly pregnant  
 






oral HC use visits 
Non-pregnant & 
injectable HC use 
visits 
Non-pregnant & 



























Chlamydia 400 5935 6.7 7 182 3.8 31 201 15.4 84 2067 4.1 146 1440 10.1 132 2045 6.5 
Gonorrhea 165 6130 2.7 12 194 6.2 8 212 3.8 34 2114 1.6 49 1508 3.2 62 2103 2.9 
Trichomoniasis 420 5935 7.1 17 183 9.3 19 207 9.2 115 2040 5.6 109 1469 7.4 160 2036 7.9 




Table 4.5a Unadjusted and adjusted hazard ratios estimating the relationship between pregnancy 
status and incident chlamydia infections (N=4,549) 
  
Unadjusted relative hazard 
(HR) of incident chlamydia 
Adjusted relative hazard 
(HR)* of incident chlamydia 
 
HR 95%CI p value HR 95%CI p value 
Pregnancy exposure group   
  
  
      Pregnant 1.5 1.1-2.2 0.02 1.2 0.8-1.8 0.28 
    Not pregnant/oral contraceptive use 0.6 0.5-0.9 <0.01 0.9 0.6-1.3 0.53 
    Not pregnant/injectable contraceptive 1.6 1.2-2.0 <0.01 1.3 1.0-1.7 0.07 
    Not pregnant/no hormonal contraceptives 1.0 - NA 1.0 - NA 
Time fixed covariates   
  
  
  Study location   
  
  
       Harare, Zimbabwe 1.0 - NA 1.0 - NA 
     Johannesburg, South Africa 2.7 2.3-3.6 <0.0001 2.4 1.7-3.2 <0.0001 
     Durban, South Africa 2.9 2.2-3.7 <0.0001 2.5 1.8-3.5 <0.0001 
Age    
  
  
       18-24 5.0 3.5-7.1 <0.0001 5.6 3.8-8.2 <0.0001 
     25-34 2.1 1.4-3.1 <0.01 2.4 1.7-3.6 <0.0001 





Completed high school (11 years school) 1.5 1.2-1.8 <0.01 1.1 0.9-1.3 0.51 
Diaphragm randomization arm (ref: control) 1.2 1.0-1.5 0.07 1.2 0.9-1.5 0.12 
Contraceptive use at enrollment   
  
  
      None 1.0 - NA 1.0 - NA 
    Oral contraceptives 0.7 0.5-0.9 0.03 1.0 0.7-1.7 0.86 
    Injectable contraceptives 1.4 1.0-2.1 0.05 1.0 0.7-1.5 0.95 
    Other (diaphragm, IUD, condoms, vasectomy) 1.2 0.8-1.7 0.35 1.1 0.8-1.6 0.59 
High risk sex at enrollment 1.3 1.0-1.6 0.03 1.2 0.9-1.5 0.08 
Partner high risk at enrollment 1.3 1.0-1.5 0.03 1.1 0.8-1.3 0.66 
STI at enrollment** 1.2 0.9-1.5 0.07 1.5 1.2-1.9 <0.01 
Time varying covariates   
  
  
  Vaginal sex since last visit (ref:none) 0.9 0.6-1.4 0.58 1.0 0.6-1.6 0.95 
>3 Vaginal sex acts per week (ref:0-2) 0.9 0.8-1.2 0.19 1.2 0.9-1.5 0.13 
No condom use at last sex  1.1 0.8-1.3 0.62 0.9 0.7-1.2 0.54 
Unprotected sex since last visit  1.4 1.1-1.7 <0.01 1.3 1.0-1.7 0.04 
High risk sex^ 1.7 1.3-2.1 <0.0001 1.2 0.9-1.6 0.09 
Suspects/knows partner concurrency 1.6 1.3-2.0 <0.0001 1.3 1.0-1.6 0.04 
Vaginal washing (any reported) 1.0 0.8-1.2 0.86 0.9 0.7-1.2 0.68 
Vaginal wiping (any reported) 0.9 0.7-1.1 0.35 0.9 0.7-1.2 0.51 
Insertion of paper products (any reported) 1.1 0.9-1.5 0.38 1.3 0.9-1.7 0.12 
 
*Multivariable models were adjusted for all covariates listed in the table 
**STIs at enrollment: chlamydia, gonorrhea, trichomoniasis, HSV-2 




Table 4.5b Unadjusted and adjusted hazard ratios estimating the relationship between pregnancy 
status and incident gonorrhea infections (N=4,549) 
  
Unadjusted relative hazard 
(HR) of incident gonorrhea 
Adjusted relative hazard 
(HR)* of incident gonorrhea 
 
HR 95%CI p value HR 95%CI p value 
Pregnancy exposure group   
  
  
      Pregnant  1.6 0.9-2.6 0.07 1.5 0.9-5.2 0.14 
    Not pregnant/oral contraceptive use 0.6 0.4-0.8 0.01 0.8 0.5-1.4 0.47 
    Not pregnant/injectable contraceptive 1.1 0.8-1.6 0.65 0.9 0.6-1.5 0.73 
    Not pregnant/no hormonal contraceptives 1.0 - NA 1.0 - NA 
Time fixed covariates   
  
  
  Study location   
  
  
       Harare, Zimbabwe 1.0 - NA 1.0 - NA 
     Johannesburg, South Africa 2.9 2.0-4.2 <0.0001 2.2 1.4-3.6 <0.01 
     Durban, South Africa 2.6 1.7-3.9 <0.0001 2.2 1.3-3.8 <0.01 
Age    
  
  
       18-24 4.2 2.5-7.06 <0.0001 5.2 3.0-9.2 <0.0001 
     25-34 1.8 1.0-3.2 0.04 2.3 1.3-4.2 0.01 
     >35 1.0 - NA 1.0 - NA 
Completed high school (11 years school) 1.3 0.9-1.8 0.09 1.0 0.7-1.4 0.87 
Diaphragm randomization arm (ref: control) 0.9 0.7-1.3 0.69 1.1 0.8-1.5 0.70 
Contraceptive use at enrollment   
  
  
      None 1.0 - NA 1.0 - NA 
    Oral contraceptives 0.9 0.5-1.7 0.73 1.7 0.8-3.8 0.16 
    Injectable contraceptives 1.6 0.9-3.0 0.14 1.4 0.7-2.8 0.31 
    Other (diaphragm, IUD, condoms, vasectomy) 1.8 0.9-3.3 0.07 1.7 0.9-3.1 0.11 
High risk sex at enrollment 0.8 0.5-1.2 0.22 0.7 0.5-1.0 0.06 
Partner high risk at enrollment 1.8 1.3-2.5 <0.01 1.4 0.9-2.0 0.07 
STI at enrollment** 1.9 1.3-2.7 <0.01 2.2 1.5-3.1 <0.0001 
Time varying covariates   
  
  
  Vaginal sex since last visit (ref:none) 1.0 0.5-2.0 1.00 1.3 0.6-2.7 0.52 
>3 Vaginal sex acts per week (ref:0-2) 0.7 0.5-0.9 0.03 0.8 0.6-1.2 0.30 
No condom use at last sex  0.6 0.4-0.9 0.02 0.6 0.4-0.9 0.01 
Unprotected sex since last visit  1.1 0.8-1.5 0.47 1.2 0.9-1.8 0.25 
High risk sex^ 1.9 1.4-2.7 <0.01 1.5 1.1-2.2 0.02 
Suspects/knows partner concurrency 2.4 1.8-3.3 <0.0001 1.8 1.3-2.5 <0.01 
Vaginal washing 1.1 0.8-1.6 0.64 1.1 0.8-1.7 0.59 
Vaginal wiping 1.0 0.7-1.4 0.93 1.0 0.7-1.5 0.80 
Insertion of paper products  0.9 0.5-1.4 0.57 0.9 0.5-1.5 0.71 
 
*Multivariable models were adjusted for all covariates listed in the table 
**STIs at enrollment: chlamydia, gonorrhea, trichomoniasis, HSV-2 





Table 4.5c Unadjusted and adjusted hazard ratios estimating the relationship between pregnancy 
status and incident trichomoniasis infections (N=4,549) 
  
Unadjusted relative hazard 
(HR) of incident 
trichomoniasis 
Adjusted relative hazard 
(HR)* of incident 
trichomoniasis 
 
HR 95%CI p value HR 95%CI p value 
Pregnancy exposure group   
  
  
      Pregnant  1.1 0.8-1.6 0.51 1.3 0.9-1.9 0.24 
    Not pregnant/oral contraceptive use 0.7 0.6-0.9 0.01 0.9 0.7-6-1.3 0.65 
    Not pregnant/injectable contraceptive 0.9 0.7-1.2 0.60 1.0 0.7-1.4 0.98 
    Not pregnant/no hormonal contraceptives 1.0 - NA 1.0 - NA 
Time fixed covariates   
  
  
  Study location   
  
  
       Harare, Zimbabwe 1.0 - NA 1.0 - NA 
     Johannesburg, South Africa 1.7 1.4-2.2 <0.0001 1.5 1.2-2.0 <0.01 
     Durban, South Africa 1.3 0.9-1.7 0.07 1.3 0.9-1.8 0.14 
Age    
  
  
       18-24 1.0 0.8-1.2 0.75 1.2 0.9-1.6 0.12 
     25-34 0.7 0.6-0.9 0.01 0.9 0.7-1.2 0.46 
     >35 1.0 - NA 1.0 - NA 
Completed high school (11 years school) 0.7 0.6-0.9 <0.01 0.8 0.7-1.0 0.06 
Diaphragm randomization arm (ref: control) 0.9 0.8-1.1 0.41 0.9 0.8-1.2 0.36 
Contraceptive use at enrollment   
  
  
      None 1.0 - NA 1.0 - NA 
    Oral contraceptives 0.5 0.4-0.7 <0.0001 0.8 0.6-1.2 0.31 
    Injectable contraceptives 0.7 0.5-0.9 0.01 0.8 0.5-1.1 0.12 
    Other (diaphragm, IUD, condoms, vasectomy) 0.6 0.4-0.8 <0.01 0.6 0.4-0.8 <0.01 
High risk sex at enrollment 1.2 0.9-1.5 0.07 1.1 0.9-1.4 0.27 
Partner high risk at enrollment 1.4 1.1-1.7 <0.01 1.2 0.9-1.5 0.11 
STI at enrollment** 2.0 1.6-2.4 <0.0001 1.8 1.4-2.3 <0.0001 
Time varying covariates   
  
  
  Vaginal sex since last visit (ref:none) 0.8 0.6-1.2 0.33 0.9 0.6-1.5 0.78 
>3 Vaginal sex acts per week (ref:0-2) 0.8 0.6-0.9 0.03 0.9 0.7-1.2 0.40 
No condom use at last sex  1.1 0.8-1.3 0.65 1.0 0.8-1.4 0.79 
Unprotected sex since last visit  1.2 0.9-1.4 0.11 1.1 0.9-1.4 0.46 
High risk sex^ 1.4 1.1-1.8 <0.01 1.1 0.9-1.4 0.31 
Suspects/knows partner concurrency 1.5 1.2-1.8 <0.01 1.3 1.0-1.6 0.03 
Vaginal washing 1.0 0.8-1.28 0.93 1.0 0.8-1.3 0.98 
Vaginal wiping 1.0 0.8-1.3 0.64 0.9 0.7-1.16 0.51 
Insertion of paper products  1.4 1.1-1.8 0.02 1.3 0.9-1.8 0.06 
 
*Multivariable models were adjusted for all covariates listed in the table 
**STIs at enrollment: chlamydia, gonorrhea, trichomoniasis, HSV-2 






Table 4.5d Unadjusted and adjusted hazard ratios estimating the relationship between pregnancy 
status and incident HIV infections (N=4,549) 
  
Unadjusted relative hazard 
(HR) of incident HIV 
Adjusted relative hazard 
(HR)* of incident HIV 
 
HR 95%CI p value HR 95%CI p value 
Pregnancy exposure group   
  
  
      Pregnant  0.8 05-1.3 0.36 0.7 0.4-1.2 0.20 
    Not pregnant/oral contraceptive use 0.6 0.4-0.8 <0.01 0.8 0.5-1.3 0.39 
    Not pregnant/injectable contraceptive 1.1 0.8-1.5 0.67 0.8 0.6-1.2 0.27 
    Not pregnant/no contraceptive use 1.0 - NA 1.0 - NA 
Time fixed covariates   
  
  
  Study location   
  
  
       Harare, Zimbabwe 1.0 - NA 1.0 - NA 
     Johannesburg, South Africa 2.7 2.0-3.5 <0.0001 2.0 1.7-2.9 <0.01 
     Durban, South Africa 1.3 0.9-1.9 0.18 1.0 0.6-1.6 0.95 
Age    
  
  
       18-24 2.1 1.4-3.0 <0.0001 2.6 1.7-3.9 <0.0001 
     25-34 1.3 0.9-2.0 0.14 1.7 1.1-2.5 0.02 
     >35 1.0 - NA 1.0 - NA 
Completed high school (11 years school) 1.2 0.9-1.5 0.19 1.1 0.9-1.5 0.33 
Diaphragm randomization arm (ref: control) 1.0 0.8-1.3 0.98 1.0 0.8-1.3 0.92 
Contraceptive use at enrollment   
  
  
      None 1.0 - NA 1.0 - NA 
    Oral contraceptives 0.8 0.5-1.4 0.53 1.3 0.7-2.5 0.37 
    Injectable contraceptives 1.8 1.1-3.0 0.03 1.8 1.0-3.1 0.04 
    Other (diaphragm, IUD, condoms, vasectomy) 1.4 0.9-2.4 0.17 1.5 0.9-2.5 0.16 
High risk sex at enrollment 1.1 0.8-1.5 0.56 1.1 0.8-1.5 0.47 
Partner high risk at enrollment 1.6 1.2-2.1 <0.01 1.3 0.9-1.7 0.12 
STI at enrollment** 2.0 1.5-2.7 <0.0001 2.1 1.5-2.8 <0.0001 
Time varying covariates   
  
  
  Vaginal sex since last visit (ref:none) 1.1 0.6-1.9 0.86 1.1 0.6-2.1 0.76 
>3 Vaginal sex acts per week (ref:0-2) 0.8 0.6-1.0 0.07 0.9 0.6-1.2 0.31 
No condom use at last sex  1.0 0.7-1.3 0.98 0.9 0.7-1.3 0.14 
Unprotected sex since last visit  1.3 0.9-1.6 0.09 1.3 0.9-1.7 0.15 
High risk sex^ 1.5 1.1-2.1 0.01 1.1 0.8-1.6 0.42 
Suspects/knows partner concurrency 2.0 1.5-2.6 <0.0001 1.5 1.1-2.0 0.01 
Vaginal washing 1.1 0.8-1.4 0.72 0.9 0.7-1.3 0.56 
Vaginal wiping 1.4 1.1-1.8 0.01 1.5 1.1-2.0 0.01 
Insertion of paper products  1.3 0.9-1.8 0.18 1.1 0.8-1.7 0.50 
 
*Multivariable models were adjusted for all covariates listed in the table 
**STIs at enrollment: chlamydia, gonorrhea, trichomoniasis, HSV-2 






Table 4.5e Unadjusted and adjusted hazard ratios estimating the relationship between pregnancy 
status and first incidence of any of the four STIs (chlamydia, gonorrhea, trichomoniasis or HIV) 
(N=4,549) 
  
Unadjusted relative hazard (HR) 
of incidence of any STI 
Adjusted relative hazard (HR)* 
of incidence of any STI 
 
HR 95%CI p value HR 95%CI p value 
Pregnancy exposure group   
  
  
      Pregnant  1.2 0.9-1.5 0.18 1.1 0.9-1.4 0.38 
    Not pregnant/oral contraceptive use 0.7 0.6-0.8 <0.0001 0.8 0.7-1.0 0.12 
    Not pregnant/injectable contraceptive 1.1 1.0-1.3 0.12 1.0 0.9-1.3 0.67 
    Not pregnant/no hormonal 
contraceptives 1.0 - NA 1.0 - NA 
Time fixed covariates   
  
  
  Study location   
  
  
       Harare, Zimbabwe 1.0 - NA 1.0 - NA 
     Johannesburg, South Africa 2.1 1.8-2.5 <0.0001 1.8 1.5-2.2 <0.0001 
     Durban, South Africa 1.8 1.5-2.1 <0.0001 1.6 1.3-2.0 <0.0001 
Age    
  
  
       18-24 1.8 1.5-2.2 <0.0001 2.3 1.9-2.8 <0.0001 
     25-34 1.1 0.9-1.3 0.56 1.3 1.1-1.6 0.01 
     >35 1.0 
 
NA 1.0 - NA 
Completed high school (11 years school) 1.1 0.9-1.2 0.35 1.0 0.9-1.1 0.89 
Diaphragm randomization arm (ref: 
control) 1.0 0.9-1.1 0.96 1.0 0.9-1.2 0.88 
Contraceptive use at enrollment   
  
  
      None 1.0 - NA 1.0 - NA 
    Oral contraceptives 0.6 0.5-0.8 <0.01 1.0 0.8-1.4 0.77 
    Injectable contraceptives 1.0 0.8-1.3 0.94 0.9 0.7-1.2 0.51 
    Other (diaphragm, IUD, condoms, 
vasectomy) 0.9 0.7-1.1 0.41 0.9 0.7-1.2 0.51 
High risk sex at enrollment 1.1 0.9-1.2 0.33 1.0 0.9-1.2 0.85 
Partner high risk at enrollment 1.4 1.2-16 <0.0001 1.2 1.0-1.3 0.03 
STI at enrollment** 1.6 1.4-1.9 <0.0001 1.8 1.5-2.0 <0.0001 
Time varying covariates   
  
  
  Vaginal sex since last visit (ref:none) 0.9 0.7-1.1 0.31 1.0 0.8-1.4 0.83 
>3 Vaginal sex acts per week (ref:0-2) 0.8 0.7-0.9 <0.01 1.0 0.8-1.1 0.72 
No condom use at last sex  1.0 0.9-1.1 0.88 0.9 0.8-1.1 0.31 
Unprotected sex since last visit  1.2 1.1-1.4 <0.01 1.2 1.0-1.4 0.01 
High risk sex^ 1.4 1.2-1.7 <0.0001 1.2 1.0-1.3 0.08 
Suspects/knows partner concurrency 1.6 1.4-1.8 <0.0001 1.3 1.1-1.5 <0.01 
Vaginal washing 1.0 0.9-1.2 0.91 1.0 0.8-1.1 0.70 
Vaginal wiping 1.0 0.9-1.2 0.73 1.0 0.9-1.2 0.95 
Insertion of paper products  1.2 1.0-1.4 0.12 1.2 1.0-1.4 0.13 
 
*Other contraceptives at enrollment: diaphragm, IUD, condoms, male partner vasectomy 
**STIs at enrollment: chlamydia, gonorrhea, trichomoniasis, HSV-2 




Table 4.6a Unadjusted and adjusted hazard ratios estimating the relationship between pregnancy 
status and incident chlamydia infection distinguishing new and established pregnancies (N=4,549) 
  
Unadjusted relative hazard 
(HR) of incident chlamydia 
Adjusted relative hazard 
(HR)* of incident chlamydia 
 
HR 95%CI p value HR 95%CI p value 
Pregnancy exposure group   
  
  
      Pregnant (established) 0.6 0.3-1.3 0.17 0.5 0.2-1.1 0.07 
    Newly pregnant  2.4 1.6-3.5 <0.0001 1.9 1.3-2.8 <0.01 
    Not pregnant/oral contraceptive use 0.6 0.5-0.8 <0.01 0.9 0.6-1.3 0.58 
    Not pregnant/injectable contraceptive 1.6 1.2-2.0 <0.01 1.3 0.9-1.7 0.08 
    Not pregnant/no hormonal contraceptives 1.0 - NA 1.0 - NA 
Time fixed covariates   
  
  
  Study location   
  
  
       Harare, Zimbabwe 1.0 - NA 1.0 - NA 
     Johannesburg, South Africa 2.7 2.3-3.6 <0.0001 2.4 1.7-3.2 <0.0001 
     Durban, South Africa 2.9 2.2-3.7 <0.0001 2.5 1.8-3.4 <0.0001 
Age    
  
  
       18-24 5.0 3.5-7.1 <0.0001 5.6 3.8-8.3 <0.0001 
     25-34 2.1 1.4-3.1 <0.01 2.5 1.7-3.7 <0.0001 
     >35 1.0 
 
NA 1.0 - NA 
Completed high school (11 years school) 1.5 1.2-1.8 <0.01 1.1 0.9-1.4 0.40 
Diaphragm randomization arm (ref: control) 1.2 1.0-1.5 0.07 1.2 0.9-1.4 0.15 
Contraceptive use at enrollment   
  
  
      None 1.0 - NA 1.0 - NA 
    Oral contraceptives 0.7 0.5-0.9 0.03 1.0 0.7-1.6 0.89 
    Injectable contraceptives 1.4 1.0-2.1 0.05 1.0 0.6-1.4 0.86 
    Other (diaphragm, IUD, condoms, vasectomy) 1.2 0.8-1.7 0.35 1.1 0.8-1.6 0.65 
High risk sex at enrollment 1.3 1.0-1.6 0.03 1.2 1.0-1.6 0.06 
Partner high risk at enrollment 1.3 1.0-1.5 0.03 1.0 0.8-1.3 0.69 
STI at enrollment** 1.2 0.9-1.5 0.07 1.5 1.2-1.8 <0.01 
Time varying covariates   
  
  
  Vaginal sex since last visit (ref:none) 0.9 0.6-1.4 0.58 1.0 0.6-1.6 0.98 
>3 Vaginal sex acts per week (ref:0-2) 0.9 0.8-1.2 0.19 1.2 0.9-1.5 0.19 
No condom use at last sex  1.1 0.8-1.3 0.62 0.9 0.7-1.2 0.55 
Unprotected sex since last visit  1.4 1.1-1.7 <0.01 1.3 1.0-1.7 0.04 
High risk sex^ 1.7 1.3-2.1 <0.0001 1.2 1.0-1.2 0.10 
Suspects/knows partner concurrency 1.6 1.3-2.0 <0.0001 1.3 1.0-1.6 0.04 
Vaginal washing 1.0 0.8-1.2 0.86 1.0 0.7-1.2 0.15 
Vaginal wiping 0.9 0.7-1.1 0.35 0.9 0.7-1.2 0.47 
Insertion of paper products  1.1 0.9-1.5 0.38 1.3 0.9-1.7 0.12 
 
*Multivariable models were adjusted for all covariates listed in the table 
**STIs at enrollment: chlamydia, gonorrhea, trichomoniasis, HSV-2 






Table 4.6b Unadjusted and adjusted hazard ratios estimating the relationship between pregnancy 
status and incident gonorrhea infection distinguishing new and established pregnancies (N=4,549) 
  
Unadjusted relative hazard 
(HR) of incident gonorrhea 
Adjusted relative hazard (HR)* 
of incident gonorrhea 
 
HR 95%CI p value HR 95%CI p value 
Pregnancy exposure group   
  
  
      Pregnant (established) 1.9 1.0-3.6 0.04 1.8 0.9-3.4 0.08 
    Newly pregnant  1.3 0.6-2.7 0.52 1.2 0.6-2.5 0.68 
    Not pregnant/oral contraceptive use 0.6 0.4-0.8 0.01 0.8 0.5-1.4 0.46 
    Not pregnant/injectable contraceptive 1.1 0.8-1.6 0.66 0.9 0.6-1.4 0.69 
    Not pregnant/no hormonal contraceptives 1.0 - NA 1.0 - NA 
Time fixed covariates   
  
  
  Study location   
  
  
       Harare, Zimbabwe 1.0 - NA 1.0 - NA 
     Johannesburg, South Africa 2.9 2.0-4.2 <0.0001 2.2 1.4-3.6 <0.01 
     Durban, South Africa 2.6 1.7-3.9 <0.0001 2.3 1.3-3.8 <0.01 
Age (changed due to small number of outcomes)   
  
  
       18-24 4.2 2.5-7.06 <0.0001 5.3 3.0-9.3 <0.0001 
     25-34 1.8 1.0-3.2 0.04 2.3 1.3-4.2 0.01 
     >35 1.0 - NA 1.0 - NA 
Completed high school (11 years school) 1.3 0.9-1.8 0.09 1.0 0.7-1.4 0.91 
Diaphragm randomization arm (ref: control) 0.9 0.7-1.3 0.69 1.1 0.8-1.4 0.76 
Contraceptive use at enrollment   
  
  
      None 1.0 - NA 1.0 - NA 
    Oral contraceptives 0.9 0.5-1.7 0.73 1.7 0.8-3.8 0.15 
    Injectable contraceptives 1.6 0.9-3.0 0.14 1.4 0.7-2.8 0.31 
    Other (diaphragm, IUD, condoms, vasectomy) 1.8 0.9-3.3 0.07 1.7 0.9-3.2 0.10 
High risk sex at enrollment 0.8 0.5-1.2 0.22 0.7 0.5-1.0 0.06 
Partner high risk at enrollment 1.8 1.3-2.5 <0.01 1.4 1.0-2.0 0.06 
STI at enrollment** 1.9 1.3-2.7 <0.01 2.2 1.5-3.2 <0.0001 
Time varying covariates   
  
  
  Vaginal sex since last visit (ref:none) 1.0 0.5-2.0 1.00 1.3 0.6-2.7 0.54 
>3 Vaginal sex acts per week (ref:0-2) 0.7 0.5-0.9 0.03 0.8 0.6-1.2 0.35 
No condom use at last sex  0.6 0.4-0.9 0.02 0.6 0.4-0.9 0.01 
Unprotected sex since last visit  1.1 0.8-1.5 0.47 1.2 0.9-1.7 0.27 
High risk sex^ 1.9 1.4-2.7 <0.01 1.5 1.1-2.2 0.02 
Suspects/knows partner concurrency 2.4 1.8-3.3 <0.0001 1.8 1.3-2.5 <0.01 
Vaginal washing 1.1 0.8-1.6 0.64 1.1 0.8-1.7 0.54 
Vaginal wiping 1.0 0.7-1.4 0.93 1.0 0.7-1.5 0.83 
Insertion of paper products  0.9 0.5-1.4 0.57 0.9 0.5-1.5 0.70 
 
*Multivariable models were adjusted for all covariates listed in the table 
**STIs at enrollment: chlamydia, gonorrhea, trichomoniasis, HSV-2 





Table 4.6c Unadjusted and adjusted hazard ratios estimating the relationship between pregnancy 
status and incident trichomoniasis infection distinguishing new and established pregnancies (N=4,549) 
  
Unadjusted relative hazard 
(HR) of incident 
trichomoniasis 
Adjusted relative hazard (HR)* 
of incident trichomoniasis 
 
HR 95%CI p value HR 95%CI p value 
Pregnancy exposure group   
  
  
      Pregnant (established) 1.1 0.7-1.8 0.69 1.2 0.7-2.0 0.49 
    Newly pregnant  1.1 0.7-1.8 0.57 1.2 0.8-2.0 0.39 
    Not pregnant/oral contraceptive use 0.7 0.6-0.9 0.01 0.9 0.6-1.3 0.56 
    Not pregnant/injectable contraceptive 0.9 0.7-1.2 0.60 1.0 0.7-1.3 0.80 
    Not pregnant/no hormonal contraceptives 1.0 - NA 1.0 - NA 
Time fixed covariates   
  
  
  Study location   
  
  
       Harare, Zimbabwe 1.0 - NA 1.0 - NA 
     Johannesburg, South Africa 1.7 1.4-2.2 <0.0001 1.5 1.2-2.0 <0.01 
     Durban, South Africa 1.3 0.9-1.7 0.07 1.3 0.9-1.8 0.14 
Age    
  
  
       18-24 1.0 0.8-1.2 0.75 1.3 0.9-1.7 0.08 
     25-34 0.7 0.6-0.9 0.01 0.9 0.7-1.2 0.52 
     >35 1.0 - NA 1.0 - NA 
Completed high school (11 years school) 0.7 0.6-0.9 <0.01 0.8 0.7-1.0 0.06 
Diaphragm randomization arm (ref: control) 0.9 0.8-1.1 0.41 0.9 0.8-1.1 0.49 
Contraceptive use at enrollment   
  
  
      None 1.0 - NA 1.0 - NA 
    Oral contraceptives 0.5 0.4-0.7 <0.0001 0.8 0.5-1.2 0.29 
    Injectable contraceptives 0.7 0.5-0.9 0.01 0.7 0.5-1.1 0.11 
    Other (diaphragm, IUD, condoms, vasectomy) 0.6 0.4-0.8 <0.01 0.6 0.4-0.8 <0.01 
High risk sex at enrollment 1.2 0.9-1.5 0.07 1.1 0.9-1.4 0.28 
Partner high risk at enrollment 1.4 1.1-1.7 <0.01 1.2 0.9-1.5 0.09 
STI at enrollment** 2.0 1.6-2.4 <0.0001 1.8 1.4-2.3 <0.0001 
Time varying covariates   
  
  
  Vaginal sex since last visit (ref:none) 0.8 0.6-1.2 0.33 0.9 0.6-1.5 0.74 
>3 Vaginal sex acts per week (ref:0-2) 0.8 0.6-0.9 0.03 0.9 0.7-1.2 0.49 
No condom use at last sex  1.1 0.8-1.3 0.65 1.0 0.8-1.4 0.84 
Unprotected sex since last visit  1.2 0.9-1.4 0.11 1.1 0.7-1.4 0.44 
High risk sex^ 1.4 1.1-1.8 <0.01 1.1 0.9-1.4 0.31 
Suspects/knows partner concurrency 1.5 1.2-1.8 <0.01 1.3 1.0-1.6 0.03 
Vaginal washing 1.0 0.8-1.28 0.93 1.0 0.8-1.3 0.90 
Vaginal wiping 1.0 0.8-1.3 0.64 0.9 0.7-1.2 0.51 
Insertion of paper products  1.4 1.1-1.8 0.02 1.3 1.0-1.7 0.06 
 
*Multivariable models were adjusted for all covariates listed in the table 
**STIs at enrollment: chlamydia, gonorrhea, trichomoniasis, HSV-2 





Table 4.6d Unadjusted and adjusted hazard ratios estimating the relationship between pregnancy 
status and incident HIV infection distinguishing new and established pregnancies (N=4,549) 
  
Unadjusted relative hazard 
(HR) of incident HIV 
Adjusted relative hazard (HR)* 
of incident HIV 
 
HR 95%CI p value HR 95%CI p value 
Pregnancy exposure group   
  
  
      Pregnant (established) 0.6 0.3-1.3 0.18 0.5 0.2-1.2 0.13 
    Newly pregnant  1.0 0.5-1.9 1.00 0.9 0.5-1.8 0.82 
    Not pregnant/oral contraceptive use 0.6 0.4-0.8 <0.01 0.8 0.5-1.3 0.37 
    Not pregnant/injectable contraceptive 1.1 0.8-1.5 0.67 0.8 0.5-1.1 0.22 
    Not pregnant/no hormonal contraceptives 1.0 - NA 1.0 - NA 
Time fixed covariates   
  
  
  Study location   
  
  
       Harare, Zimbabwe 1.0 - NA 1.0 - NA 
     Johannesburg, South Africa 2.7 2.0-3.5 <0.0001 2.0 1.4-2.9 <0.01 
     Durban, South Africa 1.3 0.9-1.9 0.18 1.0 0.6-1.5 0.95 
Age    
  
  
       18-24 2.1 1.4-3.0 <0.0001 2.6 1.7-3.9 <0.0001 
     25-34 1.3 0.9-2.0 0.14 1.7 1.1-2.5 0.01 
     >35 1.0 - NA 1.0 - NA 
Completed high school (11 years school) 1.2 0.9-1.5 0.19 1.2 0.9-1.6 0.22 
Diaphragm randomization arm (ref: control) 1.0 0.8-1.3 0.98 1.0 0.8-1.3 0.95 
Contraceptive use at enrollment   
  
  
      None 1.0 - NA 1.0 - NA 
    Oral contraceptives 0.8 0.5-1.4 0.53 1.4 0.7-2.5 0.35 
    Injectable contraceptives 1.8 1.1-3.0 0.03 1.8 1.1-3.2 0.03 
    Other (diaphragm, IUD, condoms, vasectomy) 1.4 0.9-2.4 0.17 1.5 0.9-2.5 0.12 
High risk sex at enrollment 1.1 0.8-1.5 0.56 1.1 0.8-1.5 0.56 
Partner high risk at enrollment 1.6 1.2-2.1 <0.01 1.3 0.9-1.8 0.07 
STI at enrollment** 2.0 1.5-2.7 <0.0001 2.1 1.6-2.9 <0.0001 
Time varying covariates   
  
  
  Vaginal sex since last visit (ref:none) 1.1 0.6-1.9 0.86 1.1 0.6-2.1 0.80 
>3 Vaginal sex acts per week (ref:0-2) 0.8 0.6-1.0 0.07 0.9 0.6-1.2 0.31 
No condom use at last sex  1.0 0.7-1.3 0.98 0.9 0.7-1.3 0.73 
Unprotected sex since last visit  1.3 0.9-1.6 0.09 1.2 0.9-1.7 0.18 
High risk sex^ 1.5 1.1-2.1 0.01 1.1 0.8-1.6 0.74 
Suspects/knows partner concurrency 2.0 1.5-2.6 <0.0001 1.5 1.1-1.9 0.01 
Vaginal washing 1.1 0.8-1.4 0.72 0.9 0.7-1.3 0.67 
Vaginal wiping 1.4 1.1-1.8 0.01 1.4 1.1-1.9 0.02 
Insertion of paper products  1.3 0.9-1.8 0.18 1.1 0.8-1.7 0.51 
 
*Multivariable models were adjusted for all covariates listed in the table 
**STIs at enrollment: chlamydia, gonorrhea, trichomoniasis, HSV-2 




Table 4.6e Unadjusted and adjusted hazard ratios estimating the relationship between pregnancy 
status and first incidence of any of the four STIs distinguishing new and established pregnancies 
(N=4,549)  
  
Unadjusted relative hazard (HR) 
of incident chlamydia 
Adjusted relative hazard (HR)* 
of incident chlamydia 
 
HR 95%CI p value HR 95%CI p value 
Pregnancy exposure group   
  
  
      Pregnant (established) 1.0 0.7-1.5 0.96 1.0 0.7-1.4 0.85 
    Newly pregnant  1.3 1.0-1.8 0.06 1.3 0.9-1.7 0.15 
    Not pregnant/oral contraceptive use 0.7 0.6-0.8 <0.0001 0.8 0.7-1.0 0.11 
    Not pregnant/injectable contraceptive 1.1 1.0-1.3 0.12 1.0 0.9-1.3 0.67 
    Not pregnant/no hormonal 
contraceptives 1.0 - NA 1.0 - NA 
Time fixed covariates   
  
  
  Study location   
  
  
       Harare, Zimbabwe 1.0 - NA 1.0 - NA 
     Johannesburg, South Africa 2.1 1.8-2.5 <0.0001 1.8 1.5-2.2 <0.0001 
     Durban, South Africa 1.8 1.5-2.1 <0.0001 1.6 1.3-2.0 <0.0001 
Age    
  
  
       18-24 1.8 1.5-2.2 <0.0001 2.3 1.9-2.8 <0.0001 
     25-34 1.1 0.9-1.3 0.56 1.3 1.1-1.6 0.01 
     >35 1.0 
 
NA 1.0 - NA 
Completed high school (11 years school) 1.1 0.9-1.2 0.35 1.0 0.9-1.1 0.89 
Diaphragm randomization arm (ref: 
control) 1.0 0.9-1.1 0.96 1.0 0.9-1.2 0.88 
Contraceptive use at enrollment   
  
  
      None 1.0 - NA 1.0 - NA 
    Oral contraceptives 0.6 0.5-0.8 <0.01 1.0 0.8-1.4 0.76 
    Injectable contraceptives 1.0 0.8-1.3 0.94 0.9 0.7-1.2 0.51 
    Other (diaphragm, IUD, condoms, 
vasectomy) 0.9 0.7-1.1 0.41 0.9 0.7-1.2 0.51 
High risk sex at enrollment 1.1 0.9-1.2 0.33 1.0 0.9-1.2 0.85 
Partner high risk at enrollment 1.4 1.2-16 <0.0001 1.2 1.0-1.3 0.03 
STI at enrollment** 1.6 1.4-1.9 <0.0001 1.8 1.5-2.0 <0.0001 
Time varying covariates   
  
  
  Vaginal sex since last visit (ref:none) 0.9 0.7-1.1 0.31 1.0 0.8-1.4 0.84 
>3 Vaginal sex acts per week (ref:0-2) 0.8 0.7-0.9 <0.01 1.0 0.8-1.3 0.69 
No condom use at last sex  1.0 0.9-1.1 0.88 0.9 0.8-1.1 0.31 
Unprotected sex since last visit  1.2 1.1-1.4 <0.01 1.2 1.0-1.4 0.01 
High risk sex^ 1.4 1.2-1.7 <0.0001 1.2 1.0-1.3 0.08 
Suspects/knows partner concurrency 1.6 1.4-1.8 <0.0001 1.3 1.1-1.5 <0.01 
Vaginal washing 1.0 0.9-1.2 0.91 1.0 0.8-1.1 0.70 
Vaginal wiping 1.0 0.9-1.2 0.73 1.0 0.9-1.2 0.94 
Insertion of paper products  1.2 1.0-1.4 0.12 1.2 1.0-1.4 0.14 
 
*Other contraceptives at enrollment: diaphragm, IUD, condoms, male partner vasectomy 
**STIs at enrollment: chlamydia, gonorrhea, trichomoniasis, HSV-2 









Sexually transmitted infections (STI) pose significant threats to the health of women, primarily 
those of reproductive age who face infertility from untreated infections and poor birth outcomes, 
including mother-to-child transmission of some infections.  Given the risks, it is critical to understand 
more about when and how women are contracting STIs and whether they are at greater risk of infection 
during pregnancy. This dissertation explored changes in women’s sexual risk behaviors during pregnancy 
and examined whether women had higher STI incidence while pregnant.  
In Chapter 2 of this dissertation, I examined existing evidence documenting STI acquisition 
among pregnant women and available data comparing pregnant women’s risk to that of non-pregnant 
women. Very few studies were found documenting incidence of STIs during pregnancy and even fewer 
evaluated whether women are at higher risk during pregnancy. Although there is a good deal of 
prevalence data available for pregnant women, only 18 studies were found that reported STI incidence 
among pregnant women and just five studies compared STI risk in pregnant and non-pregnant women. 
From the limited available evidence it appears that women do continue to acquire STIs during pregnancy 
although incidence varied within and across infection types, populations and geographic settings. 
Overall the review in Chapter 1 revealed the paucity of data on women’s STI risk with the few existing 
studies documenting outcomes only for chlamydia, gonorrhea, HPV, HSV-2 and HIV. No studies were 
found examining trichomoniasis and syphilis, STIs that cause adverse birth outcomes and can affect the 
long term health of women and children. The lack of data overall and on certain common STIs highlights 
the need for more studies on incidence among pregnant women. This information is needed to 
understand which infections pregnant women may be most vulnerable to, what behavioral and 
biological factors drive incidence during pregnancy and to identify whether pregnancy increases risk of 
STI acquisition.  
The aim of Chapter 3 was to describe changes in sexual behaviors during pregnancy in order to 




sexual behavior and vaginal practice data collected over follow-up during the Methods for Improving 
Reproductive Health in Africa (MIRA) trial which was conducted in South Africa and Zimbabwe 2003-
2006. The analysis used several different analytic approaches, including matched pairs and regression 
modeling to compare behaviors reported before and during pregnancies. The analysis found that 
pregnant women continued having sex but with lower frequency over the course of pregnancy and that 
pregnant women were more likely to report sex without a condom, but significantly less likely to engage 
in other risk factors for STI acquisition, including anal sex, concurrent sexual relationships and having 
new sex partners. These findings are similar to those reported from a small number of studies that have 
previously compared the sexual risk behaviors of pregnant and non-pregnant women, and present a 
complex picture of STI risk during pregnancy. The data suggest that pregnant women may have 
increased risk through unprotected sex but potentially lower risk resulting from fewer other risk 
behaviors.  
Chapter 3 also reported changes in vaginal practices during pregnancy and found that wiping 
and insertion of paper or cloth into the vagina was less frequent when women were pregnant.  This 
finding is both unique and interesting; no previous studies have examined changes in vaginal practices 
during pregnancy and the findings suggest that pregnant women may reduce their risk for STIs through 
this specific pathway. The reasons why women might engage in fewer vaginal practices while pregnant 
is not clear however previous studies have shown vaginal practices to be associated with transactional 
sex100 and pregnant women report less sex in exchange for drugs and money which could, in part, help 
explain the decrease in vaginal practices during pregnancy. More studies are needed of vaginal practices 
during pregnancy to understand their potential impact on STI risk and also in relation to adverse birth 
outcomes.   
The analysis in Chapter 3 also found that sexual risk behaviors and vaginal practices differed not 




contraceptives that were used during non-pregnant periods. Women using injectable contraceptives 
were most likely to report high risk sexual behaviors (anal sex, exchange sex, concurrency, new partners 
and drugs and alcohol use during sex) but were less likely to report vaginal practices compared to 
women using oral contraceptives. Although contraceptive use was not the focus of this dissertation, this 
information is relevant to increasing concerns regarding whether injectable contraceptives increase STI 
and HIV acquisition.120  
Overall, the analysis in Chapter 3 is one of only a few studies to explore sexual risk behaviors 
that are known to be associated with STI incidence during pregnancy and is the only analysis to date 
examining the impact of pregnancy on vaginal practices. These data are therefore an important 
contribution to developing a better understanding of sexual behaviors and STI risk factors in women of 
reproductive age. 
Finally, in Chapter 4, I examined the incidence of four common STIs (chlamydia, gonorrhea, 
trichomoniasis and HIV) and evaluated whether women were at increased risk of infection during 
pregnancy. The analysis included 4,549 women 18-50 years of age from the MIRA trial who attended 
over 24,300 study visits. Similar to Chapter 3, in this analysis sexual risk behavior and vaginal practices 
were compared during pregnant and non-pregnant periods but this analysis also included women who 
did not have pregnancies during follow-up (findings were similar to those reported in the previous 
chapter). The analysis in Chapter 4 also reported incidence rates of four STIs during pregnant and non-
pregnant periods and found pregnant women had high incidence of chlamydia, gonorrhea and 
trichomoniasis. In multivariable models, adjusted for demographic and time-varying behavioral risk 
factors and vaginal practices, pregnant women did not appear to have higher incidence than non-




The analysis in Chapter 4 provides previously undocumented data on trichomoniasis incidence 
among pregnant women (which has not been previously reported), as well as new, higher quality 
evidence on incidence of chlamydia and gonorrhea during pregnancy (both of which have been 
previously reported but not from studies with rigorous follow-up). Overall the analysis found that 
women had continued incidence of STIs during pregnancy but that their risk did not appear higher than 
women who were not pregnant. This finding differs from some previous studies and is consistent with 
others, suggesting the need for further examination of this question. 
The analysis in Chapter 4 also identified risk factors for STI incidence including younger age, 
being in settings with higher STI prevalence and having had an STI enrollment. Other risk factors were 
less consistent in their associations with STIs, including unprotected sex (without a condom), reporting 
of high risk sexual behaviors such as sex in exchange for drugs or money and anal sex. Knowledge of a 
male partner’s concurrency was a strong predictor of acquisition of all STIs which is a factor warranting 
further study.  
A unique aspect of the analysis in Chapter 4 is that we examined differences in sexual risk 
behaviors and STI risk for established pregnancies as well as for the periods when pregnancies occurred. 
We found that in periods when women became pregnant they were more likely to report sexual risk 
behaviors that would put them at greater risk for acquiring STIs with the exception of unprotected sex 
(without a condom) which they reported less frequently than women during established pregnancies. 
This finding has potentially important methodological implications as it suggests that there may be 
systematic bias in reporting of condom use, with women who are not pregnant or newly pregnant 
potentially over reporting use of condoms. Further exploration of the extent of this bias and greater 
understanding of the factors that lead to the potential over reporting are needed in light of the 
importance of this particular risk factor and in its use as a variable in statistical adjustment for STI 




periods when they became pregnant compared to when they were not pregnant. This finding is unique 
as previous analyses have not described the timing of STI incidence with regard to occurrence of 
pregnancies.  
Although pregnancy was not found to increase risk for STI acquisition, we did find that pregnant 
women do have incident STIs which underscores the importance of identifying effective strategies to 
help prevent STIs in women of reproductive age in order to protect their own health and to reduce 
congenital and peri-natal STI infections in children. There is clear evidence with regard to HIV that 
incident infection during pregnancy dramatically increases the risk of MTCT, with an increasing 
proportion of peri-natal infections in children attributed to maternal HIV acquisition during 
pregnancy.66,81-86 While there is no evidence regarding incident infection during pregnancy and MTCT 
risk in relation to other STIs, it is possible that, as with HIV, there may be higher risk of congenital 
infection with gonorrhea and chlamydia when women are infected during pregnancy. While this 
dissertation was not designed to answer this question, it is an important avenue for future research.  
Unfortunately behavioral interventions to increase and improve the consistency of condom use 
have had limited impact generally, however it is important to note that pregnancy is a period when 
some women and their male partners may be highly motivated to take steps to reduce risk in order to 
protect their unborn child. Some promising evidence in this area was reported from the PartnerPlus 
Project in South Africa which showed that education and counseling improved reported condom use 
improved among pregnant women and their male partners.98 In contrast, a more recent study of an 
intervention aimed at increasing condom use during pregnancy showed that while reported condom use 
increased, STI incidence among women attending antenatal care in South Africa did not improve146, 




Going forward, more studies are needed to measure the incidence of STIs during pregnancy, 
specifically those that have not been previously well documented. More data are needed to assess 
whether pregnant women in certain populations may be at greater risk of acquiring infections, which 
types of infections they may be most vulnerable to and whether there are any biological pathways 
through which pregnancy increases risk for certain infections. Greater documentation of vaginal 
practices among pregnant women are also needed as these behaviors may have implications both for 
STI risk, specifically HIV, and could also be associated with adverse birth outcomes. And finally, as noted 
above, regardless of whether pregnancy increases risk, greater efforts are needed to identify effective 
behavioral interventions that can be implemented to help protect women and children from these 
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Appendix Table 3.1 Characteristics at enrollment, MIRA subjects included in the analysis and those 
excluded, N=4,802 
Characteristics at enrollment Total  






women p value 
 
N % N % N % N % 
 
 
4802 100.0% 3830 79.8% 483 10.1% 489 10.2% 
 Study location         
    Harare 2391 49.8% 1881 49.1% 274 56.7% 236 48.3% 0.0265 
    Durban 1434 29.9% 1165 30.4% 124 25.7% 145 29.7%  
    Johannesburg 977 20.4% 784 20.5% 85 17.6% 108 22.1%  
Age          
     Median age (range) 27  (18-45) 27 (18-45) 24 (18-44) 27  (18-45) <0.0001 
     18-24 1891 39.4% 1388 36.3% 247 51.1% 256 52.4% <0.0001 
     25-34 1939 40.4% 1551 40.5% 199 41.2% 189 38.7%  
     >35 971 20.2% 890 23.2% 37 7.7% 44 9.0%  
Completed high school (11 years school) 2550 53.1% 1987 51.9% 276 57.1% 287 58.7% 0.0030 
Paid employment 1092 22.8% 888 23.2% 97 20.1% 107 21.9% 0.2739 
Married 2809 58.5% 2250 58.8% 296 61.3% 263 53.8% 0.0466 
Lives with male partner 3230 67.3% 2591 67.7% 337 69.8% 302 61.8% 0.0414 
Number of previous pregnancies          
     None 426 8.9% 294 7.7% 63 13.0% 69 14.1% <0.0001 
     1 previous pregnancy 1572 32.7% 1178 30.8% 195 40.4% 199 40.7%  
     2+ 2804 58.4% 2358 61.6% 225 46.6% 221 45.2%  
Current birth control (not mutually exclusive)        
     Combined pills 1070 22.3% 791 20.7% 149 30.9% 130 26.6% <0.0001 
     Injectable hormones 1216 25.3% 1068 27.9% 64 13.3% 84 17.2% <0.0001 
     Progesterone only pills 723 15.1% 600 15.7% 60 12.4% 63 12.9% 0.0623 
     Intrauterine device 16 0.3% 15 0.4% 1 0.2% 0 0.0% 0.6417 
     Condoms (male or female) (only) 1829 38.1% 1453 37.9% 182 37.7% 194 39.7% 0.7409 
     None (natural, withdrawal, tradition) 261 5.4% 192 5.0% 38 7.9% 31 6.3% 0.0218 
Regular sexual partner 1989 41.4% 1577 41.2% 186 38.5% 226 46.2% 0.1066 
Age at first sex (mean and range) 18 (10-31) 18 (10-31) 18 (11-26) 18 (12-27) 0.3681 
Sex acts per week          
     None 1924 40.1% 1522 39.7% 210 43.5% 192 39.3% 0.2698 
     1-2 per week 291 6.1% 229 6.0% 35 7.3% 27 5.5%  
     >3 per week 2587 53.9% 2079 54.3% 238 49.3% 270 55.2%  
Number of sexual partners in past 3 months          
     None 274 5.7% 239 6.3% 11 2.3% 24 4.9% 0.0004 
     1 partner 4101 85.6% 3267 85.6% 427 8.4% 407 83.2%  
     2+ 415 8.7% 312 8.2% 45 9.3% 58 11.9%  
Condom use (male or female) at last sex 3388 70.6% 2701 70.5% 339 70.2% 348 71.2% 0.9407 
Condom use (vaginal sex) in last three months 
           Never 1359 29.3% 1123 29.4% 136 28.2% 136 27.8% 0.2103 
     Sometimes 1887 38.9% 1487 38.9% 185 38.3% 215 44.0% 
      Every time 1509 31.9% 1209 31.7% 162 33.5% 138 28.2% 
Sex in exchange for money or drugs 382 8.0% 306 8.0% 38 7.9% 38 7.8% 0.9828 






Appendix 3.1 continued  
Characteristics at enrollment Total  






women p value 
Sex while intoxicated 174 26.3% 136 26.8% 20 27.8% 18 22.2% 0.6591 
High risk  1109 23.1% 879 23.0% 123 25.5% 107 21.9% 0.3725 
(>2 partners, exchange, anal, sex w/ drugs/alcohol)       
Partner age          
     Same age (+/-5 years) 2675 58.2% 2114 57.8% 277 58.9% 284 60.0% 0.4147 
     Younger (more than 5 years) 44 1.0% 38 1.0% 1 0.2% 5 1.1%  
     Older (more than 5 years) 1878 40.9% 1502 41.1% 192 40.9% 184 40.9%  
Partner tested HIV positive          
     Yes 162 3.4% 136 3.6% 14 2.9% 12 2.5% 0.3642 
     No/don't know 4626 96.6% 3680 96.4% 469 97.1% 477 97.6%  
Partner away from home >2 months 535 11.1% 425 11.1% 47 9.7% 63 12.9% 0.2880 
Partner circumcised 1031 21.5% 821 21.5% 106 22.0% 104 21.3% 0.4253 
Partner has other sexual partners 
(suspects/knows) 
1464 30.6% 1164 30.5% 138 28.6% 162 33.1% 0.2971 
Physical or verbal abuse  877 33.4% 715 33.3% 74 33.0% 88 34.8% 0.8856 
Partner used force to get sex 259 9.9% 213 9.9% 21 9.4% 25 9.9% 0.9671 
Sex w/ partner  with  drugs/alcohol 1711 35.9% 1368 36.0% 179 37.1% 164 33.7% 0.5034 
Partner high risk  2990 62.3% 2386 62.3% 299 61.9% 305 62.4% 0.9852 
(HIV+, away >1 month, other partners, drugs)        
Vaginal washing          
     Daily 2939 61.4% 2331 61.1% 301 62.3% 307 62.8% 0.6048 
     Weekly 695 14.5% 562 14.7% 61 12.6% 72 14.7%  
     Monthly or less 337 7.0% 268 7.0% 31 6.4% 38 7.8%  
     None 819 17.1% 657 17.2% 90 18.6% 72 14.7%  
     ANY 3983 83.0% 3173 82.9% 393 81.4% 417 85.3% 0.2533 
Vaginal wiping          
     Daily 1944 40.6% 1546 40.5% 195 40.4% 203 41.5% 0.6024 
     Weekly 458 9.6% 362 9.5% 56 11.6% 40 8.2%  
     Monthly or less 303 6.3% 237 6.2% 30 6.2% 36 7.4%  
     None 2085 43.5% 1673 43.8% 202 41.8% 210 42.9%  
     ANY 2717 56.6% 2157 56.3% 281 58.8% 279 57.1% 0.7255 
Vaginal insertion (non-menstruation 
related) 
         
     Daily 622 13.0% 502 13.2% 58 12.0% 62 12.7% 0.9780 
     Weekly 163 3.4% 126 3.3% 18 373.0% 19 3.9%  
     Monthly or less 197 4.1% 158 4.1% 20 4.1% 19 3.9%  
     None 3804 79.5% 3028 79.4% 387 80.1% 389 79.6%  
     ANY 998 20.8% 802 21.0% 96 19.9% 100 20.5% 0.8455 
Diaphragm arm 2385 49.7% 1901 49.6% 231 47.8% 253 51.7% 0.4737 
Positive for STI (enrollment)          
     Chlamydia 215 4.5% 159 4.2% 28 5.8% 28 5.7% 0.0957 
     Gonorrhea 36 0.8% 30 0.8% 3 0.6% 3 0.6% 0.8659 
     Trichomoniasis 175 3.7% 137 3.6% 20 4.1% 18 3.7% 0.8233 






Appendix 4.1 Enrollment characteristics enrollment of 4,935 MIRA participants included excluded in 
analysis  
Characteristics at enrollment Total  
Women with 





women p value 
 
N % N % N % N % 
 4935 100.0% 3783 83.2% 766 15.5% 386 7.8%  
Study location          
    Harare 2443 49.5% 1847 48.9% 408 53.3% 188 48.7% 0.06 
    Durban 1484 30.1% 1173 30.9% 199 26.0% 112 29.0%  
    Johannesburg 1008 20.4% 763 20.2% 159 20.8% 86 22.3%  
Age          
     Median age (range) 27 (18-50) 28 (18-50) 25 (18-47) 26 (18-49) <0.0001 
     18-24 1891 38.3% 1342 35.5% 383 50.0% 166 43.0% <0.0001 
     25-34 198 39.3% 1472 38.9% 310 40.5% 456 40.4%  
     >35 1106 22.4% 969 25.6% 73 9.5% 64 16.6%  
Completed high school (11 yrs school) 2556 51.8% 1904 50.3% 443 57.8% 209 54.2% <0.01 
Paid employment 1130 22.9% 883 23.4% 156 20.4% 91 23.6% 0.19 
Married 2910 59.0% 2245 59.4% 450 58.8% 215 55.7% 0.38 
Lives with male partner 3339 67.7% 2572 68.0% 509 66.5% 258 66.8% 0.02 
Number or previous pregnancies          
     None 429 8.7% 280 7.4% 107 14.0% 42 10.9% <0.0001 
     1 previous pregnancy 1580 32.0% 1151 30.4% 295 38.5% 134 34.7%  
     2+ previous pregnancies 2926 59.3% 2352 62.2% 364 47.5% 210 54.4%  
Current birth control (not mutually exclusive)         
     Combined pills 1078 21.9% 770 20.4% 221 28.9% 87 22.5% <0.0001 
     Injectable hormones 1226 24.9% 1029 27.2% 100 13.1% 97 25.1% <0.0001 
     Progesterone only pills 723 14.7% 566 15.0% 97 12.7% 60 15.5% 0.23 
     Intrauterine device 17 0.3% 15 0.4% 1 0.1% 1 0.3% 0.79 
     Condoms (male or female) (only) 1860 37.7% 1419 37.5% 304 39.7% 137 35.5% 0.34 
     None (natural, withdrawal, tradition) 273 5.5% 194 5.1% 53 6.9% 26 6.7% 0.08 
Regular sexual partner 2021 40.9% 1537 40.6% 315 41.1% 169 43.8% 0.01 
Age at first sex (mean, range) 18 (10-31) 18 (10-31) 18 (11-27) 18 (12-26) 0.43 
Sex acts per week          
     None 1991 40.3% 1551 41.0% 326 42.6% 114 29.5% <0.01 
     1-2 per week 302 6.1% 227 6.0% 48 6.3% 27 7.0%  
     >3 per week 2642 53.5% 2005 53.0% 392 51.2% 245 63.5%  
Number of sexual partners in past 3 months        
     None 291 5.9% 249 6.6% 24 3.1% 18 4.7% <0.01 
     1 partner 4212 85.5% 3222 85.4% 655 85.5% 335 86.8%  
     2+ 420 8.5% 300 8.0% 87.0 11.4% 33.0 8.6%  
Condom use (male or female) last sex 3466 70.2% 2653 70.1% 547 71.4% 266 68.9% 0.65 
Condom use last three months          
     Never 1455 29.6% 1132 30.0% 206 26.9% 117 30.3% 0.15 
     Sometimes 1930 39.2% 1449 38.4% 318 41.5% 163 42.2%  
     Every time 1539 31.3% 1191 31.6% 242 31.6% 106 24.5%  
Exchange for money or drugs  394 8.0% 303 8.0% 57 7.4% 34 8.8% 0.72 






Appendix 4.1 continued  
Characteristics at enrollment Total  
Women with 





women p value 
 
N % N % N % 
  
 
Sex while intoxicated 177 26.1% 136 26.8% 32 26.0% 9 18.4% 0.43 
High risk  1140 23.1% 874 23.1% 185 24.2% 81 21.0% 0.48 
(>2 partners, exchange, anal, sex w/ drugs/alcohol) 
  
     
Partner age 
        
 
     Same age (+/-5 years) 2747 58.2% 2077 57.7% 433 58.2% 237 63.7% 0.04 
     Younger (more than 5 years) 52 1.1% 47 1.3% 3 0.4% 2 0.5%   
     Older (more than 5 years) 1918 40.7% 1477 41.0% 308 41.4% 133 35.8% 
 
Partner tested HIV positive 
        
 
     Yes 165 3.4% 135 3.6% 21 2.7% 9 2.3% 0.25 
     No/don't know 4757 96.7% 3635 96.4% 745 97.3% 377 97.7% 
 
Partner away from home >2 months 549 11.1% 413 10.9% 77 10.1% 59 15.3% 0.02 
Partner circumcised 1016 21.6% 805 21.4% 171 22.3% 87 22.5% 0.53 
Suspects/knows partner concurrency 1505 30.6% 1159 30.7% 233 30.4% 113 29.3% 0.83 
Physical or verbal abuse  903 33.3% 693 33.0% 128 33.4% 82 36.1% 0.63 
Partner used force to get sex 265 9.8% 208 9.9% 36 9.4% 21 9.3% 0.92 
Sex w/ partner under influence of drugs 
alcohol 1752 35.7% 1351 36.0% 271 35.5% 130 33.9% 
0.71 
Partner high risk  3067 62.2% 2363 62.5% 473 61.8% 231 59.8% 0.59 
(HIV+, away >1 month, other partners, drugs) 
      
 
Vaginal washing 
        
 
     Daily 3014 61.2% 2289 61.0% 480 62.7% 236 61.1% 0.85 
     Weekly 710 14.4% 558 14.8% 100 13.1% 52 13.5% 
 
     Monthly or less 346 7.0% 263 7.0% 57 7.4% 26 6.7% 
 
     None 83 17.3% 652 17.3% 129 16.8% 72 18.7% 
 
     ANY 4070 82.5% 3119 82.5% 637 83.2% 314 81.4% 0.73 
Vaginal wiping 
        
 
     Daily 1989 40.4% 1525 40.5% 307 40.1% 157 40.7% 0.76 
     Weekly 470 9.6% 353 9.4% 82 10.7% 35 9.1% 
 
     Monthly or less 313 6.4% 239 6.3% 54 7.1% 20 5.2% 
 
     None 2151 43.7% 1654 43.9% 323 42.2% 174 45.1% 
 
     ANY 2772 56.2% 2117 56.0% 443 57.8% 212 54.9% 0.61 
Vaginal insertion (non-menstruation 
related) 
        
 
     Daily 641 13.0% 504 13.4% 94 12.3% 43 11.2% 0.54 
     Weekly 167 3.4% 130 3.5% 29 3.8% 8 2.1% 
 
     Monthly or less 203 4.1% 156 4.1% 33 4.3% 14 3.7% 
 
     None 3908 79.4% 2979 79.0% 610 79.6% 319 83.1% 
 
     ANY 1011 20.5% 790 20.9% 156 20.4% 67 17.4% 0.19 
Diaphragm arm 2466 50.0% 1890 50.0% 383 50.0% 193 50.0% 1.00 
Positive for STI (enrollment) 
        
 
     Chlamydia 217 4.4% 155 4.1% 40 5.2% 22 5.7% 0.17 
     Gonorrhea 37 0.8% 29 0.8% 5 0.7% 3 0.8% 0.94 
     Trichomoniasis 181 3.7% 133 3.5% 33 4.3% 15 3.9% 0.55 






Appendix 4.2 Risk behaviors reported at follow-up visits by 4,549 women and the association with 
pregnancy status using the broader definition of pregnancy* (unadjusted odds ratios) (N=2,4337 
visits)   
*pregnancy defined as any lab confirmed or reported at visit (including miscarriages and terminations) 









No HC use 
visits 
 
N % N % N % N % N % 
 
24336 100.0% 1744 7.2% 8336 34.2% 6004 24.7% 8252 33.9% 
Any vaginal sex since last visit 22933 94.2% 1648 94.5% 8134 91.6% 5615 93.5% 7536 91.3% 
Sex >3 times per week 15948 65.5% 1135 65.1% 6021 72.2% 3893 64.8% 4899 65.5% 
Condom use (male or female) 
at last sex 
16856 69.3% 1085 62.2% 5789 69.5% 4107 68.4% 5875 71.2% 
Unprotected sex (any report)  14334 58.9% 1262 72.4% 4965 59.6% 3647 60.7% 4459 54.0% 
Sex in exchange for money or 
drugs 
728 3.0% 41 2.4% 259 3.1% 195 3.3% 233 2.8% 
2 or more male sex partners 
since last visit 
1584 6.5% 85 4.9% 252 3.0% 449 7.5% 798 9.7% 
New sex partner  2831 11.6% 174 10.0% 715 8.6% 844 14.1% 1098 13.3% 
Suspects/knows partner 
concurrency 
6064 24.9% 410 23.5% 1630 19.6% 1676 27.9% 2348 28.5% 











     Daily 13312 54.7% 975 55.9% 4912 58.9% 3136 52.2% 4289 52.0% 
     Weekly 2819 11.6% 210 12.0% 739 8.9% 755 12.6% 1115 13.5% 
     Monthly or less 2197 9.0% 144 8.3% 835 10.0% 547 9.1% 671 8.1% 
     None (ref) 5901 24.3% 407 23.3% 1831 22.0% 1540 25.7% 2123 25.7% 











     Daily 7096 29.2% 504 28.9% 2743 32.9% 1575 26.2% 2274 27.6% 
     Weekly 1581 6.5% 95 5.5% 456 5.5% 410 6.8% 620 7.5% 
     Monthly or less 1223 5.0% 74 4.2% 448 5.4% 317 5.3% 384 4.7% 
     None (ref) 14329 58.9% 1063 61.0% 4670 56.0% 3676 61.2% 4920 59.6% 
     ANY 9900 40.7% 673 38.6% 3647 43.8% 2302 38.3% 3278 39.7% 








     Daily 1823 7.5% 107 6.1% 689 8.3% 411 6.9% 616 7.5% 
     Weekly 530 2.2% 32 1.8% 173 2.1% 118 2.0% 207 2.5% 
     Monthly or less 798 3.3% 38 2.2% 293 3.5% 182 3.0% 285 3.5% 
     None (ref) 21076 86.6% 1559 89.4% 7162 85.9% 5265 87.7% 7090 85.9% 






Appendix 4.2 continued 
Reported behaviors at follow-
up OR pregnant vs. OC OR pregnant vs. injectable OR pregnant vs. no HC use 
 







  Any vaginal sex since last visit 1.8 1.4-2.3 <0.0001 0.8 0.6-1.1 0.18 0.6 0.5-0.8 <0.01 
Sex >3 times per week 1.5 1.3-1.7 <0.0001 0.9 0.8-1.1 0.42 0.9 0.8-0.9 0.01 
Condom use (male or female) 
at last sex 
1.3 1.1-1.4 <0.01 1.3 1.1-1.5 <0.01 1.5 1.3-1.7 <0.0001 
Unprotected sex (any report)  0.7 0.6-0.8 <0.0001 0.7 0.6-0.8 <0.0001 0.6 0.5-0.7 <0.0001 
Sex in exchange for money or 
drugs 
1.5 1.1-2.2 0.02 1.5 1.0-2.2 0.03 1.5 1.0-2.1 0.03 
2 or more male sex partners 
since last visit 
1.0 0.8-1.3 0.94 1.9 1.4-2.5 <0.0001 2.4 1.8-3.2 <0.0001 
New sex partner  1.0 0.8-1.2 0.97 1.4 1.2-1.8 <0.01 1.5 1.2-1.8 <0.0001 
Suspects/knows male partner 
concurrency 
1.0 0.8-1.1 0.51 1.3 1.1-1.5 <0.01 1.2 1.1-1.4 <0.01 
High risk sex*  1.1 0.9-1.3 0.21 1.4 1.2-1.7 <0.0001 1.5 1.3-1.7 <0.0001 






     Daily 1.2 1.1-1.3 <0.01 1.1 1.0-1.2 0.10 1.1 0.9-1.2 0.33 
     Weekly 1.0 0.9-1.2 0.90 1.1 1.0-1.3 0.19 1.1 1.0-1.3 0.09 
     Monthly or less 1.4 1.2-1.7 <0.01 1.2 0.9-1.4 0.16 1.1 0.9-1.3 0.62 
     None (ref) 1.0 - - 1.0 - - 1.0 - - 
     ANY 1.2 1.1-1.3 <0.01 1.1 1.0-1.3 0.07 1.1 1.0-1.2 0.09 






     Daily 1.3 1.2-1.5 <0.0001 1.1 1.0-1.3 0.09 1.2 1.1-1.4 <0.01 
     Weekly 1.2 1.0-1.5 0.07 1.3 1.1-1.7 0.02 1.4 1.1-1.8 <0.01 
     Monthly or less 1.4 1.1-1.8 <0.01 1.3 1.0-1.7 0.06 1.2 1.0-1.5 0.12 
     None (ref) 1.0 - - 1.0 - - 1.0 - - 
     ANY 1.4 1.2-1.5 <0.0001 1.2 1.1-1.4 <0.01 1.3 1.1-1.4 <0.0001 




     Daily 1.4 1.2-1.8 <0.01 1.2 0.9-1.5 0.17 1.3 1.1-1.7 0.01 
     Weekly 1.5 1.0-2.1 0.05 1.2 0.8-1.8 0.41 1.5 1.1-2.2 0.02 
     Monthly or less 1.8 1.3-2.5 <0.01 1.4 1.0-2.1 0.05 1.8 1.3-2.5 <0.01 
     None (ref) 1.0 - - 1.0 - - 1.0 - - 
     ANY 1.5 1.3-1.8 <0.0001 1.2 1.0-1.5 0.03 1.5 1.2-1.8 <0.0001 








Appendix 4.3 Incidence rates of four STIs by pregnancy and hormonal contraceptive exposure group using broader definition of 




  Overall Pregnant visits 
Non-pregnant & oral 
HC use visits 
Non-pregnant & 
injectable HC use 
visits 
























Chlamydia 400 5935 6.7 40 416 9.6 84 2056 4.1 145 1434 10.1 131 2028 6.5 
Gonorrhea 165 6130 2.7 22 442 5.0 34 2103 1.6 49 1501 3.3 60 2085 2.9 
Trichomoniasis 420 5935 7.1 41 425 9.6 113 2030 5.6 108 1462 7.4 158 2017 7.8 





Appendix 4.4a  Unadjusted and adjusted hazard ratios estimating the relationship between pregnancy 
status and incident chlamydia infections using broader definition of pregnancy (all lab and reported) 
(N=4,549) 
  
Unadjusted relative hazard 
(HR) of incident chlamydia 
Adjusted relative hazard 
(HR)* of incident chlamydia 
 
HR 95%CI p value HR 95%CI p value 
Pregnancy exposure group   
  
  
      Pregnant (lab+ and reported) 1.5 1.0-2.1 0.03 1.2 0.8-1.7 0.37 
    Not pregnant/oral contraceptive use 0.6 0.5-0.9 <0.01 0.9 0.6-1.3 0.55 
    Not pregnant/injectable contraceptive 1.6 1.2-2.0 <0.01 1.3 0.9-1.7 0.08 
    Not pregnant/no hormonal contraceptives 1.0 - NA 1.0 - NA 
Time fixed covariates   
  
  
  Study location   
  
  
       Harare, Zimbabwe 1.0 - NA 1.0 - NA 
     Johannesburg, South Africa 2.7 2.2-3.5 <0.0001 2.4 1.7-3.2 <0.0001 
     Durban, South Africa 2.9 2.2-3.7 <0.0001 2.5 1.8-3.5 <0.0001 
Age    
  
  
       18-24 5.0 3.5-7.1 <0.0001 5.6 3.8-8.2 <0.0001 
     25-34 2.1 1.4-3.1 <0.01 2.5 1.7-3.7 <0.0001 
     >35 1.0 - NA 1.0 - NA 
Completed high school (11 years school) 1.5 1.2-1.8 <0.01 1.1 0.9-1.3 0.51 
Diaphragm randomization arm (ref: control) 1.2 0.9-1.5 0.07 1.2 0.9-1.5 0.12 
Contraceptive use at enrollment   
  
  
      None 1.0 - NA 1.0 - NA 
    Oral contraceptives 0.7 0.5-0.9 0.03 1.0 0.7-1.7 0.88 
    Injectable contraceptives 1.4 1.0-2.1 0.05 1.0 0.7-1.5 0.94 
    Other (diaphragm, IUD, condoms, vasectomy) 1.2 0.8-1.7 0.35 1.1 0.8-1.6 0.60 
High risk sex at enrollment 1.3 1.0-1.6 0.03 1.2 0.9-1.5 0.08 
Partner high risk at enrollment 1.3 1.0-1.5 0.03 1.1 0.8-1.3 0.66 
STI at enrollment** 1.2 0.9-1.50 0.07 1.5 1.2-1.9 <0.01 
Time varying covariates   
  
  
  Vaginal sex since last visit (ref:none) 0.9 0.6-1.6 0.58 1.0 0.6-1.6 0.95 
>3 Vaginal sex acts per week (ref:0-2) 0.9 0.8-1.2 0.54 1.2 0.9-1.5 0.13 
No condom use at last sex  1.1 0.8-1.3 0.62 0.9 0.7-1.2 0.55 
Unprotected sex since last visit  1.4 1.1-1.7 <0.01 1.3 1.0-1.7 0.04 
High risk sex^ 1.7 1.3-2.1 <0.0001 1.2 0.9-1.6 0.94 
Suspects/knows partner concurrency 1.6 1.3-2.0 <0.0001 1.3 1.0-1.6 0.04 
Vaginal washing 1.0 0.8-1.2 0.86 0.9 0.7-1.2 0.67 
Vaginal wiping 0.9 0.7-1.1 0.35 0.9 0.7-1.2 0.51 
Insertion of paper products  1.1 0.9-1.5 0.38 1.3 0.9-1.7 0.12 
 
*Multivariable models were adjusted for all covariates listed in the table 
**STIs at enrollment: chlamydia, gonorrhea, trichomoniasis, HSV-2 




Table 4.4b  Unadjusted and adjusted hazard ratios estimating the relationship between pregnancy 
status and incident gonorrhea infections using broader definition of pregnancy (all lab and reported) 
(N=4,549) 
  
Unadjusted relative hazard 
(HR) of incident gonorrhea 
Adjusted relative hazard (HR)* 
of incident gonorrhea 
 
HR 95%CI p value HR 95%CI p value 
Pregnancy exposure group   
  
  
      Pregnant (lab+ and reported) 1.6 1.0-2.7 0.05 1.5 0.9-2.5 0.11 
    Not pregnant/oral contraceptive use 0.6 0.4-0.9 0.01 0.9 0.5-1.5 0.58 
    Not pregnant/injectable contraceptive 1.1 0.8-1.64 0.55 1.0 0.6-1.5 0.86 
    Not pregnant/no hormonal contraceptives 1.0 - NA 1.0 - NA 
Time fixed covariates   
  
  
  Study location   
  
  
       Harare, Zimbabwe 1.0 - NA 1.0 - NA 
     Johannesburg, South Africa 2.9 2.0-4.2 <0.0001 2.2 1.4-3.7 <0.01 
     Durban, South Africa 2.6 1.7-3.9 <0.0001 2.3 1.3-3.8 <0.01 
Age    
  
  
       18-24 4.2 2.5-7.1 <0.0001 5.2 2.9-9.1 <0.0001 
     25-34 1.8 1.0-3.2 0.04 2.3 1.9-4.1 0.01 
     >35 1.0 - NA 1.0 - NA 
Completed high school (11 years school) 1.3 0.9-1.8 0.09 1.0 0.7-1.4 0.87 
Diaphragm randomization arm (ref: control) 0.9 0.7-1.3 0.69 1.1 0.8-1.5 0.70 
Contraceptive use at enrollment   
  
  
      None 1.0 - NA 1.0 - NA 
    Oral contraceptives 0.9 0.5-1.7 0.73 1.7 0.8-3.7 0.17 
    Injectable contraceptives 1.6 0.9-3.0 0.14 1.4 0.7-2.8 0.33 
    Other (diaphragm, IUD, condoms, vasectomy) 1.8 0.9-3.3 0.07 1.7 0.9-3.1 0.11 
High risk sex at enrollment 0.8 0.5-1.2 0.22 0.7 0.5-1.0 0.06 
Partner high risk at enrollment 1.8 1.3-2.5 <0.01 1.4 0.9-2.0 0.07 
STI at enrollment** 1.9 1.3-2.7 <0.01 2.2 1.5-3.1 <0.0001 
Time varying covariates   
  
  
  Vaginal sex since last visit (ref:none) 1.0 0.5-1.9 0.99 1.3 0.6-2.7 0.51 
>3 Vaginal sex acts per week (ref:0-2) 0.7 0.5-1.0 0.03 0.8 0.6-1.8 0.30 
No condom use at last sex  0.6 0.4-0.9 0.02 0.6 0.4-0.9 0.01 
Unprotected sex since last visit  1.1 0.8-1.5 0.47 1.2 0.9-1.8 0.25 
High risk sex^ 1.9 1.4-2.7 <0.01 1.5 1.1-2.2 0.02 
Suspects/knows partner concurrency 2.4 1.8-3.3 <0.0001 1.8 1.3-2.5 <0.01 
Vaginal washing 1.1 0.8-1.6 0.64 1.1 0.8-1.7 0.59 
Vaginal wiping 1.0 0.7-1.4 0.93 1.0 0.7-1.5 0.71 
Insertion of paper products  0.9 0.5-1.4 0.57 0.9 0.5-1.5 0.71 
 
*Multivariable models were adjusted for all covariates listed in the table 
**STIs at enrollment: chlamydia, gonorrhea, trichomoniasis, HSV-2 





Table 4.4c  Unadjusted and adjusted hazard ratios estimating the relationship between pregnancy 
status and incident trichomoniasis infections using broader definition of pregnancy (all lab and 
reported) (N=4,549) 
  
Unadjusted relative hazard 
(HR) of incident 
trichomoniasis 
Adjusted relative hazard 
(HR)* of incident 
trichomoniasis 
 
HR 95%CI p value HR 95%CI p value 
Pregnancy exposure group   
  
  
      Pregnant (lab+ and reported) 1.2 0.8-1.7 0.35 1.3 0.9-1.9 0.15 
    Not pregnant/oral contraceptive use 0.7 0.6-0.9 0.01 0.9 0.6-1.3 0.57 
    Not pregnant/injectable contraceptive 0.9 0.7-1.9 0.59 1.0 0.7-1.4 0.97 
    Not pregnant/no hormonal contraceptives 1.0 - NA 1.0 - NA 
Time fixed covariates   
  
  
  Study location   
  
  
       Harare, Zimbabwe 1.0 - NA 1.0 - NA 
     Johannesburg, South Africa 1.7 1.4-2.2 <0.0001 1.5 1.2-2.0 <0.01 
     Durban, South Africa 1.3 0.9-1.7 0.07 1.3 0.9-1.8 0.14 
Age    
  
  
       18-24 1.0 0.8-1.2 0.75 1.2 0.9-1.6 0.13 
     25-34 0.7 0.6-0.9 0.01 0.9 0.7-1.2 0.45 
     >35 1.0 - NA 1.0 - NA 
Completed high school (11 years school) 0.7 0.6-0.9 <0.01 0.8 0.7-1.0 0.06 
Diaphragm randomization arm (ref: control) 0.9 0.8-1.1 0.41 0.9 0.8-1.2 0.56 
Contraceptive use at enrollment   
  
  
      None 1.0 - NA 1.0 - NA 
    Oral contraceptives 0.5 0.4-0.7 <0.0001 0.8 0.6-1.2 0.34 
    Injectable contraceptives 0.7 0.5-0.9 0.01 0.8 0.5-1.1 0.13 
    Other (diaphragm, IUD, condoms, vasectomy) 0.6 0.4-0.8 <0.01 0.6 0.4-0.8 <0.01 
High risk sex at enrollment 1.2 0.9-1.5 0.07 1.1 0.9-1.4 0.27 
Partner high risk at enrollment 1.4 1.1-1.7 <0.01 1.2 0.9-1.5 0.11 
STI at enrollment** 2.0 1.6-2.4 <0.0001 1.8 1.4-2.3 <0.0001 
Time varying covariates   
  
  
  Vaginal sex since last visit (ref:none) 0.8 0.6-1.2 0.33 0.9 0.6-1.5 0.78 
>3 Vaginal sex acts per week (ref:0-2) 0.8 0.6-0.9 0.03 0.9 0.7-1.2 0.40 
No condom use at last sex  1.1 0.8-1.3 0.65 1.0 0.8-1.4 0.80 
Unprotected sex since last visit  1.2 0.9-1.4 0.11 1.1 0.9-1.4 0.47 
High risk sex^ 1.4 1.1-1.8 <0.01 1.1 0.9-1.4 0.31 
Suspects/knows partner concurrency 1.5 1.2-1.8 <0.01 1.3 1.0-1.6 0.03 
Vaginal washing 1.0 0.8-1.3 0.93 1.0 0.8-1.3 0.98 
Vaginal wiping 1.0 0.9-1.3 0.64 0.9 0.7-1.2 0.51 
Insertion of paper products  1.4 1.1-1.8 0.02 1.3 0.9-1.8 0.06 
 
*Multivariable models were adjusted for all covariates listed in the table 
**STIs at enrollment: chlamydia, gonorrhea, trichomoniasis, HSV-2 




Table 4.4d  Unadjusted and adjusted hazard ratios estimating the relationship between pregnancy 
status and incident HI infections using broader definition of pregnancy (all lab and reported) (N=4,549) 
  
Unadjusted relative hazard 
(HR) of incident HIV 
Adjusted relative hazard 
(HR)* of incident HIV 
 
HR 95%CI p value HR 95%CI p value 
Pregnancy exposure group   
  
  
      Pregnant (lab+ and reported) 0.9 0.6-1.5 0.65 0.8 0.4-1.3 0.37 
    Not pregnant/oral contraceptive use 0.6 0.4-0.8 <0.01 0.8 0.5-1.2 0.27 
    Not pregnant/injectable contraceptive 1.1 0.8-1.4 0.71 0.8 0.6-1.2 0.23 
    Not pregnant/no hormonal contraceptives 1.0 - NA 1.0 - NA 
Time fixed covariates   
  
  
  Study location   
  
  
       Harare, Zimbabwe 1.0 - NA 1.0 - NA 
     Johannesburg, South Africa 2.7 2.0-3.5 <0.0001 2.0 1.4-2.9 <0.01 
     Durban, South Africa 1.3 0.9-1.9 0.18 1.0 0.6-1.6 0.98 
Age    
  
  
       18-24 2.1 1.4-3.0 <0.0001 2.6 1.7-3.9 <0.0001 
     25-34 1.3 0.9-2.0 0.14 1.7 1.1-2.5 0.02 
     >35 1.0 - NA 1.0 - NA 
Completed high school (11 years school) 1.2 0.9-1.5 0.19 1.1 0.9-1.5 0.33 
Diaphragm randomization arm (ref: control) 1.0 0.8-1.3 0.98 1.0 0.8-1.3 0.93 
Contraceptive use at enrollment   
  
  
      None 1.0 - NA 1.0 - NA 
    Oral contraceptives 0.8 0.5-1.4 0.53 1.4 0.7-2.6 0.32 
    Injectable contraceptives 1.8 1.1-3.0 0.03 1.8 1.1-3.2 0.03 
    Other (diaphragm, IUD, condoms, vasectomy) 1.4 0.9-2.4 0.17 1.5 0.9-2.5 0.15 
High risk sex at enrollment 1.1 0.8-1.5 0.56 1.1 0.8-1.5 0.48 
Partner high risk at enrollment 1.6 1.2-2.1 <0.01 1.3 0.9-1.7 0.12 
STI at enrollment** 2.0 1.5-2.7 <0.0001 2.1 1.5-2.8 <0.0001 
Time varying covariates   
  
  
  Vaginal sex since last visit (ref:none) 1.1 0.6-1.9 0.86 1.1 0.5-2.1 0.76 
>3 Vaginal sex acts per week (ref:0-2) 0.8 0.6-1.0 0.07 0.9 0.6-1.2 0.32 
No condom use at last sex  1.0 0.7-1.3 0.98 0.9 0.7-1.3 0.70 
Unprotected sex since last visit  1.3 0.9-1.6 0.09 1.3 0.9-1.7 0.15 
High risk sex^ 1.5 1.1-2.1 0.01 1.1 0.8-1.6 0.42 
Suspects/knows partner concurrency 2.0 1.5-2.6 <0.0001 1.5 1.1-1.9 0.01 
Vaginal washing 1.1 0.8-1.4 0.72 0.9 0.7-1.3 0.56 
Vaginal wiping 1.4 1.1-1.8 0.01 1.5 1.1-2.0 0.01 
Insertion of paper products  1.3 0.9-1.8 0.18 1.1 0.8-1.7 0.48 
 
*Multivariable models were adjusted for all covariates listed in the table 
**STIs at enrollment: chlamydia, gonorrhea, trichomoniasis, HSV-2 





Appendix 4.5a  Unadjusted and adjusted hazard ratios estimating the relationship between pregnancy 
status and incident chlamydia infections using only those women with complete data (N=3,518) 
 
  
Unadjusted relative hazard 
(HR) of incident chlamydia 
Adjusted relative hazard (HR)* 
of incident chlamydia 
 
HR 95%CI p value HR 95%CI p value 
Pregnancy exposure group   
  
  
      Pregnant  1.5 0.7-2.3 0.08 1.1 0.7-1.8 0.65 
    Not pregnant/oral contraceptive use 0.6 0.5-0.9 <0.01 0.8 0.5-1.9 0.26 
    Not pregnant/injectable contraceptive 1.5 1.3-2.0 <0.01 1.2 0.9-1.6 0.33 
    Not pregnant/no hormonal contraceptives 1.0 - NA 1.0 - NA 
Time fixed covariates   
  
  
  Study location   
  
  
       Harare, Zimbabwe 1.0 - NA 1.0 - NA 
     Johannesburg, South Africa 2.6 2.0-3.4 <0.0001 2.3 1.6-3.2 <0.0001 
     Durban, South Africa 2.7 2.1-3.6 <0.0001 2.4 1.7-3.4 <0.0001 
Age    
  
  
       18-24 5.4 3.6-8.0 <0.0001 6.1 4.0-9.4 <0.0001 
     25-34 2.4 1.6-3.6 <0.0001 2.8 1.8-4.4 <0.0001 
     >35 1.0 - NA 1.0 - NA 
Completed high school (11 years school) 1.5 1.2-1.9 <0.01 1.1 0.9-1.4 0.30 
Diaphragm randomization arm (ref: control) 1.2 0.9-1.5 0.09 1.1 0.9-1.4 0.31 
Contraceptive use at enrollment   
  
  
      None 1.0 - NA 1.0 - NA 
    Oral contraceptives 0.7 0.4-1.0 0.05 1.0 0.6-1.7 0.93 
    Injectable contraceptives 1.5 0.9-2.2 0.07 1.0 0.6-1.5 0.90 
    Other (diaphragm, IUD, condoms, vasectomy) 1.1 0.8-1.7 0.55 1.0 0.7-1.5 0.94 
High risk sex at enrollment 1.3 1.1-1.7 0.01 1.3 1.0-1.4 0.06 
Partner high risk at enrollment 1.4 1.1-1.7 0.01 1.1 0.9-1.4 0.32 
STI at enrollment** 1.2 0.9-1.5 0.14 1.5 1.2-1.9 <0.01 
Time varying covariates   
  
  
  Vaginal sex since last visit (ref:none) 1.2 0.7-2.0 0.50 1.3 0.7-2.3 0.43 
>3 Vaginal sex acts per week (ref:0-2) 0.8 0.5-1.3 0.30 1.2 0.9-1.6 0.12 
No condom use at last sex  1.2 0.9-1.5 0.19 1.1 0.8-1.5 0.57 
Unprotected sex since last visit  1.4 1.1-1.7 0.01 1.2 0.9-1.6 0.13 
High risk sex^ 1.7 1.3-2.2 <0.0001 1.2 0.9-1.6 0.13 
Suspects/knows partner concurrency 1.7 1.3-2.1 <0.0001 1.3 0.9-1.6 0.07 
Vaginal washing 0.9 0.7-1.2 0.65 0.7 0.7-1.2 0.61 
Vaginal wiping 0.8 0.7-1.1 0.15 0.8 0.7-1.1 0.18 
Insertion of paper products  1.2 0.9-1.6 0.32 1.4 1.0-1.9 0.05 
 
*Multivariable models were adjusted for all covariates listed in the table 
**STIs at enrollment: chlamydia, gonorrhea, trichomoniasis, HSV-2 





Appendix 4.5b  Unadjusted and adjusted hazard ratios estimating the relationship between pregnancy 
status and incident gonorrhea infections using only those women with complete data (N=3,518) 
 
  
Unadjusted relative hazard 
(HR) of incident gonorrhea 
Adjusted relative hazard (HR)* 
of incident gonorrhea 
 
HR 95%CI p value HR 95%CI p value 
Pregnancy exposure group   
  
  
      Pregnant  1.8 1.0-3.2 0.06 1.5 0.8-2.8 0.18 
    Not pregnant/oral contraceptive use 0.6 0.4-0.9 0.02 0.8 0.5-1.6 0.60 
    Not pregnant/injectable contraceptive 1.2 0.8-1.8 0.34 1.0 0.7-1.7 0.88 
    Not pregnant/no hormonal contraceptives 1.0 - NA 1.0 - NA 
Time fixed covariates   
  
  
  Study location   
  
  
       Harare, Zimbabwe 1.0 - NA 1.0 - NA 
     Johannesburg, South Africa 3.1 2.1-4.7 <0.0001 2.6 1.5-4.5 <0.01 
     Durban, South Africa 2.7 1.8-4.3 <0.0001 2.4 1.4-4.3 <0.01 
Age    
  
  
       18-24 5.2 2.8-9.4 <0.0001 6.2 3.2-11.7 <0.0001 
     25-34 2.1 1.1-4.1 0.02 2.7 1.4-5.2 <0.01 
     >35 1.0 - NA 1.0 - NA 
Completed high school (11 years school) 1.4 1.0-2.0 0.04 1.1 0.7-1.5 0.73 
Diaphragm randomization arm (ref: control) 1.0 0.7-1.4 0.85 1.0 0.7-1.5 0.89 
Contraceptive use at enrollment   
  
  
      None 1.0 - NA 1.0 - NA 
    Oral contraceptives 1.0 0.5-2.2 0.92 2.1 0.9-4.9 0.09 
    Injectable contraceptives 1.8 0.9-3.7 0.11 1.4 0.6-3.0 0.40 
    Other (diaphragm, IUD, condoms, vasectomy) 2.0 1.1-4.2 0.05 1.9 0.9-3.9 0.08 
High risk sex at enrollment 0.8 0.5-1.2 0.22 0.6 0.4-0.9 0.04 
Partner high risk at enrollment 1.8 1.2-2.6 0.00 1.4 0.9-2.1 0.08 
STI at enrollment** 1.9 1.3-2.8 0.00 2.3 1.5-3.4 <0.0001 
Time varying covariates   
  
  
  Vaginal sex since last visit (ref:none) 1.0 0.5-2.0 0.91 1.1 0.5-2.6 0.75 
>3 Vaginal sex acts per week (ref:0-2) 0.8 0.5-1.1 0.13 0.9 0.6-1.4 0.75 
No condom use at last sex  0.7 0.4-1.0 0.06 0.6 0.4-0.9 0.04 
Unprotected sex since last visit  1.2 0.9-1.7 0.27 1.3 0.9-1.9 0.18 
High risk sex^ 2.1 1.5-3.0 <0.0001 1.6 1.1-2.4 0.01 
Suspects/knows partner concurrency 2.4 1.7-3.4 <0.0001 1.7 1.2-2.5 <0.01 
Vaginal washing 1.2 0.8-1.8 0.36 1.3 0.9-2.0 0.22 
Vaginal wiping 0.9 0.7-1.3 0.71 1.0 0.7-1.4 0.82 
Insertion of paper products  0.9 0.5-1.5 0.55 0.9 0.5-1.6 0.70 
 
*Multivariable models were adjusted for all covariates listed in the table 
**STIs at enrollment: chlamydia, gonorrhea, trichomoniasis, HSV-2 




Appendix 4.5c  Unadjusted and adjusted hazard ratios estimating the relationship between pregnancy 
status and incident trichomoniasis infections using only those women with complete data (N=3,518) 
 
  
Unadjusted relative hazard 
(HR) of incident trichomoniasis 
Adjusted relative hazard (HR)* 
of incident trichomoniasis 
 
HR 95%CI p value HR 95%CI p value 
Pregnancy exposure group   
  
  
      Pregnant  1.1 0.7-1.7 0.60 1.3 0.8-2.0 0.33 
    Not pregnant/oral contraceptive use 0.7 0.5-0.9 <0.01 0.9 0.6-1.3 0.67 
    Not pregnant/injectable contraceptive 0.9 0.7-2.0 0.56 1.0 0.7-1.4 0.98 
    Not pregnant/no hormonal contraceptives 1.0 - NA 1.0 - NA 
Time fixed covariates   
  
  
  Study location   
  
  
       Harare, Zimbabwe 1.0 - NA 1.0 - NA 
     Johannesburg, South Africa 1.9 1.5-2.4 <0.0001 1.7 1.3-2.3 <0.01 
     Durban, South Africa 1.4 1.1-1.9 0.02 1.4 1.0-2.0 0.05 
Age    
  
  
       18-24 0.9 0.7-1.2 0.40 1.2 0.9-1.6 0.28 
     25-34 0.7 0.6-0.9 0.02 0.9 0.7-1.3 0.70 
     >35 1.0 - NA 1.0 - NA 
Completed high school (11 years school) 0.8 0.6-0.9 0.01 0.8 0.7-1.1 0.12 
Diaphragm randomization arm (ref: control) 0.9 0.7-1.1 0.35 0.9 0.7-1.1 0.43 
Contraceptive use at enrollment   
  
  
      None 1.0 - NA 1.0 - NA 
    Oral contraceptives 0.5 .04-0.7 <0.0001 0.8 0.5-1.2 0.23 
    Injectable contraceptives 0.6 0.5-0.9 0.01 0.7 0.5-1.0 0.07 
    Other (diaphragm, IUD, condoms, vasectomy) 0.6 0.4-0.8 <0.01 0.6 0.5-0.9 0.01 
High risk sex at enrollment 1.2 0.9-1.6 0.08 1.1 0.9-1.4 0.36 
Partner high risk at enrollment 1.4 1.1-1.8 <0.01 1.2 0.9-1.6 0.08 
STI at enrollment** 2.0 1.5-2.5 <0.0001 1.8 1.4-2.3 <0.0001 
Time varying covariates   
  
  
  Vaginal sex since last visit (ref:none) 0.9 0.6-1.4 0.74 1.1 0.6-1.8 0.79 
>3 Vaginal sex acts per week (ref:0-2) 0.8 0.6-0.9 0.04 0.9 0.7-1.2 0.44 
No condom use at last sex  1.0 0.8-1.3 0.98 1.0 0.8-1.4 0.96 
Unprotected sex since last visit  1.1 0.9-1.4 0.27 1.1 0.8-1.4 0.59 
High risk sex^ 1.5 1.2-1.9 <0.01 1.2 0.9-1.6 0.16 
Suspects/knows partner concurrency 1.5 1.2-1.9 <0.01 1.3 1.0-1.6 0.05 
Vaginal washing 1.1 0.9-1.4 0.38 1.1 0.9-1.5 0.33 
Vaginal wiping 1.1 0.9-1.3 0.51 0.9 0.7-1.2 0.47 
Insertion of paper products  1.4 1.0-1.8 0.02 1.3 0.9-1.8 0.08 
 
*Multivariable models were adjusted for all covariates listed in the table 
**STIs at enrollment: chlamydia, gonorrhea, trichomoniasis, HSV-2 




Appendix 4.5d  Unadjusted and adjusted hazard ratios estimating the relationship between pregnancy 
status and incident HIV infections using only those women with complete data (N=3,518) 
 
  
Unadjusted relative hazard 
(HR) of incident HIV 
Adjusted relative hazard (HR)* 
of incident HIV 
 
HR 95%CI p value HR 95%CI p value 
Pregnancy exposure group   
  
  
      Pregnant  1.1 0.6-1.9 0.82 0.9 0.5-1.6 0.78 
    Not pregnant/oral contraceptive use 0.6 0.4-0.9 0.01 0.8 0.5-1.3 0.34 
    Not pregnant/injectable contraceptive 1.1 0.8-1.5 0.48 0.8 0.5-1.1 0.19 
    Not pregnant/no hormonal contraceptives 1.0 - NA 1.0 - NA 
Time fixed covariates   
  
  
  Study location   
  
  
       Harare, Zimbabwe 1.0 - NA 1.0 - NA 
     Johannesburg, South Africa 2.6 2.0-3.5 <0.0001 2.0 1.3-2.9 <0.01 
     Durban, South Africa 1.2 0.8-1.8 0.43 0.9 0.6-1.5 0.70 
Age    
  
  
       18-24 2.2 1.5-3.3 <0.0001 2.7 1.8-4.1 <0.0001 
     25-34 1.4 0.9-2.2 0.07 1.8 1.5-2.7 0.01 
     >35 1.0 - NA 1.0 - NA 
Completed high school (11 years school) 1.2 0.9-1.6 0.13 1.2 0.9-1.6 0.13 
Diaphragm randomization arm (ref: control) 1.1 0.8-1.4 0.51 1.1 0.8-1.5 0.55 
Contraceptive use at enrollment   
  
  
      None 1.0 - NA 1.0 - NA 
    Oral contraceptives 0.9 0.5-1.6 0.79 1.5 0.8-2.9 0.24 
    Injectable contraceptives 1.9 1.1-3.3 0.02 2.0 1.1-3.6 0.02 
    Other (diaphragm, IUD, condoms, vasectomy) 1.4 0.8-2.4 0.22 1.5 0.9-2.5 0.17 
High risk sex at enrollment 1.1 0.8-1.4 0.71 1.0 0.8-1.4 0.82 
Partner high risk at enrollment 1.6 1.2-2.2 <0.01 1.3 1.0-1.8 0.06 
STI at enrollment** 2.2 1.6-3.0 <0.0001 2.4 1.8-3.4 <0.0001 
Time varying covariates   
  
  
  Vaginal sex since last visit (ref:none) 1.2 0.6-2.5 0.58 1.3 0.6-2.6 0.49 
>3 Vaginal sex acts per week (ref:0-2) 0.8 0.6-1.1 0.79 0.9 0.6-1.6 0.31 
No condom use at last sex  1.0 0.7-1.4 0.97 0.9 0.6-1.3 0.46 
Unprotected sex since last visit  1.3 1.0-1.8 0.04 1.3 0.9-1.9 0.07 
High risk sex^ 1.6 1.2-2.2 <0.01 1.2 0.9-1.7 0.22 
Suspects/knows partner concurrency 2.0 1.5-2.6 <0.0001 1.4 1.1-1.9 0.02 
Vaginal washing 1.1 0.8-1.4 0.72 0.9 0.6-1.3 0.53 
Vaginal wiping 1.5 1.1-1.9 0.01 1.5 1.1-2.0 0.01 
Insertion of paper products  1.2 0.9-1.8 0.24 1.1 0.7-1.6 0.65 
 
*Multivariable models were adjusted for all covariates listed in the table 
**STIs at enrollment: chlamydia, gonorrhea, trichomoniasis, HSV-2 




Appendix 4.6 Enrollment characteristics and risk behaviors reported at follow-up visits by 4,549 
women and the association with location (N=24,337 visits) 
  Total 
Harare, 
Zimbabwe 






N % N % N % N % 








      18-24 1725 37.9% 816 36.2% 564 41.1% 345 37.4% 
     25-34 1782 39.2% 1029 45.6% 420 30.6% 333 36.1% 
     >35 1042 22.9% 410 18.2% 388 28.3% 244 26.5% 
Completed high school  2347 51.6% 1111 49.3% 589 42.9% 647 70.2% 
Randomization arm 2271 50.0% 1134 50.3% 684 49.9% 453 49.2% 





     None 474 10.4% 116 5.1% 244 17.8% 114 12.4% 
    Oral  1642 36.1% 1444 64.0% 87 6.3% 111 12.0% 
    Injectable  1129 24.8% 314 13.9% 534 38.9% 281 30.5% 
    Other*  1304 28.7% 381 16.9% 507 37.0% 416 45.1% 
High risk sex  1059 23.3% 535 23.7% 257 18.7% 267 29.0% 
Partner high risk  2836 62.3% 1333 59.1% 902 65.7% 601 65.2% 
STI at enrollment** 2776 61.0% 1186 52.6% 972 70.9% 618 67.0% 
 
Follow-up visits 
N % N % N % N % 
24337 100.0% 13018 53.5% 6743 27.7% 4576 18.8% 







      Pregnant 1609 6.6% 875 6.7% 428 6.4% 306 6.7% 
    Not pregnant/oral HC 8375 34.4% 7358 56.5% 400 5.9% 617 13.5% 
    Not pregnant/injectable HC 6028 24.8% 2041 15.7% 2547 37.8% 1440 31.5% 
    Not pregnant/no HC 8325 34.2% 2744 21.1% 3368 50.0% 2213 48.4% 
Any vaginal sex since last visit 22933 94.2% 12725 97.8% 6378 94.6% 3830 83.7% 
Sex >3 times per week 15948 65.5% 9424 72.4% 4194 62.2% 2330 50.9% 
Condom use last sex 16856 69.3% 9101 69.9% 4878 72.3% 2877 62.9% 
Unprotected sex (any report)  14334 58.9% 7481 57.5% 3780 56.1% 3073 67.2% 
Sex in exchange money/drugs 728 3.0% 445 3.4% 130 1.9% 153 3.3% 
>2 sex partners since last visit 1584 6.5% 215 1.7% 454 6.7% 915 20.0% 
New sex partner  2831 11.6% 966 7.4% 1108 16.4% 757 16.5% 
Partner has other sex partners 
(suspects/knows) 
6064 24.9% 2572 19.8% 2202 32.7% 1290 28.2% 
High risk sex*** 4415 18.1% 1828 14.0% 1501 22.3% 1086 23.7% 
Vaginal washing (any) 18328 75.3% 10072 77.4% 4770 70.7% 3486 76.2% 
Vaginal wiping (any) 9900 40.7% 5653 43.5% 2599 38.5% 1648 36.0% 
Vaginal insertion (any) 3151 13.0% 1760 13.5% 721 10.7% 670 14.6% 
 
*Other contraceptives at enrollment: diaphragm, IUD, condoms, male partner vasectomy 
**STIs at enrollment: chlamydia, gonorrhea, trichomoniasis, HSV-2 





Appendix 4.6 continued 
  OR Durban vs. Harare OR Johannesburg vs. Harare 
 
OR   95%CI p-value OR   95%CI p-value 
Enrollment characteristics   
  
  
  Age    
  
  
       18-24 0.6 0.5-0.7 <0.0001 0.8 0.6-0.9 <0.01 
     25-34 1.4 1.1-1.6 <0.01 1.4 1.2-1.7 <0.01 
     >35 1.0 - NA 1.0 - NA 
Completed high school  0.8 0.7-0.9 <0.01 2.4 2.1-2.9 <0.0001 
Diaphragm randomization arm 1.0 0.9-1.1 0.80 1.0 0.8-1.1 0.63 
Contraceptive use at enrollment   
  
  
      None 1.0 - NA 1.0 - NA 
    Oral contraceptives <0.1 <0.1-0.1 <0.0001 0.1 0.1-0.2 <0.0001 
    Injectable contraceptives 0.8 0.6-1.1 0.11 0.9 0.7-1.2 0.55 
    Other*  0.6 0.5-0.8 <0.01 1.1 0.8-1.5 0.48 
High risk sex at enrollment 0.7 0.6-0.9 <0.01 1.3 1.1-1.6 <0.01 
Partner high risk at enrollment 1.3 1.2-1.5 <0.001 1.3 1.1-1.5 <0.01 
STI at enrollment** 2.2 1.9-2.5 <0.001 1.8 1.6-2.2 <0.001 
 
 
Follow-up visits OR   95%CI p-value OR   95%CI p-value 
Pregnancy/HC use at visit   
  
  
       Pregnant 0.3 0.3-0.4 <0.0001 0.4 0.3-0.4 <0.0001 
     Non-pregnant/oral HC 0.1 0.0-0.1 <0.0001 0.1 0.1-0.2 <0.001 
     Non-pregnant/injectable HC 1.1 1.0-1.3 0.19 1.0 0.8-1.1 0.72 
     Non-pregnant/no HC 1.0 - - 1.0 - - 
Any vaginal sex since last visit 0.5 0.4-6 <0.0001 0.1 0.1-0.2 <0.0001 
Sex >3 times per week 0.4 0.4-0.5 <0.0001 0.2 0.2-0.3 <0.0001 
Condom use last sex 1.3 1.2-1.5 <0.0001 1.2 1.1-1.3 0.02 
Unprotected sex (any report)  0.9 0.8-1.0 0.08 1.5 1.3-1.7 <0.0001 
Sex in exchange money/drugs 0.5 0.4-0.7 <0.0001 0.9 0.7-1.3 0.65 
>2 sex partners since last visit 4.4 3.5-5.6 <0.0001 14.6 11.8-18.2 <0.0001 
New sex partner  2.5 2.1-2.8 <0.0001 2.5 2.1-2.8 <0.0001 
Partner has other sex partners 
(suspects/knows) 
2.1 1.8-2.3 <0.0001 1.6 1.4-1.8 <0.0001 
High risk sex*** 1.7 1.5-1.9 <0.0001 1.9 1.7-2.1 <0.0001 
Vaginal washing (any) 0.7 0.6-0.8 <0.0001 1.0 0.8-1.1 0.58 
Vaginal wiping 0.8 0.7-0.9 <0.0001 0.7 0.7-0.8 <0.0001 
Vaginal insertion (any) 0.7 0.6-0.9 <0.0001 1.1 0.9-1.3 0.38 
 
*Other contraceptives at enrollment: diaphragm, IUD, condoms, male partner vasectomy 
**STIs at enrollment: chlamydia, gonorrhea, trichomoniasis, HSV-2 





Appendix 4.7 Incidence rates of four STIs by pregnancy and hormonal contraceptive exposure group 
by location  
 
Harare, Zimbabwe 
  Overall Pregnant visits 
Non-pregnant & oral 
HC use visits 
Non-pregnant & 
injectable HC use 
visits 























Chlamydia 116 3223 3.6 14 215 3.6 62 1825 3.4 20 500 4.0 20 683 2.9 
Gonorrhea 48 3287 1.5 9 222 4.1 25 1859 1.3 3 512 0.6 11 694 1.6 
Trichomoniasis 177 3158 5.6 20 214 9.3 95 1788 5.3 26 492 5.3 36 664 5.4 
 HIV 85 3307 2.6 8 225 3.6 48 1868 2.6 11 516 2.1 18 698 2.6 
                
Durban, South Africa 
  Overall 
Pregnant visits                         
(lab+ and reported) 
Non-pregnant & oral 
HC use visits 
Non-pregnant & 
injectable HC use 
visits 























Chlamydia 166 1618 10.3 12 98 12.2 4 100 4.0 76 603 12.6 74 817 9.1 
Gonorrhea 73 1689 4.3 7 106 6.6 2 100 2.0 33 634 5.2 31 849 3.7 
Trichomoniasis 162 1636 9.9 13 101 12.9 9 99 9.1 60 620 9.7 80 817 9.8 
HIV 117 1715 6.8 5 111 4.5 4 102 3.9 48 645 7.4 60 857 7.0 
Johannesburg, South Africa 
  Overall 
Pregnant visits                         
(lab+ and reported) 
Non-pregnant & oral 
HC use visits 
Non-pregnant & 
injectable HC use 
visits 























Chlamydia 118 1094 10.8 12 71 16.9 18 142 12.7 50 336 14.9 38 546 7.0 
Gonorrhea 44 1154 3.8 4 78 5.1 7 154 4.5 13 363 3.6 20 560 3.6 
Trichomoniasis 81 1141 7.1 3 76 3.9 11 153 7.2 23 357 6.4 44 556 7.9 






Appendix 4.8 Post-hoc power calculations 
Power calculations were performed in NCSS Power Analysis and Sample Size (PASS)© 2008 software for 
each of the four STI outcomes. Alpha was set at 0.05 and the sample size of 4,549 women was used for 
analyses in a Cox Proportional Hazards model. The overall incidence observed for each STI was used for 
the estimate of the overall event rate and the observed log of the hazard ratio was input for the 
comparison between pregnant and non-pregnant/no HC periods. Two estimates for the r-square of the 
exposure with the other covariates were used, 0.4 and 0.7 (indicating high correlation between the 
other exposure and the variables in the model which was observed in the analysis of pregnancy status 
predicting reported behaviors in Chapter 3) and the standard deviation was estimated using the 
proportion of outcomes in the overall group and the pregnancy-exposed group to give two estimates for 
each outcome. The results below indicate that the sample was adequate as evidenced by power >80% to 
detect differences in incidence for each of the STIs given high correlation between exposure and the 
other covariates in the model.  
Chlamydia 
     R-Squared   
 Sample Reg. S.D. Event X1 vs Two-  
 Size Coef. of X1 Rate Other X's Sided  
Power (N) (B) (SD) (P) (R2) Alpha Beta 
1.00000 4549 0.4055 2.5000 0.0670 0.4000 0.05000 0.00000 
1.00000 4549 0.4055 2.9000 0.0670 0.4000 0.05000 0.00000 
1.00000 4549 0.4055 2.5000 0.0670 0.7000 0.05000 0.00000 
1.00000 4549 0.4055 2.9000 0.0670 0.7000 0.05000 0.00000 
 
Gonorrhea  
     R-Squared   
 Sample Reg. S.D. Event X1 vs Two-  
 Size Coef. of X1 Rate Other X's Sided  
Power (N) (B) (SD) (P) (R2) Alpha Beta 
1.00000 4549 0.4700 1.6000 0.0270 0.4000 0.05000 0.00000 
1.00000 4549 0.4700 2.2000 0.0270 0.4000 0.05000 0.00000 
0.99540 4549 0.4700 1.6000 0.0270 0.7000 0.05000 0.00460 






     R-Squared   
 Sample Reg. S.D. Event X1 vs Two-  
 Size Coef. of X1 Rate Other X's Sided  
Power (N) (B) (SD) (P) (R2) Alpha Beta 
0.91255 4549 0.0953 2.5000 0.0710 0.4000 0.05000 0.08745 
0.97831 4549 0.0953 3.0000 0.0710 0.4000 0.05000 0.02169 
0.64997 4549 0.0953 2.5000 0.0710 0.7000 0.05000 0.35003 
0.80353 4549 0.0953 3.0000 0.0710 0.7000 0.05000 0.19647 
 
HIV 
     R-Squared   
 Sample Reg. S.D. Event X1 vs Two-  
 Size Coef. of X1 Rate Other X's Sided  
Power (N) (B) (SD) (P) (R2) Alpha Beta 
0.99210 4549 -0.2231 1.9000 0.0390 0.4000 0.05000 0.00790 
0.99590 4549 -0.2231 2.0000 0.0390 0.4000 0.05000 0.00410 
0.87129 4549 -0.2231 1.9000 0.0390 0.7000 0.05000 0.12871 
0.90238 4549 -0.2231 2.0000 0.0390 0.7000 0.05000 0.09762 
 
